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Abstract 
Nanoparticles are emerging drug delivery platforms for improved stability and bioavailability of 
drugs and vasoprotective nutraceutical compounds, such as resveratrol (RV) for the treatment of 
cardiovascular disease (CVD). Hypertension is a significant contributor to CVD, and while its 
pathophysiology is unclear, oxidative stress is thought to be a key contributor. It is evident that there 
is a growing need for treatment strategies to prevent future cardiovascular events. This project aimed 
to develop a potential therapeutic tool for the treatment of CVDs associated with oxidative stress. 
Nanoparticles (inorganic and organic) were synthesised and characterised using a range of chemi-
analytical techniques and their potential for the delivery of nutraceutical compounds assessed.  The 
effects of the drug-loaded nanoparticles were assessed using human coronary artery endothelial cells 
(HCAECs) in vitro and using a developed model of acute hypertension in isolated coronary and 
cerebral vessels to replicate an oxidative environment. Silica nanoparticles (SiNPs) functionalised 
with cerium oxide (CeO2) reduced SiNP surface reactivity and demonstrated antioxidant capacity, 
improving biocompatibility in vitro. Uptake of novel RV-loaded NLCs (RV-NLCs) by HCAECs 
maintained their viability and reduced both mitochondrial and cytosolic superoxide levels; vessel 
incubation in RV-NLCs restored the magnitude of dilation via NO following acute pressure elevation, 
mediated via AMPK in the coronary artery. In contrast, organic nanoparticles (RV-NLCs and TMS-
liposomes) were incapable of restoring elevated pressure induced attenuated dilation in cerebral 
arteries, suggesting alternate mechanisms of impairment.  
Findings from the present study support the use of nanoparticles for the treatment of CVD, whereby 
they offer improved biocompatibility, potency and sustained drug release into the vasculature; whilst 
also highlighting the tissue-specific variability in treatment responses, hence a need for in-depth, 
comparative studies in the development of novel clinical solutions.
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1.1 Nanomedicine  
 
The field of nanomedicine has advanced exponentially since its establishment in the 1990s 
and is focused on the development and application of nanotechnology for the diagnosis, 
prevention and treatment of disease. Interest has been heightened due to current constraints 
and limitations conferred by conventional treatments, including; the unspecific targeting of 
drugs, toxicity, and inadequate bioavailability. Nanoparticles have become widely adopted 
in the nanomedical field in recent years due to their ease of synthesis, adaptability and 
potential use within a variety of biomedical disciplines. Whilst the precise definition of a 
nanoparticle is disputed amongst scientific and international regulatory corporations, it is 
generally defined as a nano-object with all three external dimensions in the nanoscale; 
ranging in size from approximately 1-100 nm (Royaume, 2011). At the nanoscale, 
nanoparticles exhibit novel physicochemical properties, distinct from those of their 
conventional bulk chemical equivalents, typically attributed to an increased surface area to 
volume ratio and heightened reactivity. These unique properties, as well as the versatility of 
nanoparticles, owing to the extensive range of material composites and surface chemistry 
available, have resulted in the application of nanoparticles for diagnosis and therapeutic 
intervention. Whilst oncology was the first field to harness the properties of nanoparticles 
for drug delivery, with several formulations receiving clinical approval to date; interest in 
the development of cardiovascular nanomedicines is now growing and is supported by a 
significant increase in promising laboratory and clinical research (Flores et al., 2019). This 
thesis will focus on the use of nanoparticles to target the vasculature with the long-term goal 
of vascular disease treatment. 
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1.2 The use of nanoparticles as a drug delivery modality in the treatment of cardiovascular 
disease 
 
Nanoparticles are exceedingly adjustable in terms of size, shape and surface 
functionalisation, allowing specific alterations to suit distinct requirements, such as; targeted 
and optimised drug release, enhanced circulation and/or clearance time (Figure 1.1). 
Furthermore, the underlying material composition of nanoparticles can significantly alter 
their properties, with various materials hosting diverse intrinsic effects (Tong et al., 2009; 
Wahajuddin and Arora, 2012). Nanoparticles may be sub-categorised according to their 
material composition as organic, (including liposomes and nanolipid carriers) or inorganic, 
(including silica and cerium oxide nanoparticles). Both physical and surface characteristics 
are significant in determining how nanoparticles interact with their environment; where size, 
shape, and surface charge can directly influence the efficiency, mode of uptake and 
circulation time (Huang et al., 2010; Gramatke, 2014; Suk et al., 2016).  
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Figure 1.1. A schematic illustration of the variable physicochemical characteristics of 
nanoparticles. Nanoparticle synthesis is highly versatile, with a variety of adjustments 
available. These modifiable components include physical characteristics such as size and 
shape; surface modification via the alteration of surface charge (zeta potential) or addition 
of glycol groups (PEGylation); interactions with biological components resulting in corona 
formation; and changes in chemical composition and potential drug loading. Adapted from 
(Borgos et al., 2017). 
 
Common pharmacological treatment strategies are principally concerned with maximising 
therapeutic delivery and/or exposure time; hence, it is evident that the large surface area 
conferred by vascular endothelial cells is vitally important as it constitutes the first site of 
exposure to any systemically delivered drug/compound. However, very little is known about 
the potential vascular effects of introducing nanoparticles into the systemic circulation. The 
variable size and function of vessels, as well as the increased reactivity and exposure of 
nanoscale compounds to cellular proteins and endothelial beds, make it imperative that the 
underlying effects are appropriately assessed prior to clinical use.  This project will assess 
the potential use of these nanoparticles (inorganic & organic) in the restoration of endothelial 
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dysfunction using an ex vivo model of hypertension and hence, evidence implicating these 
nanoparticles in the treatment of CVD will be discussed in further detail below. 
 
1.2.1 Inorganic Nanoparticles 
 
1.2.1.1 Silica Nanoparticles 
 
Silicon dioxide (SiO2) nanoparticles, otherwise known as silica nanoparticles (SiNPs), are 
non-metal oxides extensively utilised in the biomedical sector, with applications in bio-
sensing, drug-delivery and imaging-diagnostics (Wunderbaldinger et al., 2002; Li et al., 
2010; Masood, 2016). The rapid adoption of SiNPs can be attributed to several factors 
including, low cost; ease of fabrication; and of particular interest, their well characterised 
and tunable surface chemistry. The fabrication of SiNPs results in a high density of silanol 
groups (Si-OH) on the particle surface, increasing their solubility, making them highly 
effective within in vivo applications. Combined with their large surface area to volume ratio, 
allowing efficient interaction with biological material, SiNPs provide an excellent 
therapeutic delivery platform and biomedical research imaging tool. 
The addition of different dyes and a range of modifications to surface groups allows the 
creation of multimodal nanoparticles for theranostic applications, e.g. the incorporation of 
an imaging component along with a therapeutic payload. These properties have resulted in 
the successful use of mesoporous silica nanoparticles (MSNs) as a potential delivery 
platform for the release of vasodilator drugs into tissues ex vivo and in in vivo cardiovascular 
disease (CVD) models (Farooq et al., 2016, 2018; Hou et al., 2018). Whilst the health effects 
of SiNPs have been widely investigated and are considered largely biocompatible both in 
vitro and in vivo (Lai et al., 2003; Lu et al., 2007, 2010); biocompatibility is highly dependent 
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on size, dosage, cell type and production method (Asefa and Tao, 2012; Gramatke, 2014). 
Furthermore, several studies have implicated surface group reactivity as a critical modulator 
of biocompatibility, implicating SiNP mediated oxidative stress in the generation of reactive 
oxygen species (ROS) and as an inducer of cytotoxicity both in vitro and in vivo (Corbalan 
et al., 2012; Ahamed, 2013; Duan et al., 2013a).  
In order to assess the biocompatibility of SiNPs in the cardiovascular system, studies from 
the Azzawi group focus on the use of isolated vessels; demonstrating that the influence of 
SiNPs on dilator responses is dependent on size, surface charge, dye-encapsulation, as well 
as vessel diameter. For example, isolated conduit arteries were incubated in vitro with SiNPs 
of variable size (100 nm or 200 nm) and charge (positive and neutral). In response to 
cumulative doses of acetylcholine (ACh; 0.01 µM - 1.0 mM) and sodium nitroprusside 
(SNP; 0.01 -10 µM), endothelial-dependent and -independent responses were assessed prior 
to and following 30-minutes incubation with SiNPs (1 x 1011 NPs/ml), respectively. SiNPs 
had no significant impact on dilator responses, however, positively charged SiNPs resulted 
in greater attenuation compared to non-modified, suggesting the effects of surface 
modification may be more pronounced in comparison to size (Akbar et al., 2011). 
Subsequent studies built upon these findings, demonstrating that attenuation was more 
specifically related to surface area rather than size, as well as dye-encapsulation (Farooq et 
al., 2014a). A study on the influence of SiNP dosage (1.01 x 1011 and 5.32 × 1011 NPs/ml)  
on small mesenteric arterial function, both ex vivo and in vivo demonstrated that exposure to 
5.32 × 1011 NPs/ml ex vivo, under static conditions, attenuated endothelial-dependent ACh 
dilator responses (ACh, 10-13-10-3 M); whereas lower SiNP dosages (1.01 × 1011 NPs/ml) 
had no effect (Shukur et al., 2016). The endothelial-independent (SNP) vasodilator responses 
were unaffected by incubation in SiNPs, suggesting impairment was localised to the 
endothelial cells and not vascular smooth muscle cells (VSMC). In contrast, when 
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administered in vivo, SiNPs only had a detrimental effect on endothelial-dependent (ACh) 
dilator responses at lower concentrations. Furthermore, inhibition studies demonstrated the 
attenuated dilator responses observed following SiNPs exposure to be related to alterations 
in the production and/or release of endothelial-derived relaxing factors. This study will 
investigate the potential to reduce SiNP-mediated oxidative stress using the antioxidant 
mimetic, cerium oxide.  
 
1.2.1.2 Cerium oxide  
 
Cerium oxide (CeO2) is a rare-earth element belonging to the lanthanide series of the periodic 
table. One of CeO2’s most notable qualities is its ability to exist in both trivalent (Ce3+) or 
tetravalent (Ce4+) oxidation states, in comparison to that of its lanthanide counterparts which 
exist primarily in a trivalent state. Progressive advancements within material science have 
stimulated research into their potential use as therapeutic agents, owing to their antioxidant-
mimetic activity. CeO2 nanoparticles (CeNPs) have demonstrated their capacity to actively 
scavenge a range of ROS both in vitro and in vivo, owing to the active redox cycling between 
Ce3+ and Ce4+ ions on the nanoparticle surface (Hirst et al., 2013; Fiorani et al., 2015; Kwon 
et al., 2016; El Shaer et al., 2017). The ratio of Ce3+ / Ce4+ sites on the nanoparticle surface 
is strongly associated with antioxidant activity; with initial studies having identified the 
ability to catalyse the dismutation of superoxide (O2•-) into hydrogen peroxide 
(H2O2)(Korsvik et al., 2007). Subsequent studies investigated these mechanisms, 
demonstrating that CeNPs synthesised with a higher ratio of Ce3+ displayed heightened 
SOD-mimetic efficiency (Heckert et al., 2008); whilst counterparts fabricated with higher 
Ce4+ displayed catalase (CAT)-mimetic activity in the presence of H2O2 (Rzigalinski et al., 
2006). Collectively, both studies demonstrate the importance of the nanoparticle surface on 
the regulation of catalytic activity, whether as a predominant SOD- or CAT-mimetic. These 
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properties are highly dependent on the mode of synthesis, purity of reagents and method of 
surface functionalisation.  
Several groups have examined the effects of CeNPs on cell viability and vascular reactivity. 
Gojova et al. discovered that CeO2 was largely non-toxic in human aortic endothelial cells 
following 4-hours exposure, resulting in significantly less inflammation in comparison to 
materials such as zinc oxide or yttrium oxide, even at the highest dosages (Gojova et al., 
2009). They have also been shown to improve vascular dysfunction in hypertensive rats via 
the reduction of ROS (Minarchick et al., 2015), apoptosis (Chen et al., 2014), and promotion 
of angiogenesis through the modulation of oxygen within intracellular environments (Das et 
al., 2012). Vascular function studies within the Azzawi group have demonstrated that the 
use of CeNP conjugated SiNPs resulted in partially restored vasodilatory function in murine 
aortic vessels ex vivo (Farooq, 2014), suggesting CeO2 has a capacity to be used as a 
therapeutic tool for the treatment of ROS associated diseases. These studies highlight the 
need for improved biocompatibility of SiNPs and potential of CeO2 as a means of attenuating 
ROS-mediated toxicity; however, further assessment into their safety is essential prior to 
clinical application. This study will investigate whether CeO2 modification of SiNPs can 
improve their biocompatibility using isolated human coronary artery endothelial cells 
(HCAECs), offering a potential mechanism for antioxidant delivery. 
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1.2.2 Organic Nanoparticles  
 
1.2.2.1 Liposomes 
 
Lipidic delivery systems have gained popularity due to their improved biocompatibility 
when compared with inorganic nanoparticles such as silica; furthermore, they possess the 
ability to cross challenging physiological barriers (e.g. the blood-brain barrier). They can be 
categorised according to their mode of synthesis and physicochemical characteristics; one 
of the most heavily investigated of these is liposomes. Liposomes are spherical vesicles 
composed of a phospholipid bilayer made of cholesterol, other natural lipids and an aqueous 
core (Pattni et al., 2015). To date, several liposome formulations have received clinical 
approval and are used for pain management (e.g. DepoDur®), cancer treatment (e.g. Doxil®), 
and vaccine delivery (e.g. Inflexal®)(Li et al., 2019); however, none are currently available 
for the treatment of CVD. Whilst useful, liposomes are limited in their potential applications 
because of short shelf-life, poor stability and low encapsulation efficiency; stimulating 
research into the generation of more reliable, robust delivery modalities.  
 
1.2.2.2 Nanolipid carriers 
 
Nanostructured lipid carriers (NLCs) are an emerging drug delivery platform developed to 
overcome the limitations affiliated with previous-generation counterparts (such as 
liposomes). In contrast to liposomal delivery systems, NLCs can be administered 
intravenously or orally, increasing patient stratification and improving outcome. However, 
the most notable improvement associated with NLCs is their improved drug loading 
capacity, primarily attributed to their mode of fabrication. NLCs have been shown to 
increase the bioavailability of poorly soluble antihypertensive drugs (Cirri et al., 2018; Khan 
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et al., 2018) and vasoprotective nutraceutical products (Magyar et al., 2012; Theodotou et 
al., 2017), protecting contents from rapid metabolism, whilst also allowing fine manipulation 
of release kinetics (Burns et al., 2002; Teskac and Kristl, 2010; Neves et al., 2013). The 
development of site-specific delivery systems that have the potential to preserve drug 
stability whilst enhancing bioavailability is an attractive option (Shah et al., 2016).  
NLC fabrication involves the use of a mixture of liquid and solid lipid, resulting in the 
formation of partially crystallised lipid matrix dispersed within an aqueous phase containing 
emulsifiers, enhancing drug loading (within matrix imperfections) and reduced leaching of 
the drug during storage (Khosa et al., 2018). It is well documented that the specific type, 
concentrations and ratios of lipids, oils and emulsifiers used during fabrication are essential 
in determining the degradation and release behaviour of NLCs (Khosa et al., 2018). The 
release profile of NLCs is typically biphasic, characterised by an initial burst release due to 
the rapid diffusion of contents within the liquid phase of the NLC, and the comparatively 
slower release of contents from the solid lipid core. The unique chemical structure of 
individual lipids, such as that of the triglyceride triolein, have demonstrated the potential to 
disrupt the packing of trimyristin crystals, altering the release kinetics of NLCs (Yang et al., 
2014). For the first time, this project will assess the use of novel trimyristin (solid lipid) 
based NLCs stabilised with the triglyceride, triolein (liquid lipid) for improved stability, 
encapsulation efficiency and sustained delivery of antioxidant compounds for the treatment 
of CVD. 
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1.3 Hypertension – A clinical perspective and unmet need for innovative treatment 
strategies 
 
Hypertension is a significant contributor to CVD, characterised by a persistent elevation of 
arterial blood pressure, and is the most prevalent risk factor associated with cardiovascular 
morbidity and mortality. Due to global acculturation to the western lifestyle, the incidence 
of hypertension has increased exponentially since 1990, accounting for 14% of total deaths 
(Forouzanfar et al., 2017). Despite extensive study, the multifactorial nature of hypertension 
makes its pathophysiology unclear; however, much attention has been focused on the 
vascular endothelium, which has been shown to be aberrantly regulated in hypertension in 
the presence of oxidative stress (Massaro et al., 2019). The vascular endothelium is integral 
in the maintenance of vascular health, regulating a multitude of processes, including vascular 
tone. Although it is unknown if dysfunction of the vascular endothelium is the cause or 
consequence of hypertension, it is evident that there is a growing need for treatment 
strategies that target the direct cause of the disease or help manage its associated symptoms. 
Antioxidants are an attractive therapeutic strategy; however, many suffer from low 
bioavailability and poor stability. This thesis will investigate the use of nanoparticles for the 
improved delivery and release of drugs for the treatment of hypertension associated 
endothelial dysfunction. Hypertension associated endothelial dysfunction will be discussed 
in further detail in this chapter; hence, an overview of the mechanisms regulating vessel 
diameter will first be provided below. 
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1.3.1 Regulation of vessel diameter 
 
The vascular endothelium is a highly differentiated monolayer of simple squamous 
epithelium which plays an integral role in regulating a multitude of critical processes 
including vascular permeability, immune responses, coagulation/anticoagulation cascades 
and vascular tone (Krüger-Genge et al., 2019). The regulatory function of the endothelium 
is heavily reliant on its ability to detect ions, agonists and physical forces, as well as its 
interactions with the surrounding VSMC layer; which is critical in providing structural 
integrity to the blood vessel wall and maintaining vascular tone, through dynamic 
modulation of constriction and dilation, in response to mechanical and vasoactive stimuli 
(external or endothelial-derived). Arteries release a range of dilators via three major 
pathways, including; nitric oxide (NO); prostaglandin (PGI); and endothelial-derived 
hyperpolarising factor (EDHF) -dependent pathways, the distribution of which are vascular 
bed and size-specific. These are briefly described below. 
 
1.3.1.1 Nitric oxide 
 
 
Nitric oxide (NO) was the first gaseous molecule discovered that was produced by the 
endothelium and led to the relaxation of VSMCs (Furchgott and Zawadzki, 1980). The 
production and release of NO from the endothelium are mediated by NO synthases (NOS), 
including endothelial NOS (eNOS), promoting the conversion of L-arginine into 
stoichiometric L-citrulline (Tejero et al., 2019). NO diffuses out of the endothelial cells into 
surrounding VSMCs, stimulating the activation of Protein Kinase G (PKG); promoting ion 
channel activation (e.g. large-conductance Ca2+ activated K+ channels (BKCa)), Ca2+ 
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reduction (e.g. sarcoplasmic reticulum mediated sequestration, plasma membrane extrusion) 
and activation of the myosin light-chain phosphatase apparatus. 
1.3.1.2 Prostacyclin  
 
Prostacyclin (PGI2) is a cyclooxygenase (COX) derived metabolite, produced within 
endothelial cells in response to mechanical, endogenous and pharmacological agonist 
stimulation. The production of PGI2 is heavily reliant on the release of arachidonic acid (AA) 
from phospholipids by the enzyme phospholipase A2 (PLA2); the activity of which is 
determined by intracellular calcium concentrations. Following its release, AA is converted 
into a range of prostanoid mediators (such as PGI2) by COX-1 and COX-2 enzymes. PGI2 is 
a lipid-soluble compound capable of traversing cellular membranes, readily diffusing out of 
endothelial cells and binding to prostacyclin receptors (IP) on the VSMC surface. The 
activation of IP receptors results in vasorelaxation by activating adenylate cyclase (AC), 
which leads to the production of cyclic adenosine monophosphate (cAMP). Elevated cAMP 
leads to the activation of protein kinase A (PKA), which subsequently phosphorylates 
myosin light chain kinase; reducing constriction and promoting dilation (Mitchell and 
Kirkby, 2019).  
 
1.3.1.3 Endothelial hyperpolarisation  
 
 
Endothelial hyperpolarisation is a consequence of potassium (K+) efflux, with several 
mechanisms known to exist that can induce endothelial and VSMC hyperpolarisation. The 
process involves the activation of endothelial K+ channels; the small (SKCa) and intermediate 
(IKCa) conductance Ca2+-sensitive K+ channels. The electrical coupling of cells within the 
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endothelial and VSMC layer promotes the propagation and subsequent hyperpolarisation 
and closing of voltage-gated K+ channels in VSMCs. Alternatively, K+ efflux may result in 
the activation of sodium/potassium channels (Na+/K+). Endothelium-derived 
hyperpolarizing factor (EDHF) is the third class of endothelial-derived vasodilator identified 
since the initial observations of researchers in the 1980s, demonstrating that an endothelial-
derived substance was capable of inducing VSMC hyperpolarisation in NOS and COX-
independent experimental models, elegantly reviewed elsewhere (Goto and Kitazono, 2019). 
Several substances have been found to induce VSMC hyperpolarisation directly and are 
hence called EDHFs, including; epoxyeicosatrienoic acids (EETs), potassium ions (K+) and 
H2O2 (Ellinsworth et al., 2016). Epoxyeicosatrienoic acids (EETs) are metabolically derived 
products of cytochrome P450 epoxygenases (CYP450) and arachidonic acid (AA) (Imig, 
2016). Following their synthesis, EETs traverse the extracellular compartment, leading to 
VSMC hyperpolarisation and relaxation via the activation of large-conductance BKCa+ 
channels (Yang et al., 2015). H2O2 is a metabolic by-product of cellular metabolism in 
aerobic organisms, primarily produced through the dismutation of O2•- by the enzyme 
superoxide dismutase (SOD). Despite the reputation of H2O2 as a cell-damaging oxidative 
agent, recent studies have suggested H2O2 plays an integral role in cell signalling and K+ 
release. Whereas ROS such as O2•- have previously demonstrated an ability to attenuate 
endothelium-dependent relaxation, H2O2 has been found to promote endothelium-dependent 
as well as independent responses, mediating hyperpolarisation via the activation of 
endothelial K+ channels; however, there is considerable species-specific variation in the type 
of K+ channels activated (Shimokawa, 2010) (Figure 1.2). 
It is clear that the types of mediators elaborated during endothelium-dependent relaxation 
vary according to the particular vascular bed as well as vessel size. Experimental studies 
suggest that the role of endothelial-derived hyperpolarisation (EDH) increases as the vessel 
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size decreases, whereby EDHF activity predominates in resistance vessels, often 
compensating for any reduced NO availability. The respective contribution of these 
pathways in mediating endothelial-dependent dilator responses in an ex vivo model of 
hypertension will be assessed, using pressure myography.  
 
Figure 1.2. Mechanisms for endothelial cell mediated relaxation. Activation of agonist-
sensitive (ACh) or mechanosensitive (shear stress) receptors leads to elevated intracellular 
Ca2+, resulting in the activation of NO-, PGI- and EDHF-dilator pathways. Endothelial 
nitric oxide synthase (eNOS); nitric oxide (NO); prostacyclin I2 (PGI2); arachidonic acid 
(AA); cytochrome P450 (CYP450); epoxyeicosatrienoic acid (EET); oxygen (O2); 
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superoxide (O2•-); hydrogen peroxide (H2O2); soluble guanylate cyclase (sGC); cyclic 
guanosine monophosphate (cGMP); prostacyclin receptor (IP); adenylate cyclase (AC); 
cyclic adenosine monophosphate (cAMP); calcium (Ca2+); calcium activated potassium 
channel (KCa+); phospholipase A2 (PLA2); cyclooxygenase 1 & 2 (COX-1 & COX-2); 
receptor (R); mechanoreceptor (MR). Adapted from (Ozkor and Quyyumi, 2011).  
 
1.3.2 Mechanism of impaired dilation in hypertension 
 
1.3.2.1 Endothelial dysfunction  
 
Endothelial dysfunction is a pathological condition of the vascular endothelium, associated 
with elevated oxidative stress and modulation of pathways important for the control 
of systemic vascular resistance, including NO (Hamilton et al., 2001; Hendre et al., 2013). 
Decreased bioavailability of NO has been observed in several experimental models of 
hypertension, resulting in elevated vascular resistance and blunting of vasodilator responses 
to endothelium-dependent vasodilator agonists (Watt and Thurston, 1989; Linder et al., 
1990; Deng et al., 1995; Adler and Huang, 2002; Paulis et al., 2008). Studies have also shown 
that endothelial-independent dilator responses caused by dilators such as nitro-glycerine 
remained unchanged, suggesting the aberrant function was related to the endothelium and 
not the VSMCs. Studies have recapitulated these findings, demonstrating the importance of 
NO in the resistance vasculature, with inhibitors of eNOS or NO attenuating dilation and 
promoting constriction (Hsieh et al., 2004); restorable following NO donor administration 
(Torok and Kristek, 2002). The reduced bioavailability of NO in endothelial dysfunction is 
concurrently associated with elevated ROS production; chemically reactive compounds with 
oxidative capacity, damaging proteins, carbohydrates, lipids and DNA. ROS are known to 
scavenge NO, reducing its bioavailability within endothelial cells. Furthermore, studies have 
demonstrated the ability of ROS by-products (e.g. peroxynitrite) to inhibit PGI2 synthase via 
tyrosine nitration (Zou, 2007), as well as inactivate EDH receptors (Brzezinska et al., 2000; 
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Yanping et al., 2002). The resulting imbalance of these critical mediators leads to an 
impairment of endothelium-dependent vasodilatory responses (Craige, 2015).  
 
1.3.2.2 Reactive oxygen species 
 
Multiple endogenous examples of ROS exist in mammalian biology, including, O2•- and 
hydroxyl radical (•OH). Although not strictly considered free radicals, H2O2 and 
peroxynitrite (ONOO-) obtain a similar classification due to their wide-spanning oxidative 
effects. Several sources of ROS production have been identified, though three have been 
studied extensively within the cardiovascular system; xanthine oxidase; NADH/NAD(P)H 
oxidase; and NO synthase. Studies have suggested that NADH/NADPH oxidases are the key 
enzyme complex and predominant source of O2•- (Lennicke et al., 2015; Panday et al., 2015). 
eNOS is a CYP450 enzyme responsible for the catalysation of flavin mediated electron 
transport from NADH donor molecules. In order to promote the active production of NO, 
eNOS requires the binding cofactor tetrahydrobiopterin (BH4), or sapropterin as it is 
otherwise known, and is thought to interact with L-arginine, synthesising NO (Bendall et al., 
2013). The oxidative depletion of this essential cofactor has been shown to shift eNOS from 
a dimeric to a monomeric form, becoming uncoupled; this process referred to as eNOS 
uncoupling and is associated with the formation of O2•-, H2O2 and secondary by-products 
such as ONOO-; propagating a self-perpetuating cycle of free radical formation. The 
significance of BH4 and its contribution to eNOS uncoupling has been demonstrated on 
several occasions, whereby BH4 supplementation lowered systemic blood pressure and 
restored attenuated endothelial-dependent dilator responses in models of hypertension 
(Khoo et al., 2005; Porkert et al., 2008; Francis et al., 2018).  
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In addition to impaired dilator bioavailability, the production of ROS can facilitate and 
exacerbate the appearance of conditions associated with cardiovascular complications (e.g. 
atherosclerosis); including the generation of oxidised low-density lipoprotein and the 
activation of immunoregulatory transcription factors (Rhoads and Major, 2018). Several 
endogenous defence mechanisms have evolved to afford protection and mitigate oxidative 
damage in tissues, the most notable being SOD and CAT. SOD is a biological enzyme found 
within the cytoplasmic compartment and mitochondria and is one of the body’s primary 
defence mechanisms, eliminating O2•- through a two-step dismutation reaction, producing 
H2O2 and O2 (Fukai and Fukai, 2011). Through comparable mechanisms, CAT converts 
H2O2 into chemically inert H2O and O2. In addition to endogenous sources of ROS, several 
exogenous sources of ROS are implicated in the generation of oxidative stress; including, 
smoke, pollutants, radiation and drugs (Prasad et al., 2017). In the vasculature, oxidative 
stress has demonstrated its ability to interfere with endothelial derived relaxing factor 
(EDRF) signalling in a range of models and vascular beds, resulting in attenuated dilator 
responses (Salheen et al., 2015; Zaabalawi et al., 2019). Small size arteries, such as those 
found within the coronary and cerebral vasculature, play a vital role in the regulation of 
peripheral resistance; however, due to their elevated metabolic demand, they are highly 
susceptible to oxidative injury. As such, these vascular beds will be the primary focus for 
the duration of this investigation. 
1.3.2.3 Coronary artery dilation 
 
The coronary arteries play a pivotal role in providing a continuous supply of oxygen and 
nutrients to the metabolically active myocardium of the heart. The maintenance of normal 
vascular function is integral to health since a disruption may precede the development of 
conditions such as atherosclerosis or present as clinical manifestations such as myocardial 
ischemia (Biswas and Khan, 2019). Multiple studies have attempted to clarify the 
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mechanistic regulation of dilation in the coronary arteries in order to combat disease; 
however, limited studies have focused on characterising the underlying dilator component 
since the turn of the century. In the healthy coronary endothelium, NO is believed to be the 
dominant vasodilator; with inhibition increasing basal coronary vascular resistance and 
blunting vasodilator responses to endothelium-dependent vasodilator agonists (Beverelli et 
al., 1997).  
Furthermore, incubation with COX inhibitors have demonstrated an ability to significantly 
impair endothelial-dependent dilation, indicating that a portion of dilator component is 
mediated by endogenous prostanoids (Hiroto and Gutterman, 1998); however, the effects of 
endogenous prostanoids have been found to decrease with age both in pigs and humans, 
which may reflect an age-dependent role in coronary arterial control of tone (Willis and 
Leffler, 1999; Beyer et al., 2017). In addition to NO- and PGI-mediated responses, the 
coronary endothelium is known to produce factors resulting in EDH, with inhibition 
resulting in attenuated dilation (Hiroto et al., 1999; Toyotaka et al., 2003). However, as 
discussed previously, EDRF release is known to be not only species-dependent but also 
tissue bed and vessel size-dependent also. In the dog coronary artery, responsiveness to 
different relaxing factors was found to differ between proximal and distal parts of the vessel;  
suggesting that ACh-induced dilation in large coronary arterioles is predominantly mediated 
by NO, whereas both NO and EDHF mediate dilation in small arterioles (Nagao et al., 1992; 
Nishikawa et al., 1999). There is evidence to suggest that under physiological conditions, 
the production of EDHF is dampened by NO via feedback inhibition. Impaired NO synthesis 
may thus, at least in part, maintain endothelial vasodilator function (Bauersachs et al., 1996). 
However, whilst studies state the vessel (e.g. coronary), a significant quantity fail to specify 
the precise size or location from which the vessel was taken, producing difficulty in applying 
findings in the appropriate experimental context. Thus, there are complex anatomical, 
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biochemical, and functional interrelationships between NO and EDHF that are still 
incompletely defined.  
1.3.2.4 Cerebral artery dilation 
 
The cerebral arteries are responsible for regulating the perfusion of blood into the cerebrum 
of the brain; stimulating significant interest in assessing normal function and how this may 
be implicated in disease (e.g. hypertension, vascular dementia). Whilst the distribution of 
EDRFs within the cerebral vasculature share similarities with that of the coronary artery, i.e. 
the significance of NO and EDHF, with the size of vessels having a direct effect on dilator 
component; the cerebrovascular circulation also has distinct variations (Davis et al., 2011). 
For example, in porcine coronary arteries, abolishment of EDHF–mediated responses 
require the simultaneous inhibition of both SKCa and IKCa (Burnham et al., 2002; Bychkov 
et al., 2002); whereas inhibition of endothelial cell IKCa channels alone is sufficient to block 
EDHF-mediated relaxation and hyperpolarisation in rat middle cerebral arteries (MCAs) in 
the absence of NO (Alister et al., 2006). There is evidence to suggest that NO is capable of 
dampening EDHF-mediated responses; however, this is not the case in the MCAs, 
suggesting that it is also important in the uninjured state in the presence of NO (Schildmeyer 
and Bryan, 2002). Whilst the differential receptivity to EDRF signalling between vascular 
beds has briefly been discussed, metabolic and anatomical variations are likely to contribute 
to vascular regulation and treatment efficacy; it was, therefore, of interest to establish 
whether an ex vivo model of hypertension, discussed below, could be used to assess dilator 
function in cerebral vessels too. 
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1.4 Models of acute hypertension 
 
In several forms of hypertension, elevated arterial O2•- generation is considered a key 
contributor to the pathogenesis of endothelial dysfunction, leading to decreased 
bioavailability of NO and the promotion and activation of pathways regulating vascular 
smooth muscle contraction, contributing to maintenance elevated vascular resistance (Koller 
and Huang, 1994; Cardillo et al., 1998; Beswick et al., 2001). However, the underlying 
mechanisms of O2•- generation in hypertension are not entirely understood. Despite diverse 
and multifactorial underpinnings, oxidative stress appears to be present in all forms of 
hypertension, including genetic-, renovascular-, and angiotensin II-induced hypertension, to 
name a few (Higashi et al., 2002; Mollnau et al., 2002). Some of the first convincing 
evidence implicating ROS in the pathogenesis of hypertension was conducted by Wei and 
colleagues in 1985, using a pharmacologically induced model of hypertension. Following 
the intravenous administration of norepinephrine to feline cerebral arteries, a significant 
increase in O2•- generation was observed in the extravascular cranial space, which was 
maintained for at least an hour after hypertension subsided. The concurrent impairment of 
ACh induced endothelial-dependent relaxation was restored following the administration of 
SOD and CAT, implicating O2•- and H2O2 in the attenuation of dilator responses (Wei et al., 
1985). Subsequently, De Bruyn and colleagues investigated the relationship between 
perfusion pressure and ROS generation in the canine coronary artery. Incremental increases 
in perfusion pressure promoted serotonin (5-HT) mediated constriction, which was restored 
following incubation with SOD, CAT, and deferoxamine (inhibitor of •OH generation); 
further implicating the role of O2•-, H2O2 and their downstream metabolic by-products in 
endothelial dysregulation (De Bruyn et al., 1994).  
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Because of the multifactorial nature and variable pathologies of hypertension, the use of in 
vivo studies, although more physiologically relevant, make experimental cause and effect 
difficult to ascertain. To clarify the fundamental mechanisms underpinning elevated O2- 
production, researchers investigated whether high pressure itself could lead to the production 
of oxidative stress in vitro in the absence of neurohumoral factors. Functional studies on 
femoral arteries of Wistar rats subjected to elevated pressure over 30-minutes showed 
impaired flow-mediated dilation, which was restored following incubation with SOD 
(Ungvari et al., 2003). These findings are consistent with previous studies, showing short 
bursts of increased pressure can impair endothelial function (Wei et al., 1985; De Bruyn et 
al., 1994; Huang et al., 1998; Vecchione et al., 2009). Incubation with apocynin, 
diphenyleneiodonium (an NADP(H) oxidase inhibitors) and staurosporine/chelerythrine 
(protein kinase C inhibitors) could prevent O2•- generation, suggesting elevated pressure 
leads to the production of O2•- by inducing PKC-dependent phosphorylation and activation 
of the NAD(P)H oxidase. Similar findings were found in a chronic hypertension model in 
vivo and in vitro, with the presence of humoral factors leading to enhanced PKC-dependent 
phosphorylation (Ungvari et al., 2004) (Figure 1.3). A summary of studies implicating ROS 
in the pathogenesis of hypertension can be found in Table 1. 
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Figure 1.3. Mechanisms of hypertension-induced oxidative stress. Under normal 
conditions, vasoactive agents such as Ang-II lead to the activation and release of AA from 
phospholipids. In the presence of elevated intravascular pressure, mechanoreceptor 
activation results in the activation of CYP1B1; converting AA into 20- and 12-HETE. HETEs 
induce the activation of PKC, producing O2- as a by-product which leads to the quenching 
of NO, impairing dilation and promoting constriction. Angiotensin-II (Ang-II); receptor (R); 
mechanoreceptor (MR); L-type calcium channel (L-Ca2+); phospholipase A2 (PLA2); 
arachidonic acid (AA); cytochrome P450 1B1 (CYP1B1); 20-,12- hydroxyeicosatetraenoic 
acid (20-, 12-HETE); protein kinase C (PKC); superoxide (O2•-); nitric oxide (NO). Author 
generated.  
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Table 1. Summary of studies utilising acute pressure elevation models. 
Author 
and Date 
In vivo/ex 
vivo 
Vascular 
Bed 
Aim of the 
Study 
The technique of 
Pressure 
Elevation/Protocol 
Results Physiological Response 
Wei et al., 
1985 
Anaesthetised 
cats in vivo 
 
Feline cerebral 
arteries 
Assess superoxide 
generation in the 
extracellular 
cerebral space after 
acute hypertension. 
Intravenous 
administration of 
norepinephrine (3-6 
μg/min) for 15-minutes. 
Elevated 
superoxide. 
 Elevated pressure significantly 
impaired ACh-induced 
endothelium-dependent 
vasodilation (P < 0.05).
 Protected by SOD and CAT. 
De Bruyn et 
al., 1994 
 
 
Anaesthetised 
dogs in vivo 
 
Canine 
coronary 
arteries 
Examine the role of 
perfusion pressure 
and ROS in response 
to acute 
hypertension. 
 
Increased perfusion 
pressure from 80 to 100, 
120,150 or 200 mmHg 
for 15-minutes.  
 
Intravenous infusion of 
Ang II (50-75 μg/min) 
for 5-minutes.
Elevated ROS, 
particularly 
hydroxyl 
radicals. 
 Increased perfusion pressure and 
Ang-II infusion significantly 
augmented constriction to 5-HT 
(P < 0.05). 
 Protected by SOD, CAT and 
deferoxamine (hydroxyl radical 
scavenger). 
Huang et 
al., 1998 
WKY rats ex 
vivo 
Gracilis muscle 
arterioles 
Examine the effects 
of high intravascular 
pressure on flow- 
and agonist-induced 
dilator responses. 
Elevated perfusion 
pressure from 80 to 140 
mmHg for 30-minutes, 
using pressure 
myography. 
Elevated 
superoxide.  
 Elevated intravascular pressure 
significantly impaired 
endothelium-dependent 
vasodilation (P < 0.05).
 Prevented by SOD and CAT, but 
not CAT alone.
Ungvari et 
al., 2003 
 
 
 
Wistar rats ex 
vivo 
Femoral artery Assess the influence 
of NADPH oxidase 
and PKC-dependent 
signalling pathways 
in acute 
hypertension. 
Elevated intraluminal 
pressure from 80 to 160 
mmHg for 30-minutes, 
using pressure 
myography. 
Elevated 
superoxide.  
 
 
 Elevated pressure significantly 
impaired endothelium-dependent 
dilation (P < 0.05).
 Protected by SOD, apocynin, 
diphenyleneiodonium, 
staurosporine and chelerythrine. 
Beyer et al., 
2014 
Human 
omentum ex 
vivo 
Omental 
arterioles 
To elucidate the 
mechanism of FMD 
following a transient 
increase in 
intraluminal 
pressure. 
Pressure myography. 
Elevated intraluminal 
pressure from 60 to 150 
mmHg for 30-minutes, 
using pressure 
myography. 
Elevated 
superoxide. 
 Transient pressure elevation 
induced FMD mediator change 
from NO to mitochondria derived 
H2O2, which acts as the principal 
dilator component.
 Significantly impaired NO-
mediated dilation (P < 0.05).
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1.5 Antioxidants for the treatment of cardiovascular disease  
 
 
It is well established that treatment of CVD significantly reduces the risk of morbidity and 
mortality. Currently, guidelines recommend that the initial treatment of CVD should start 
with lifestyle intervention (i.e. weight loss, smoking cessation, regular exercise, diet); 
however, in many cases, pharmacological therapy is necessary (Stewart et al., 2017). Whilst 
these treatment strategies have demonstrated their effectiveness in mitigating the effects of 
several CVDs (e.g. hypertension, atherosclerosis, diabetes), they do not appear to target the 
underlying cause.  Given the implications of oxidative stress in the pathophysiology of 
various cardiovascular disorders, as such, an external supply of antioxidants may circumvent 
its associated damage, offering an attractive treatment strategy (Jain et al., 2015).  
A variety of antioxidants, biologically or chemically derived, are available for the 
therapeutic management of CVD (Goszcz et al., 2015). In patients with coronary artery 
disease or hyperglycaemia-induced impairment of vasodilation, NO-mediated vasodilation 
is restored with either oral (6 g over 2 days) or intra-arterial infusion (24 mg/min for 10 min) 
of vitamin C (Levine et al., 1996; Beckman et al., 2001). Similarly, antioxidant studies 
investigating coronary artery risk development in young adults have found that high-plasma 
carotenoid concentrations are associated with reduced inflammation, oxidative stress, and 
endothelial dysfunction (Hozawa et al., 2007). Whilst promising, the deliverability of 
antioxidants is often limited by their poor physicochemical and pharmacokinetic properties, 
resulting in inadequate systemic bioavailability. Antioxidants obtained from dietary sources 
play an essential role in regulating oxidative stress via endogenous action or by their 
synergistic effects on host antioxidants, with several emerging as potential treatment 
candidates due to their prevalence and noted benefits in treating CVD in vitro and in vivo; 
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such as resveratrol and its synthetically methylated analogue trans-3,4,5,4′-
tetramethoxystilbene, which will be discussed in further detail, in this section.  
Previous work within our laboratory has investigated the effects of resveratrol (RV) ex vivo 
using aged mice as a model of endothelial dysfunction. Following intervention, it was found 
that RV (45 µM) enhanced ACh induced dilator responses in the femoral arteries of both 
young and aged mice after one hour, with inhibition studies attributing the enhanced dilator 
response to elevated NO production. This dilator response was maintained in an eNOS -/- 
mouse yet was completely abolished in the presence of potassium channel blockers; 
implicating RV in the stimulation of both NO and EDHF dilator pathways. Furthermore, 
using high performance liquid chromatography it was demonstrated that RV was rapidly 
degraded over the one-hour test period, observing an average loss of  27.3 ± 4.6 % (Diaz et 
al., 2019). Building upon this work, Diaz et al. went onto conduct a clinical trial investigating 
the effects of oral RV administration (300 mg, 3x day) on the dilator responses of older 
coronary artery disease patients over a three-day period. RV supplementation was found to 
significantly improve flow-mediated dilation in patients who had undergone coronary artery 
bypass surgery, highlighting the cardioprotective effects and clinical benefit (Diaz et al., 
2020). 
Enhancement strategies, such as the encapsulation of antioxidants within nanoparticles for 
enhanced targeted delivery, may overcome these limitations and will be investigated over 
the course of this study. 
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1.5.1 Resveratrol 
 
Resveratrol (trans-3,5,4′-trihydroxystilbene; RV) is a polyphenolic phytoalexin compound 
derived from a variety of plant species. RV is found in two geometric isomers, trans and cis. 
Although both exist concurrently, trans-RV is more biologically active and is primarily used 
in research applications. RV has been shown to enhance blood pressure reduction when 
combined with traditional anti-hypertensive therapy. This is attributed to its antioxidant and 
anti-inflammatory properties (Burns et al., 2002), including scavenging a range of ROS 
moieties (Leonard et al., 2003); upregulating the expression of several antioxidant enzymes 
(Sayin et al., 2012); and increasing NO production (Thomas et al., 2002), via activation of 
SIRT-1 (silent mating type information regulation 2 homolog 1 or sirtuin 1) (Arunachalam 
et al., 2010; Ma et al., 2017) (Figure 1.4). Sirtuins have been extensively studied and 
identified as playing an integral role in multiple pathways including; metabolism, cell 
survival, stress resistance, cell senescence, inflammation, and endothelial function. 
Whether RV is a direct agonist of SIRT-1 or is a consequence of other signalling 
mechanisms, is unclear.  
The involvement of AMPK (adenosine monophosphate-activated protein kinase) as an 
alternate target has also been proposed, possibly via the inhibition of mitochondrial ATP 
synthesis (Lan et al., 2008). AMPK mediated signalling promotes an increase in the 
production of nicotinamide adenine dinucleotide (NAD+), which has the capacity to 
indirectly activate SIRT-1. Supporting evidence for this can been observed in AMPK 
deficient mice, which are resistant to the beneficial metabolic effects conferred by RV. 
Conversely, other studies have demonstrated the SIRT-1 mediated activation of AMPK via 
liver kinase B1 (LKB1) (Lan et al., 2008). It is evident that the interactions between SIRT-
1 and AMPK play an important role in potentiating the beneficial effects of RV.  
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Figure 1.4. Mechanisms influencing nitric oxide generation by resveratrol. Prolonged 
exposure to RV has been associated with the upregulation of eNOS and subsequent 
production of NO, as well as the upregulation of antioxidant enzymes such as SOD. Acute 
exposure likely results in phosphorylation and acetylation of eNOS by SIRT-1 and AMPK, 
leading to enhanced activity. Endothelial nitric oxide synthase (eNOS); nitric oxide (NO); 
superoxide dismutase (SOD); silent mating type information regulation 2 homolog) 1 (SIRT-
1); adenosine monophosphate-activated protein kinase (AMPK). Author generated. 
 
Our laboratory has recently demonstrated that RV can potentiate endothelial-dependent 
dilator responses in aortic vessels and femoral arteries from young and aged mice (Diaz et 
al., 2019). In human studies, data from the Azzawi lab has shown that RV improves flow-
mediated dilation (FMD) in CVD patients after coronary artery bypass graft surgery (Diaz 
et al., 2020); improves ventricular systolic and diastolic function, and decreases cholesterol 
levels after myocardial infarction. However, other studies have reported inconclusive or 
contradictory findings, which may be due to insufficient RV bioavailability in vivo, 
particularly following oral administration, with <1 % available globally (Cottart et al., 2010; 
Chachay et al., 2014; van der Made et al., 2015; Zortea et al., 2016). Despite RV’s good 
absorption profile (75% uptake), the resulting low plasma concentration leads to inadequate 
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systemic distribution and limited exposure to specific activation sites, resulting in 
insufficient pharmacological effects.  This lack of bioavailability is widely considered to be 
a result of RV’s metabolic instability, resulting from multiple rapid glucordination and 
sulfation reactions during phase I and II metabolism (de Santi et al., 2000). Because of its 
low bioavailability and poor stability, it is evident that different modes of RV administration 
are required. In this study, the effectiveness of nanoparticle encapsulated RV will be 
investigated, and the underlying mechanism of action within vascular tissue characterised. 
In addition, the effectiveness of the synthetically modified analogue, trans-3,4,5,4′-
tetramethoxystilbene will be investigated.  
 
1.5.2 Trans-3,4,5,4′-tetramethoxystilbene (3,4,5,4′-TMS) 
 
 
Due to the limitations conferred by RV, many studies have focused on the development and 
synthesis of novel RV derivatives with enhanced bioavailability and pharmacological 
activity (Nawaz et al., 2017). Trans-3,4,5,4′-tetramethoxystilbene (3,4,5,4′-TMS), a 
methylated analogue of RV has demonstrated promising metabolic stability and 
bioavailability (Figure 1.5). Whilst RV undergoes metabolisation into to sulphate or 
glucuronate conjugates, TMS undergoes demethylation; leaving bioactive phenolic groups 
intact, providing a compelling rationale for investigating its use as a therapeutic treatment 
strategy in conditions whereby RV might be useful. Similar to RV, TMS has demonstrated 
cardioprotective properties. In hypertension, TMS has demonstrated increased potency 
compared to RV (1000-fold) and has been shown to reduce oxidative stress via direct 
inhibition of the CYP450 pathway, improving endothelial function and vascular reactivity 
(Jennings et al., 2014). Furthermore, TMS has been shown to reduce vascular reactivity to 
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vasoconstrictor agents such as phenylephrine and endothelin-1, as well by DOCA-salt and 
angiotensin-II infusion via modulation of CYP1B1 activity (Jennings et al., 2010, 2014; 
Sahan-Firat et al., 2010). Whilst intravenous administration of TMS in murine models has 
demonstrated improved bioavailability in comparison to RV, its total availability remains 
low (Sale et al., 2004; Lin et al., 2010, 2011). The Azzawi lab has previously demonstrated 
that TMS-loaded liposomes can restore attenuated endothelial-dependent dilator responses 
induced by an oxidative stress by reducing NADPH-oxidase-derived ROS and potentiating 
the release of the vasodilator NO (Zaabalawi et al., 2019); as such, this study will assess the 
potential of encapsulated TMS-liposomes in restoring dilator function in the cerebral 
vasculature after acute pressure elevation.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Molecular structure of trans-3,4,5,4′-tetramethoxystilbene (TMS). TMS is a 
synthetic analogue of RV, with hydroxyl groups (OH) substituted for synthetically 
conjugated methyl groups (H3CO).  
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1.6 Aims & Objectives 
 
Hypothesis: The hypothesis of the present investigation is that nanoparticles will improve 
the delivery and release of RV and analogues (compared to their unencapsulated form) for 
the alleviation of ROS mediated endothelial dysfunction in hypertension.  
Overall aim: To develop a potential therapeutic tool for the treatment of CVDs associated 
with elevated ROS, including hypertension. This will be achieved in the following specific 
objectives: 
1. Synthesise and characterise nanoparticles for use in drug delivery. 
1.1. Synthesise and characterise inorganic (silica) nanoparticles and determine their 
effect on endothelial cell viability, in vitro (Chapter 3). 
1.2. Characterise organic lipid nanoparticles and define their antioxidant capacity 
and effect on endothelial cell viability in vitro (Chapter 4). 
 
2. Establish alterations in vascular function in coronary and cerebral arteries following 
acute pressure elevation using an ex vivo model of acute hypertension, via pressure 
myography (Chapter 5). 
 
3. Determine the influence of RV (and analogues)-loaded nanoparticles on the 
restoration of dilator function, using the ex vivo model of acute hypertension. 
3.1. Determine whether RV-NLCs have the capacity to restore attenuated dilation 
following acute pressure elevation in the coronary artery (Chapter 6). 
3.2. Determine whether RV-NLCs and TMS-liposomes have the capacity to restore 
attenuated dilation following acute pressure elevation in the cerebral artery 
(Chapter 7). 
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2 Chapter 2: Methodology 
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2.1 Nanoparticle synthesis 
 
2.1.1 Silica nanoparticle synthesis 
 
Dye-encapsulated SiNPs were synthesised using the Stöber sol-gel method, as previously 
described (Stöber et al., 1968). Briefly, ethanol (EtOH; 103.9 ml; 17.1 M), methanol 
(MeOH; 103.9 ml; 24.8 M), ammonium hydroxide (NH4OH; 22 ml; 1 M) and water (H2O; 
10.7 ml) were placed in a round-bottomed flask, heated to 55 oC and stirred for 1-hour. In 
order to initiate the hydrolysis and polycondensation reactions that would ultimately form 
the SiO2 colloid, tetraethyl orthosilicate (TEOS; 9.5 ml; 4.7 M) was added dropwise over a 
15-minute period. Next, entrapment of the fluorescein isothiocyanate (FITC; F2502, Sigma) 
dye was performed by adding 1 ml of the dye mixture [FITC powder (16.5 mg), anhydrous 
EtOH (6 ml; 17.1 M) and 3-aminopropyltrimethoxysilane (APTES; 36 µl; 5.46 M) stirred 
overnight under a nitrogen atmosphere] into the solution. The solution was stirred for a 
further hour and sub-divided into batches prior to further modification. Of the 250 ml stock 
produced, 50 ml was set aside and retained as blanks; another 50 ml was functionalised with 
an amine phosphonate (5 ml) solution [APTES (25 µl; 4.47 M), 3-(trihydroxysilyl) propyl 
methyl-phosphonate (25 µl; 2.09 M), anhydrous EtOH (10 ml; 17.1 M)]. The remaining 150 
ml was functionalised with a 3-mercaptopropyltriethoxysilane (MPTES; 1 ml) linker 
solution [MPTES (50 µl; 4.83 M), MeOH (100 ml; 3.70 M)]. The solutions were 
subsequently placed on a magnetic hot plate and attached to a condenser to minimise solvent 
evaporation. The solutions were heated to 80 oC, stirred for 1-hour and cooled to room 
temperature (22 oC).  
The resulting mercapto-functionalised solution was divided into two batches. One batch (75 
ml) was functionalised with a 40 µM poly(ethylene glycol) methyl ether (mPEG; 1 ml) 
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solution [mPEG (10 mg), H2O (50 ml)]. The remaining 75 ml was functionalized with mPEG 
(1 ml) and a CeNP suspension (5 ml; see 2.1.2). The reaction solutions were centrifuged at 
4,500 g for 10-minutes (x 3) in order to remove contaminants. SiNPs were re-dispersed in 
absolute EtOH (17.1 M), vortexed and sonicated at each stage. The supernatant was 
discarded and the SiNP sediment was re-dispersed in distilled water (H2O), physiological 
salt solution (PSS) or endothelial cell culture medium (MV2) prior to characterisation. Three 
batches of SiNPs were produced and subsequently functionalised over the course of these 
studies. Further information regarding the underlying chemistry of the Stöber sol-gel method 
may be found in Appendix 10.1.  
 
2.1.2 Cerium oxide nanoparticle synthesis 
 
Briefly, a 200 mM cerium(III) nitrate hexahydrate (Ce(NO3)3 6H2O) solution was made by 
dissolving Ce(NO3)3 6H2O (4.34 g) in distilled H2O (50 ml). The solution was stirred and 
heated to 70 oC, before the gradual addition of NH4OH (5 ml; 1 M) over 5-minutes. The 
solution was subsequently stirred at 100 rpm for 20-hours. A progressive colour change from 
light purple to yellow was observed, indicating the solution had become oxidized (Ce3+). 
Three batches of CeNPs were produced over the course of these studies. 
 
2.1.3 Nanostructured lipid carrier synthesis 
 
Blank (non-loaded) NLCs, RV and RV-dye-loaded NLCs were prepared using hot melt 
emulsification technique by probe sonication. Water phase containing surfactants, sodium 
cholate (0.25 g/100 ml) and Tween-80 (1 g/ 100 ml) was heated to 70 ºC, prior to 
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amalgamation with melted lipid phase comprising of trimyristin (1.5 g/100 ml), triolein (0.5 
g/ 100 ml), phosphatidylcholines (0.5 g /100 ml) and RV (1 mg/ml). The dispersion was 
mixed under magnetic stirring for 5-minutes. The pre-emulsion was sonicated using a probe 
sonicator (Fisherbrand™ Q700) for 15-minutes. The resulting emulsion was allowed to cool 
down at ambient temperature overnight to form the NLCs. For the dye-loaded RV-NLCs, 
coumarin-6 dye (15 µg/ ml) was dissolved in the lipid phase with RV, allowing entrapment 
within the NLCs. The RV-NLC dispersion was centrifuged at 1,200 g for 5-minutes at 25 
°C, in order to remove the residual titanium produced during probe sonication. RV-NLCs 
were filtered through a 0.22 µM membrane and diluted as appropriate prior to use. Three 
batches of NLCs were produced over the course of these studies. 
 
2.1.4 Liposomal carrier synthesis 
 
Liposomes were synthesised by collaborators at the University of Manchester (UoM). 
Briefly, liposomes were synthesised using the thin lipid film process as previously described 
(King et al., 2016; Cureton et al., 2017). The constituent lipids 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC; 32.5 mM), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] ammonium salt (DSPE-PEG (200); 1.875 mM) and 
cholesterol (15 mM) were dissolved in 5 ml of chloroform in a round-bottomed flask. 
Subsequent rotary evaporation (40 °C, 270 mbar) removed excess chloroform, and the lipid 
film was placed in a vacuum oven overnight (25 °C, 0 mbar). The thin film was rehydrated 
with 1 ml of with calcium and magnesium-free phosphate-buffered saline (DPBS; BE17-
161F, Lonza), vortexed for 10-minutes, heated to 55 °C, and vortexed for 5-minutes at 1-
hour intervals for a minimum of 4-hours. The suspension containing large multilamellar 
vesicles was then extruded 11-times using a 1 ml Mini-Extruder (Avanti Polar Lipids) 
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through a 200 nm polycarbonate membrane to produce unilamellar liposomes ~200 nm in 
diameter. Fluorescent brain targeting peptides (RLSSVDSDLSGC) bearing a cysteine 
residue on the N-terminus were added to the liposome suspension, allowing covalent 
coupling with maleimide groups overnight at room temperature via a Michael type addition 
reaction. To remove impurities, dialysis against PBS (8 × 500 ml; 24-hours) in a Slide-A-
Lyzer cassette with a molecular weight cut-off of 3.5 kD (Thermo Fisher Scientific, USA) 
was performed. Liposomes were then stored at 4 °C until use. For TMS-loaded liposomes, 
the lipid film was rehydrated with 1 ml TMS (2 mM; SMB00388, Sigma), heated to 55 °C 
and extruded/dialysed as above, to give a final encapsulated concentration of approximately 
0.1 mM. Three batches of liposomes were produced over the course of these studies. 
 
2.2 Nanoparticle Characterisation  
 
2.2.1 Dye and/or drug loading 
 
Dye/drug loading was determined using ultra-violet visible spectroscopy (UV-VIS) and 
fluorescence spectroscopy. Undiluted samples (approximately 2 ml) were loaded into a 
quartz cuvette (can be used in both the UV and visible region, in comparison to glass or 
plastic). The optical absorbance of nanoparticles was recorded using an ultra-violet visible 
spectrophotometer (Jenway 7305, Cole-Palmer) in the wavelength range 200-600 nm. 
Fluorescence spectra were recorded using a fluorescence spectrometer (F-7000, Hitachi) in 
the 450-700 nm range.  
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2.2.2 Particle composition 
 
Compositional information was obtained using fourier-transform infrared spectroscopy 
(FTIR). Background correction was initially performed to exclude non-specific spectra. 
Next, desiccated sample (approximately 1 mg) was loaded onto the infra-red crystal stage 
(Nicolet 380 FT-IR Spectrometer, Thermo Scientific) and transmission spectra (inversely 
proportional to absorbance) collected (resolution: 8 cm-1; scans: 16; range: 500-4,000 cm-1). 
Thermogravimetric analysis (TGA) was used to assess the thermal stability (composition & 
degradation kinetics) of samples. Desiccated sample (approximately 10 mg) was transferred 
into the sample holder (TGA 4000, Perkin Elmer); thermogravimetry and derivative 
thermogravimetry analysis were performed between 20 °C and 900 °C, at a heating rate of 
10 °C/minute under an inert nitrogen atmosphere. 
 
2.2.3 Hydrodynamic size and zeta potential 
 
Nanoparticle size and zeta potential were determined by dynamic light scattering (DLS) and 
laser doppler micro-electrophoresis (LDME), respectively (25 °C; scattering angle of 173° 
Zetasizer Nano ZS, Model ZEN3600, Malvern, UK). SiNP and NLC stock solutions were 
vortexed and sonicated for 5- and 2-minutes, respectively; producing monodisperse samples. 
Samples were diluted 1:100 (20 µl into 1,980 µl) in distilled H2O (pH 6.8), PSS (pH 7.2 – 
7.4) or endothelial cell culture medium MV2 (pH 7.2 – 7.4) and transferred into a cuvette. 
For zeta potential measurements, samples were transferred into a folded capillary zeta-cell 
(DTS1070, Malvern); specialised cuvettes equipped with gold plated copper electrodes, 
allowing the administration of an electrical current to measure the electrophoretic mobility 
of samples directly (runs: 40; duration: 10-seconds; measurements: 3; temperature: 37.5 oC). 
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SiNP stability was assessed immediately following dilution. RV-NLC size and stability was 
assessed at predetermined time points (0, 0.5, 1, 2 and 4-hours), by collaborators at the 
University of Central Lancashire (UCLAN). 
 
 
2.2.4 Physical size and morphology 
 
Nanoparticle size was determined by scanning electron microscopy (SEM; Supra 40VP, 
Zeiss Ltd).  Samples were dispersed (1 mg/ml) in industrially methylated spirit (IMS; Fisher 
Scientific), sonicated for 5-minutes and transferred onto aluminium specimen stubs. Stubs 
were dried at 60 oC for 30-minutes to promote solvent evaporation and transferred onto an 
SEM platform for imaging. In order to obtain higher resolution images and gain structural 
information, samples underwent transmission electron microscopy (TEM; FEI-T12 Biotwin, 
Tecnai). Inorganic samples (SiNPs) were prepared in the same manner as for SEM but were 
positioned on palladium-coated holey carbon films (300 mesh).  
Organic samples (NLCs, liposomes) were diluted (1 mg/ml) in 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) buffer (HEPES; 0.1 M; pH 7.2-7.4) and dried for 1-hour on 
holey carbon-coated film (300 mesh). Samples were rapidly fixed using osmium tetroxide 
(1%; 0.1 M HEPES) for 10-minutes and negatively stained with uranyl acetate (1%; 0.1 M 
HEPES) for 2-minutes in order to improve contrast. Samples were air-dried for 30-minutes 
prior to imaging. Average nanoparticle size and distribution was determined by manually 
measuring particle diameters, with reference to the scale bars on micrographs. 
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2.2.5 Drug release profile  
 
Drug release studies were performed by collaborators at the UCLAN. To determine the 
release rate of RV from NLCs, a dialysis tubing diffusion method was employed. Dialysis 
bags (Spectra/Por® 3 Dialysis Tubing, molecular weight cut off 3.5 kD) were washed with 
distilled water and saturated overnight in release medium. 5 ml  of RV-solution/RV-NLC 
dispersion (4.38 mM) was added to the dialysis bag and placed in a glass vessel (ERWEKA® 
dissolution tester, D-63150 Heusenstamm/Germany) containing 900 ml of dissolution media 
(pH 7.4) at 37 ± 0.5 °C. 1 ml samples were withdrawn at predetermined time intervals and 
analysed using high-performance liquid chromatography (HPLC) using a C18 Luna column 
[mobile phase - acetonitrile: water], detected at 306 nm (Ratola et al., 2004).  
 
2.2.6 Oxidative capacity of nanoparticles in solution 
 
The oxidative capacity of SiNPs was determined using a dichlorofluorescin diacetate 
(DCFH-DA) reagent, following a modified protocol (Zhao and Riediker, 2014). Briefly, 
DCFH-DA powder (2.5 mg) was dissolved in IMS (5 ml; 21.4 M), producing a 1 mM stock 
solution. The DCFH-DA solution was deacetylated using a strong base solution of sodium 
hydroxide (NaOH; 1 ml;  10 mM) and kept in the darkness at room temperature (22 oC) for 
30-minutes.  A working solution was produced by diluting the deacetylated stock solution 
(1:100) with sodium phosphate buffer (25 µM/pH 7.2-7.4). Nanoparticles were desiccated 
and transferred (3 mg) into Eppendorfs, along with 600 µl of working solution (5 mg/ml). 
Samples were sonicated for 15-minutes at 37 oC to aid nanoparticle dispersal and transferred 
into 96-well plates (200 µl/well). Horseradish peroxidase (HRP; 0.5U/ ml-1) catalyst was 
added into each well (18.2 µl), initiating the reaction. Plates were transferred into the plate 
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reader (Biotek, HT Synergy) and fluorescence measured after 15-minutes (exc. 485 nm; em. 
530 nm).  
The antioxidant capacity of nanoparticles was determined using an Amplex™ Red Hydrogen 
Peroxide/Peroxidase Assay Kit (A22188, ThermoFisher Scientific) following 
manufacturer’s instructions. Briefly, the Amplex red reagent was dissolved in 60 µl of 
dimethyl sulfoxide (DMSO; 10 mM) and kept in darkness. Initially, a H2O2 standard curve 
was produced (0 – 10 µM; 100 µl/well) in reaction buffer. Nanoparticle samples were diluted 
in reaction buffer (5 mg/ml) containing H2O2 (10 µM), sonicated for 15-minutes at 37 oC 
and transferred into a 96-well plate (100 µl/well). A working solution was produced by 
combining 50 µl of Amplex red reagent, 100 µl of HRP solution (0.2 U/ml-1) and 4.85 ml of 
reaction buffer; and adding to each well (100 µl/well), initiating the reaction. Plates were 
incubated at 37 oC for 30-minutes inside the plate reader (Biotek, HT Synergy) and 
fluorescence measured (exc. 530 nm; em. 590 nm). 
 
2.3 Cell culture studies 
 
2.3.1 Endothelial Cell Culture 
 
Human coronary artery endothelial cells (HCAECs; single donors (3-batches); C-12221) 
were obtained from PromoCell (Heidelberg, Germany). Cells were grown in Endothelial 
Cell Growth Medium (MV2; C-22022, PromoCell) supplemented with growth medium 
MV2 supplement pack (C-39221, PromoCell), 100 µl/ml penicillin and 100 µl/ml 
streptomycin (Lonza) prior to incubation at 37 oC with 4 % CO2. Cells were passaged 1:3 
after reaching 90 % confluency. In order to passage cells, firstly they were washed with PBS 
and incubated with TrypLE express (12605-028, ThermoFisher Scientific) for 5-minutes at 
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37 oC until dislodged. Cells were centrifuged at 300 g for 10-minutes and resuspended in 
culture medium (2-3 ml). The resulting suspension was mixed at a 1:1 ratio with 0.4 % trypan 
blue (T8154, Sigma), transferred into counting slides (145-0011, Bio-Rad) and analysed 
using the automatic cell counter (Bio-Rad, TC10); providing an estimate of average cell 
number/ml. Cells were subsequently diluted and seeded as appropriate into new 
flasks/plates. For expansion, cells were passaged at a 1:3 ratio.  Cells were used at passages 
3-6. 
Excess cells were resuspended in cell culture medium (2 x 106 cells/ml; supplemented with 
30 % FBS and 10 % DMSO; Lonza) following trypsinisation, transferred into freezing 
capsules and frozen at -80 oC for 24-hours. Cells were subsequently transferred into liquid 
nitrogen for storage (-196 oC).  
 
2.3.2 Preparation of nanoparticles  
 
The final concentration of inorganic (silica) nanoparticles was calculated as described in 
Appendix 10.2. SiNPs were centrifuged at 7,000 g for 5-minutes and washed (x 3) with IMS 
(70%) to remove contaminants. Nanoparticles were sonicated (FB15048, Fisherbrand) for 
3-minutes between washes to aid the dispersal of the nanoparticle pellet. Following 
centrifugation, the nanoparticle pellets were resuspended in cell culture medium (MV2) and 
passed through a 0.45 µm filter. Organic nanoparticles (NLCs/liposomes) were diluted as 
appropriate from the stock solution and passed through a 0.45 µm filter.  
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2.3.3 Oxidative capacity of nanoparticles in vitro 
 
The generation of mitochondrial and cytosolic O2•- was quantified using MitoSOX™ Red 
Mitochondrial Superoxide Indicator (M36008, ThermoFisher Scientific) and 
dihydroethidium (DHE), respectively (D11347, ThermoFisher Scientific). Briefly, HCAECs 
were cultured in 96-well plates at a density of 1 x 104 cells/well for 24-hours.  Initially, cells 
were exposed to H2O2 (0 - 500 µM) in cell culture medium for 30-minutes. Cells were 
washed with PBS (x 3) and fresh culture medium containing alamar blue (1:10 ratio) added. 
HCAECs were incubated in the dark at 37 ℃ for 4-hours. Fluorescence was measured at 
exc. 570 /em. 590 using a BioTek SynergyTM HT microplate reader. Cell viability was 
calculated by normalising treatment samples against negative controls. Based upon HCAEC 
tolerances to H2O2, cells were exposed to H2O2 (100 µM) in media for 30-minutes to 
stimulate ROS generation, as previously described (Coyle and Kader, 2007). Cells were 
washed with PBS, followed by addition of fresh medium in the presence/absence of RV-
NLCs for 30-minutes (0.45 µM). Following treatment, cells were washed and incubated with 
MitoSOX (5 µM) or DHE (10 µM) for 15-minutes (200 µl/well). Fluorescence was 
measured at exc. 530 /em. 590 using a BioTek SynergyTM HT microplate reader. 
Fluorescence values were normalised against negative controls. 
 
2.3.4 Cell viability 
 
The viability of HCAECs was assessed using the fluorometric assay, alamar blue, according 
to the manufacturer’s instructions (DAL1025, ThermoFisher). Briefly, cells were cultured 
on 96-well plates at a density of 1 x 104 cells/well for 24-hours.  Cells were exposed to 
cumulative concentrations of SiNPs (1 x 1010 - 1013 NPs/ml); NLCs/solution (0.045 – 90 
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µM); liposomes/solution (0.01 – 1000 nM) for 24-, 48- or 72-hours. Untreated cells were 
included as negative controls (i.e. 100 % viable). Positive controls were incubated with 0.1 
% Triton-X100 (T8787, Sigma). Following treatment, cells were washed with PBS and 
alamar blue added to fresh cell culture medium at a 1:10 ratio. HCAECs were incubated in 
the dark at 37 ℃ for 4-hours. Fluorescence was measured at exc. 570 /em. 590 using a 
BioTek SynergyTM HT microplate reader and cell viability calculated by normalising 
fluorescence values against negative controls. 
2.4 Nanoparticle uptake  
 
2.4.1 Fluorescence microscopy  
 
To determine nanoparticle uptake into cells, HCAECs were cultured on glass slides mounted 
with ProPlate® multi-well chambers at a density of 1 x 104/well. Cells were incubated in 
media supplemented with dye-loaded SiNPs (1 x 1011 NPs/ml) or NLCs (0.45 µM) for 24-
hours and 30-minutes, respectively. Control wells received standard media. Following 
exposure, cells were washed with PBS and fixed using paraformaldehyde (PFA; 4 %) at 
room temperature for 20-minutes. Cells were washed and incubated in PBS-tween (0.05 %) 
for 10-minutes in order to permeabilise cells, followed by incubation in 1 % bovine serum 
albumin (BSA)-PBS for 1-hour. Cells were washed and incubated in the phalloidin conjugate 
(1:10,000; P1951, Sigma) for 1-hour to stain the actin filaments. SiNP co-localisation was 
assessed by washing and incubating in LysoTracker™ Deep Red (50 nM; L12492, 
ThermoFisher Scientific) for 30-minutes. Slides were mounted in ProLong Gold antifade 
mounting medium containing DAPI as a nuclear counterstain; and sealed using a coverslip 
and then stored at 4 oC in the dark (P36931, Invitrogen). Slides were imaged using a 
fluorescent (Axioscope 5, Zeiss) or confocal microscope (TCS SP5, Leica). 
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2.4.2 Transmission electron microscopy  
 
HCAECs were seeded onto 60 mm culture dishes at a density of 1.2 x 106 and grown to 90% 
confluency. Cells were exposed to SiNPs (1 x 1011 NPs/ml) for 1-, 2- and 4-hours. Untreated 
cells were included as negative controls. Cells were washed with PBS and fixed [4 % 
formaldehyde + 2.5 % glutaraldehyde in 0.1 M HEPES (pH 7.2-7.4)]. Samples were taken 
for TEM processing and imaging (FEI-T12 Biotwin, Tecnai) at the University of Manchester 
imaging suite. 
 
2.5 Vascular function studies 
 
The physiological functional experiments in this study were performed using coronary 
arteries (100-200 µm) and middle cerebral arteries (100-200 µm) excised from euthanised 
animals (Male Wistar rats, 150-250g in weight, aged 8-9 weeks), obtained from the 
Biomedical Science Unit, University of Manchester. The Wistar rats were housed under 
standardised conditions (12-hour light/ dark cycles at 24 ºC). All animals were euthanised 
by stunning and cervical dislocation following institutional guidelines and in accordance 
with guidelines issued by the European Commission Directive 86/609/EEC. A total of 85 
rodents were used over the course of these studies. All procedures were conducted in 
accordance with institutional guidelines of Manchester Metropolitan University, the 
University of Manchester and the United Kingdom Animals (Scientific Procedures) Act of 
1986 (schedule 1). A risk assessment for the use and handling of animal tissue was 
conducted. 
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Septal coronary arteries (Figure 2.1A, B) and middle cerebral arteries (Figure 2.1C) were 
excised and had the perivascular adipose and connective tissue layer surrounding each vessel 
removed in order to improve visual clarity. Arteries were mounted between two glass 
cannulae in a pressure myograph chamber (Living Systems, USA; Figure 2.2) and 
pressurised to an intravascular pressure of 60 mmHg using a servo-control unit (Living 
Systems Instrumentation, USA). Vessels were secured in place by tying two knots at either 
end of the cannulae. Arteries were continuously superfused with PSS [composition [mM]: 
119 NaCl, 4.7 KCl, 1.2 MgSO4.7H2O, 25 NaHCO3, 1.17 KH2PO4, 0.03 K2EDTA, 5.5 
glucose, 1.6 CaCl22H2O; pH 7.4] supplemented with 95 % O2 and 5 % CO2 at 37 oC, and 
diameters (lumen and wall) constantly recorded using a video dimension analyser (Living 
Systems) on an inverted Nikon microscope (ECLIPSE Ti2; 10 x magnification) using 
LabChart 6 (Powerlab, AD Instruments, UK).  
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Figure 2.1. The anatomical structure of the isolated rat heart and brain vasculature. (A) 
An image of the anterior heart. A superolateral incision is made into the left ventricle, 
allowing reflection of the ventricular wall. (B) Once reflected, the septal coronary artery 
becomes visible. (C) The anatomical structure of the dorsal brain; highlighting the vascular 
architecture following immediate removal from the cranial cavity. Coronary and middle 
cerebral arteries are highlighted by the dashed boxes.   
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Figure 2.2. Pressure myography chamber. An image of the pressure myography vessel 
chamber illustrating the position of the glass cannulae (indicated by dashed arrows). 
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2.5.1 Experimental protocol 
 
After a 20-minute equilibration period, viability was assessed by ascertaining initial 
responses to high potassium solution (KPSS) [composition [mM]: 78.2 NaCl, 60 KCl, 1.2 
MgSO4.7H2O, 25 NaHCO3, 1.17 KH2PO4, 0.03 K2EDTA, 5.5 glucose, 1.6 CaCl2.2H2O; pH 
7.4]. 
Initially, 5-HT (H9523, Sigma) dose responses were performed to assess vessel contractility 
(10-10 M - 10-3 M). In subsequent studies, all arteries were pre-constricted in 5-HT (5-HT, 
10-6 - 10-7 M). Endothelial-dependent (ACh, 10-9-10-3 M; A6625, Sigma) responses and were 
assessed prior to, following or 1-hour after acute pressure elevation. Vessels were exposed 
to elevated pressure (150mmHg) for 30-minutes, and then returned down to 60mmHg for a 
further 30-minutes, in the presence/absence of RV-NLCs (0.45 µM); RV-solution (0.45 
µM); TMS-liposomes (1 nM) or TMS-solution (10 µM). In order to minimise the depletion 
of samples, superfusion was ceased for the duration of the incubation period and samples 
were added directly into the oxygenated chamber; with temperature maintained at 37.5 oC 
using an external temperature controller (TC-02, Living Systems). In order to evaluate the 
possible contribution of ROS in endothelial-dependent dilation, vessels were co-incubated 
with superoxide dismutase (SOD, 300 U-ml; S7571, Sigma), catalase (CAT, 500 U-ml; 
C4963, Sigma) or apocynin (NADPH oxidase inhibitor; 30 µM; ab120615, Abcam). 
Inhibition studies were used to determine the influence of RV-NLCs on the vasodilator 
pathways. Responses were assessed in a separate set of experiments, following incubation 
in; the NO synthase inhibitor Nω-nitro-L-arginine (L-NNA, 100 µM; N5501, Sigma), the 
small (SK) and intermediate (SK) calcium-activated potassium channel blockers apamin 
(100 µM; A1289, Sigma) and TRAM-34 (1 µM; T6700, Sigma), as well as the COX 
inhibitor, indomethacin (10 µM; I7378, Sigma). The effect of inhibitors on vessel function 
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was assessed alone, in combination or in the presence/absence of RV-NLCs. Responses were 
assessed in the continued presence of inhibitors in the superfusate. The mechanistic 
contributions of AMPK and SIRT-1 were assessed following incubation with the inhibitors 
dorsomorphin (10 µM; Ab144821, Abcam) and EX-527 (10 µM; E7034, Sigma), 
respectively. In order to assess whether RV-NLCs act via endothelial-independent 
mechanisms, the endothelium was denuded via the introduction of three air-bubbles prior to 
beginning the experiments. Endothelial-independent responses were assessed using PAPA 
(100 µM; P3510, Sigma) and SNP (100 µM; 71778, Sigma). At the end of the experiment, 
arteries were superfused with calcium-free PSS for 30-minutes in order to obtain passive 
diameters (VSMC hyperpolarisation). 
 
2.6 Ultrastructural Analysis 
 
Following treatment, vessels were dismounted and transferred into a fixative solution [4 % 
formaldehyde + 2.5 % glutaraldehyde in 0.1 M HEPES (pH 7.2-7.4)]. Samples were taken 
for TEM processing and imaging (FEI-T12 Biotwin, Tecnai) at the University of Manchester 
imaging suite. 
 
2.7 Statistical Analysis 
 
All statistical analysis was performed using Prism version 8.3.1 for Windows, GraphPad 
Software, La Jolla California, USA. DLS and LDME measurements were analysed using an 
unpaired t-test or a one-way analysis of variance (ANOVA) followed by Tukey’s multiple 
comparison or Bonferroni correction. Drug release was analysed by a two-way ANOVA. 
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Cell viability was calculated by normalising values to control wells (i.e. 100% viable) and 
expressing as a percentage. Data was analysed by a one or two-way ANOVA followed by 
Bonferroni or Tukey’s multiple comparison, respectively. Oxidative reactivity was analysed 
using an unpaired t-test or a one/two-way ANOVA followed by Dunnett’s or Tukey’s 
Multiple Comparison. Constrictor responses elicited by 5-HT are expressed as percentage 
constriction corresponding to the decrease from the passive diameter value. Responses were 
assessed using unpaired t-test or two-way ANOVA followed by Tukey’s multiple 
comparison. The dilator responses elicited by ACh are expressed as percentage relaxation 
corresponding to the increase from the pre-constricted value. The Shapiro-Wilk test was 
used to assess the conformity of the data to normal distribution. Dilator responses were 
analysed using a two-way ANOVA followed by Tukey’s multiple comparisons. In order to 
calculate EC50 values, data were normalised, transformed and plotted using a nonlinear 
regression model. LogEC50 values were calculated and compared using an extra-sum-of-
squares F test. Dilator responses elicited by PAPA and SNP were assessed using an unpaired 
t-test or one-way ANOVA followed by Tukey’s multiple comparisons. Values of P < 0.05 
were considered statistically significant. Asterisks used denote: * P < 0.05, ** P < 0.01, *** 
P < 0.001, and **** P < 0.0001. Experiments were performed in triplicate where appropriate 
and repeated three times. Data are represented as means ± standard error of the mean (SEM) 
unless stated otherwise.  
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3 Chapter 3: Synthesis and 
characterisation of inorganic 
nanoparticles 
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As discussed in the introductory chapter, SiNPs are a promising platform for the release of 
vasoactive compounds, offering a potential delivery modality for the treatment of CVD; 
however, their surface reactivity and oxidative capacity may preclude their use. The 
objective of this part of the study is to synthesise SiNPs and assess the effects of surface 
functionalisation on their oxidative capacity and in vitro biocompatibility, offering a 
potential mechanism for antioxidant delivery. The hypothesis of this part of the study is that 
CeO2 functionalisation of SiNPs will improve SiNP biocompatibility in isolated endothelial 
cells. This hypothesis will be addressed through the following specific objective: 
 
 Synthesise and characterise inorganic (silica) nanoparticles and determine their 
effect on endothelial cell viability, in vitro. 
 
SiNPs were prepared using the Stöber technique. Dye-loading was determined using ultra-
violet visible spectroscopy (UV-VIS) and composition assessed using fourier transform 
infrared spectroscopy (FTIR) and thermogravimetric analysis (TGA). Nanoparticle zeta 
potential was determined by laser doppler micro-electrophoresis (LDME), whilst size and 
morphology were assessed using scanning electron microscopy (SEM) and transmission 
electron microscopy (TEM). The oxidative capacity of SiNPs in solution was determined 
using 2'-7 dichlorofluorescein diacetate (DCFH-DA) and amplex red, respectively. The 
effects of SiNP on viability and uptake were assessed in vitro using alamar blue, 
fluorescence/confocal microscopy and TEM, respectively.  
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3.1 Results    
 
3.1.1 SiNPs were successfully synthesised and characterised  
 
SiNPs were synthesised and characterised in aqueous media. Using UV-VIS, FITC-loading 
within SiNPs was confirmed, with a characteristic absorbance peak at 490 nm (Figure 3.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Confirmation of dye-encapsulation within SiNPs. Ultraviolet-visible 
spectroscopy (UV-Vis) displaying absorbance spectra between 340-600 nm. An absorbance 
peak was observed at approximately 490 nm, confirming FITC-loading. 
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FTIR was used to confirm the molecular structure of the SiNPs. The characteristic position 
and shape of the vibrational band at 1085 cm-1 (Si-O), in addition to the bands at 940 cm-1 
(Si-O-Si symmetric stretching) and 800 cm-1 (O-Si-O symmetrical stretching), confirm the 
presence of a stoichiometric SiO2 structure. The peak at 1630 cm-1, as well as the broad 
absorption bands between 2550 and 3730 cm-1, were assigned to the stretching and bending 
of physisorbed water molecules, as well as hydrogen-bonded and partially hydrated silanols 
(Si-OH). Bands in the 1680–1620 cm-1 region are also associated with primary amine groups 
(N-H). The band at 2330 cm-1 is attributable to absorption of aqueous and gaseous CO2 
(Figure 3.2). The presence of PEG and CeO2 was not apparent in the SiNP samples using 
FTIR, due to the absence of corresponding peaks; hence, TGA was next used to assess the 
degradation kinetics of the nanoparticles as a function of temperature. 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Confirmation of SiNP molecular structure. Fourier transform infrared 
spectroscopy (FTIR) spectra of non-modified (blue), PEG-modified (red) and PEG-ceria-
modified (green) SiNPs, displaying transmittance (%) between 500-4000 cm-1. 
Characteristic transmittance peaks are indicated on the figure itself (for interpretation of 
the reference values, refer to main text). 
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An analysis of cumulative weight loss identified a gradual reduction in percentage weight as 
a function of increasing temperature in each sample (Figure 3.3A). The initial weight loss 
observed between 0 and 200 oC can be attributed to dehydration; the removal of physisorbed 
water from the surface of silica. The gradual weight loss at temperatures above 200 oC is 
attributable to dehydroxylation; the removal of surface silanol groups via condensation 
reactions, in which siloxane bonds are formed. Analysis of derivative weight loss allows for 
the precise identification of constituent chemical evaporation temperatures; defining the 
point at which weight loss is most apparent (Figure 3.3B).  
As noted above, the initial mass reduction observed between 0 and 200 oC is due to the loss 
of bulk and hydrate water. Independent analysis of FITC powder identified two prominent 
areas of weight loss, occurring at 290 oC and 500 oC (Figure 3.4A, B). Subsequent analysis 
identified two troughs at the corresponding temperatures in non-modified SiNPs, the 
shallowness of the peaks being indicative of the low encapsulated quantity. Due to its small 
degradation profile, it is not apparent in PEG- and PEG-ceria-modified SiNPs due to 
obfuscation by other elements. In PEG- and PEG-ceria-modified SiNPs, a trough is 
identifiable between 450 oC and 600 oC, attributable to PEG-maleimide. A distinct trough 
was observed between 250 oC and 500 oC in PEG-ceria-modified SiNPs, confirming the 
presence of cerium nitrate hexahydrate, the predominant component of CeNPs (Figure 
3.3B). 
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Figure 3.3. Thermal stability of SiNPs. (A) Cumulative (%) and (B) derivative weight loss 
(%/min) of non-modified (blue), PEG-modified (red) and PEG-ceria modified (green) SiNPs 
as a function of increasing temperature (0 - 900 oC) using thermogravimetric analysis. 
Analysis of derivative weight loss enabled the evaporation temperatures of water (1; 100 
oC), FITC (2; 290 oC and 500 oC), cerium nitrate (3; 390 oC) and PEG (4; 510 oC) to be 
identified.  
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Figure 3.4. Thermal stability of FITC dye. (A) Cumulative (%) and (B) derivative weight 
loss (%/min) of fluorescein isothiocyanate (FITC) as a function of increasing temperature 
(0 - 900 oC) using thermogravimetric analysis. Analysis of derivative weight loss enabled 
the evaporation temperatures of FITC to be identified, with significant reductions observed 
at 290 oC and 500 oC. 
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The next characteristic assessed was the stability and electrophoretic mobility of the SiNPs. 
The zeta potential of non-modified SiNPs in water, PSS and media was -35.8 ± 1.15 mV, -
31 ± 1.13 mV and -19.1 ± 1.32 mV, respectively. Amine-modified SiNPs in water, PSS and 
media was -43.7 ± 2.67 mV, -2.55 ± 0.22 mV and -10.7 ± 1.16 mV, respectively. PEG-
modified SiNPs in water, PSS and media was -48.53 ± 3.56 mV, -24.3 ± 2.19 mV and -18.7 
± 1.19 mV, respectively. PEG-ceria-modified SiNPs in water, PSS and media was -36.13 ± 
2.32 mV, -19.9 ± 2 mV, and -21.9 ± 1.12 mV, respectively (Figure 3.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Stability and electrophoretic mobility of SiNPs in aqueous medium. SiNP 
stability was immediately assessed in water, physiological salt solution (PSS) and 
endothelial cell growth medium MV2 using laser doppler micro-electrophoresis. Zeta 
potential measurements for non-modified SiNPs in water, PSS and media were -35.8 ± 1.15 
mV, -31 ± 1.13mV and -19.1 ± 1.32mV, respectively. Amine-modified SiNPs in water, PSS 
and media were -43.7 ± 2.67 mV, -2.55 ± 0.22 mV and -10.7 ± 1.16 m, respectively. PEG-
modified SiNPs in water, PSS and media were -48.53 ± 3.56 mV, -24.3 ± 2.19mV and -18.7 
± 1.19mV, respectively. PEG-ceria-modified SiNPs in water, PSS and media were -36.13 ± 
2.32 mV, -19.9 ± 2 mV, and -21.9 ± 1.12mV, respectively (n = 3). Data are presented as mean 
± SEM. 
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Electron microscopy was used to determine the morphological structure and size of the 
SiNPs. SEM successfully confirmed them to be spherical and monodispersed, with an 
average size of 63.2 ± 8.5 nm (Figure 3.6). TEM identified non-, amine-, PEG- and PEG-
ceria-modified SiNPs as polydisperse (Figure 3.7A-D); surface functionalisation with PEG-
ceria was confirmed morphologically, with CeNPs encompassing the SiNP periphery 
(Figure 3.7D). The size distribution of SiNPs ranged between 50 and 190 nm, with an 
average size of 105 ± 30.5 nm and were therefore deemed suitable for characterisation and 
use (Figure 3.7E).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Morphological structure of SiNPs. Representative scanning electron (SEM) 
micrographs of non-modified SiNPs. SiNPs were dried and imaged. SiNPs are seen as 
spherical and monodispersed, with an average particle size of 63.2 ± 8.5 nm. Magnification 
100,000 x. Scale bar = 300 nm. 
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Figure 3.7. Morphological structure and size distribution of SiNPs. Representative 
transmission electron (TEM) micrographs of (A) non-modified, (B) amine-modified, (C) 
PEG-modified and (D) PEG-ceria-modified SiNPs. Particle size distribution acquired from 
representative TEM micrographs (E). Random measurement sampling (n = 60) from non-
modified, amine-modified, PEG-modified and PEG-ceria-modified SiNP micrographs 
(ImageJ). SiNPs are polydispersed, with an average size of 105 ± 30.5 nm. Magnification 
23,000 x. Scale bar = 200 nm. 
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3.1.2 PEG-ceria-modified SiNPs reduce hydroxyl radical generation 
 
To ascertain the intrinsic reactivity of SiNPs, dichlorodihydrofluorescein diacetate (DCFH-
DA) was used to quantify •OH and peroxyl (HOO-) radical generation in solution. Amine-
modification of SiNPs significantly increased •OH and HOO- generating capacity in 
comparison to non-modified SiNPs (P = < 0.05); Figure 3.8); PEG-modification had no 
effect. PEG-ceria-modification resulted in a significant reduction in •OH and HOO- 
generating capacity in comparison to non-modified SiNPs (P = < 0.05). MSNs were included 
as a negative control, displaying significantly reduced •OH and HOO- generating capacity in 
solution compared to non-modified SiNPs (P = < 0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Effect of SiNP surface functionalisation on hydroxyl and peroxyl radical 
generation. DCFH-DA fluorescence quantification highlighting hydroxyl radical 
generation in solution following 15-minutes incubation with SiNPs (5 mg/ml; non-modified, 
amine-modified, PEG-modified, PEG-ceria-modified) and mesoporous silica nanoparticles 
(MSNs) (n = 3). Data expressed as fold change from control (non-modified). Amine-modified 
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SiNPs significantly increased hydroxyl and peroxyl generating capacity in comparison to 
non-modified SiNPs (P = < 0.05); PEG-modification had no effect. PEG-ceria-modification 
significantly reduced the hydroxyl and peroxyl generating capacity of SiNPs, compared to 
non-modified (P = < 0.05). MSNs were included as a negative control, displaying 
significantly reduced hydroxyl and peroxyl generating capacity in solution compared to non-
modified SiNPs (P = < 0.001). Experiment performed in triplicate and repeated three times. 
One-way ANOVA followed by a Dunnett’s multiple comparison. Data are presented as mean 
± SEM. * P < 0.05. *** P < 0.001. 
 
Amplex red was used to quantify H2O2 and other peroxide activity, allowing a determination 
of the antioxidant capacity of SiNPs. Following 30-minutes incubation with H2O2 (0-10 
µM), a concentration-response curve was produced (Figure 3.9A). A significant reduction 
in H2O2 and peroxidase activity was observed in solution following 30-minutes incubation 
with PEG-ceria-modified SiNPs, in comparison to its non-modified counterpart (Figure 
3.9B; P = < 0.001).  
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Figure 3.9. Effect of SiNP functionalisation on antioxidant capacity in solution. (A) Dose-
response effect of hydrogen peroxide (H2O2; 0 – 10 µM; n = 3) on amplex red fluorescence 
following 30-minutes incubation. (B) PEG-ceria-modification significantly reduced H2O2 
and peroxidase activity in solution, in comparison to non-modified SiNPs (5 mg/ml; P = < 
0.001; n = 3) following 30-minutes incubation in a H2O2 solution (10 µM). Experiment 
performed in triplicate and repeated three times. Data was analysed using an unpaired t-
test. Data are presented as mean ± SEM. *** P < 0.001. 
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3.1.3 PEG-ceria-modified SiNPs maintain and improve endothelial cell viability  
 
Having characterised the properties of each of the modified and non-modified SiNPs, it was 
next of interest to assess their effects on endothelial cells in vitro.  Following 24-hours co-
incubation with SiNPs (non-, PEG-, PEG-ceria-modified), no significant change in HCAEC 
viability was observed, other than at 1 x 1012 and 1013 NPs/ml (Figure 3.10). At 1 x 1012 and 
1 x 1013 NPs/ml, PEG- and PEG-ceria-modification significantly improved viability 
compared to non-modified SiNPs, respectively (P = < 0.01; P = < 0.001).  
 
3.1.4 SiNPs are successfully taken up by endothelial cells 
 
Having identified the most biocompatible concentrations for use, it was of interest to assess 
SiNP uptake and localisation within cells. Confocal microscopy demonstrated that non-
modified SiNPs (1 x 1011 NPs/ml) were taken up by HCAECs after 24-hours (Figure 3.11); 
whilst fluorescence microscopy demonstrated the apparent localisation of SiNPs within 
endosomal structures (Figure 3.12).  
TEM demonstrated uptake of SiNPs (1 x 1011 NPs/ml) into HCAECs over a 4-hour period. 
In control cells (untreated; Figure 3.13A), the cytoplasmic compartment did not appear to 
have any significant alterations. Although after 1-hour incubation, SiNPs were observed 
localised in small clusters within cytoplasmic endosomes (Figure 3.13B), with further uptake 
observed after 2- and 4-hours; with apparent fusion and degradation occurring (Figure 
3.13C, D). 
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Figure 3.10. Effect of SiNP functionalisation on cell viability. Human coronary artery 
endothelial cell (HCAEC) viability following exposure to SiNPs (non-modified, PEG-
modified and PEG-ceria modified) at concentrations of 1010, 1011, 1012, 1013 NPs/ml over 
24-hours. Cell viability determined using an Alamar blue assay (n = 3). Data normalised to 
control wells (untreated). SiNPs had no significant effects on cell viability, other than at 1 x 
1012 and 1013 NPs/ml. At 1 x 1012 NPs/ml, PEG- and PEG-ceria-modification significantly 
improved viability compared to non-modified SiNPs (P = < 0.01; P = < 0.001, respectively). 
At 1 x 1013 NPs/ml, PEG- and PEG-ceria-modification significantly improved viability 
compared to non-modified SiNPs (P = < 0.01; P = < 0.001, respectively). Experiment 
performed in triplicate and repeated three times. Cell viability was analysed by a two-way 
ANOVA followed by a Tukey’s multiple comparison. Data are presented as mean ± SEM. ** 
P < 0.01. *** P < 0.001.  
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Figure 3.11. SiNP uptake by HCAECs in culture. Representative confocal fluorescence 
micrographs of human coronary artery endothelial cells (HCAECs). Cultured cells were 
incubated with growth medium in the presence/absence of non-modified SiNPs (FITC-
loaded; 1 x 1011 NPs/ml) for 24-hours, followed by DAPI (nuclear) and phalloidin (actin) 
staining. Magnification 40 x. Scale bar = 25 µm.  Images acquired from 1 of 5 representative 
slides. 
 
 
Figure 3.12. Endosomal SiNP uptake within HCAECs in culture. Representative 
fluorescence micrographs of human coronary artery endothelial cells (HCAECs) incubated 
with growth medium in the presence/absence of non-modified SiNPs (FITC-loaded; 1 x 1011 
NPs/ml) for 24-hours, followed by DAPI (nuclear) and lysotracker (lysosomal/endosomal) 
staining. Magnification 65 x. Scale bar = 20 µm. Images acquired from 1 of 5 representative 
slides. 
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Figure 3.13. Time-dependent uptake of SiNPs by HCAECs in culture. Representative 
transmission electron micrographs illustrating the uptake of non-modified SiNPs (1 x 1011 
NPs/ml) at (A) 0-hours; (B) 1-hour; (C) 2-hours and (D) 4-hours. Following 1-hour 
incubation, SiNPs were localised in small clusters within cytoplasmic endosomes. After 2- 
and 4-hours, an increased number of SiNPs could be observed within endosomal structures; 
with apparent fusion and degradation occurring. SiNPs are represented by black structures. 
Magnification 1,200 x. Scale bars = 1 µm and 0.5 µm, respectively.  
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3.2 Discussion 
 
3.2.1 SiNPs were successfully synthesised and characterised  
 
Inorganic SiNPs of various functionalities were synthesised and characterised, with drug and 
dye entrapment confirmed using UV-VIS and fluorescence spectroscopy. While the FTIR 
confirmed the presence of characteristic silanol groups, the spectrographic profile of CeO2 
was not distinguishable, due to the lack of sensitivity of this approach; incapable of 
observing Ce-O stretching bands expected at 400-600 cm-1 (Zamiri et al., 2015). Peaks 
observed at 2330 cm-1 correlate with atmospheric CO2 (Kauffman et al., 2011). Appropriate 
background correction should mitigate the presence of such peaks; however, high-resolution 
acquisition over prolonged/extended periods of time may result in CO2 adsorption onto the 
particle. These ‘artificial’ peaks may substantially impact the interpretation of spectra at 
various wavelengths, e.g. vibrational bands at 1680–1620 cm−1 are frequently associated 
with H2O and Si-OH groups; however, adsorption of CO2 onto the silica surface can lead to 
the formation of carboxylic compounds, with absorbance found in the same range (Basyuk, 
1994). Therefore, further characterisation of the SiNPs was necessary. TGA confirmed 
successful surface modification and dye-entrapment, including that of the CeO2 component, 
cerium-nitrate. PEG is a hygroscopic compound and has been shown to marginally retard 
water loss in hydrogels, delaying its evaporation (Hackl et al., 2015); attributable to the 
presence of ether oxygen atoms (-O-) and hydroxyl end groups which can form multiple 
hydrogen bonds with water (Hsu et al., 2015). Similar observations are made in both PEG 
and PEG-ceria-modified SiNPs, reflected by a rightward shift (derivative) in the evaporation 
temperatures of volatile compounds (e.g. water) below 200 oC. Next, the stability of SiNPs 
was assessed.  
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The zeta potential measurements confirmed the stability of non-, PEG- and PEG-ceria-
modified SiNPs in water, indicative of low agglomeration and flocculation capacity (Večeř 
and Pospíšil, 2012). The conjugation of positively charged amino groups onto the particle 
surface is commonly associated with a net positive charge. The negative charge observed in 
amine-modified SiNPs, although to a lesser extent than others, is suggestive of incomplete 
surface functionalisation and hence the reason why these nanoparticles were not used in 
further experimentation. In each instance, an increase in zeta potential was observed in PSS 
and media, signifying a reduction in nanoparticle stability; attributable to ion and protein 
adsorption on the nanoparticle surface, consistent with previous findings (Krętowski et al., 
2017). Briefly, following suspension in an aqueous medium such as water, molecules engulf 
the nanoparticulate surface to produce a structured hydration layer, otherwise known as a 
Stern layer. The resulting electrostatic forces generate low-level attraction, drawing 
additional ions inward towards the Stern layer; producing an area termed as the diffuse layer. 
The electrical potential between these two layers is frequently referred to as the zeta 
potential; with values in excess of +30 mV or −30 mV being indicative of stable suspensions, 
whereby particles are not liable to aggregation or flocculation (Bhattacharjee, 2016). The 
introduction of a highly ionic medium such as PSS or culture media often results in the 
displacement of water molecules from the particle surface, reducing the integrity of the 
hydration layer and elevating zeta potential. Furthermore, the presence of serum proteins in 
culture medium has been observed to reduce particulate stability, following absorption and 
subsequent corona formation (Hao et al., 2012; Kurtz-Chalot et al., 2017). The reduced 
stability observed was to a lesser extent in PEG-modified SiNPs. Conventionally, particles 
rapidly aggregate via van der Waals and/or hydrophobic forces in high-ionic aqueous 
conditions. As a result of its hydrophilic nature, surface modification with PEG produces a 
large exclusion zone that sterically precludes SiNPs from interacting with adjacent SiNPs 
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and/or ions/proteins, retaining their colloidal stability (Kurtz-Chalot et al., 2017), making 
them a favourable model for the further studies undertaken within this project. 
SEM identified SiNPs as spherical in structure with an approximate size of 63.2 ± 8.5 nm. 
Despite the popularity of SEM for the analysis of sub-micron materials, the technique is 
hindered by limited resolution and magnification. However, TEM provided images of much 
higher clarity; identifying spherical, polydisperse SiNPs with an average size of 105 ± 30 
nm.  In colloid science, LaMer’s nucleation theory is used to describe the generation and 
growth of colloidal materials (LaMer and Dinegar, 1950). The process undergoes three 
stages: 1) monomer formation and accumulation, reaching critical supersaturation; 2) rapid 
self-nucleation of monomers; 3) end of self-nucleation, and growth by diffusion of the 
remaining monomers in solution towards the particle surface. One possibility which may 
account for the polydispersity observed is the premature cessation of the reaction, with 
SiNPs still being in the self-nucleation phase and not fully developed. Polydisperse 
nanoparticles can be problematic in relation to their use as a treatment strategy for a number 
of reasons. Most notably, several studies have demonstrated the size, uptake and toxicity 
dependent relationship of SiNPs in a variety of cell types; whereby smaller particles exhibit 
increased levels of toxicity (Napierska et al., 2009; Gramatke, 2014). Furthermore, 
nanoparticle surface area has been shown to be integral in determining reactivity with the 
local environment, with smaller particles having a larger surface area (i.e. larger surface area 
to volume ratio)(Farooq, 2014). It has been reported that SiNP surface groups have the 
potential to generate •OH radicals, which may contribute to cellular damage and toxicity 
(Shang et al., 2009). Consequently, the resulting variation in size produces an inability to 
accurately calculate the total surface area available, making predictions of treatment efficacy 
or downstream side-effects difficult.  
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3.2.2 PEG-ceria modification reduces hydroxyl radical generation 
 
The oxidative capacity of SiNPs was assessed in solution. Following PEG-ceria-
modification, a significant reduction in •OH generation and/or release was observed, 
compared to non-modified controls. The surface chemistry and reactivity of SiNPs are 
recognised as being integral in regulating their biological responses, with means of synthesis 
and density of surface silanol groups (−Si-O-H) being an important factor in the modulation 
of toxicity (Nash et al., 1966). However, the specific mechanism by which surface silanol 
groups induce toxicity is unclear. Surface groups have been shown to encourage ROS 
generation, lipid peroxidation and DNA damage upon interaction with biological 
components in vitro (Duan et al., 2013a). However, these findings are contentious, with 
some demonstrating ROS-independent impairment of cell viability and vascular function 
following SiNP exposure (Shukur et al., 2016). In some instances, silica has been shown to 
be chemically reactive in the absence of a biological environment. In the case of fumed silica, 
researchers demonstrated that the cleavage of strained siloxane rings was responsible for the 
production of •OH from the SiNP surface (Zhang et al., 2012). In contrast, this study has 
focused on the use of colloidal silica prepared via sol-gel. Despite differences in their 
respective modes of synthesis, similar underlying mechanisms of action may be present. Our 
data are consistent with previously observed results, with SiNPs generating ROS in a cell-
free system, implicating an underlying chemical reaction/mechanism of action. CeO2 has 
repeatedly demonstrated SOD and CAT catalytic activity in a range of in vitro and in vivo 
models (Rzigalinski et al., 2006; Korsvik et al., 2007); attributable to the active absorption 
and release of oxygen and effective redox cycling between Ce3+ and Ce4+ oxidation states. 
Furthermore, it has also been shown to be highly effective at reducing •OH via direct 
scavenging (Xue et al., 2011; Filippi et al., 2019). Findings from this study are consistent 
90 
 
with previously observed results, with PEG-ceria- modification resulting in a 40 % average 
reduction in radical generation. In addition to the inherent antioxidant activity of CeO2, it is 
likely that particle attachment to the SiNP surface reduces the total surface area, obscuring 
reactive silanol groups. The conjugation of surface groups onto nanoparticles has been 
shown to modulate toxicity, with PEG having been shown to sterically hinder the particle 
surface (Pozzi et al., 2014). As a result of this steric hindrance, PEG-modification would be 
expected to reduce interaction with surface groups, limiting reactivity (Mohammadi et al., 
2018). Surprisingly, however, PEG-modification resulted in a small yet non-significant 
reduction in ROS generation. In order to establish a monodisperse, heterogeneous dispersion 
and expose the total nanoparticle surface area in our studies, samples were sonicated. 
However, previous research has revealed that PEG is highly sensitive to sonolytic 
degradation, with a 25 % reduction in total PEG observed within as little as 15-minutes 
(Murali et al., 2015). Such alterations in surface chemistry may negate the beneficial effects 
that PEG-modification may confer. In contrast to PEG-modification, which is ordinarily 
used to limit cellular uptake and biological interaction, APTES conjugation is utilised as a 
means of increasing cellular uptake; a result of electrostatic interactions between positively 
charged amino groups and the negatively charged cell membrane. Some studies have 
suggested that amine-modification reduces innate reactivity in a similar capacity to that of 
PEG, reducing the number of exposed silanol moieties on the surface (via replacement with 
aminopropyl functional groups), whilst also sterically hindering surface interactions 
(Lehman et al., 2016; Morris et al., 2016). Our findings differ from previous studies, with 
amine-modification significantly elevating reactivity. Differences in experimental design 
may account for the varied observations between studies. In addition to the damaging effect 
on surface groups, it is well documented that the inertial collapse of cavitation bubbles 
during sonication are capable of inducing sonochemical reactions, generating ROS, e.g. the 
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generation of •OH and H2O2 in pure water (Makino et al., 1983). Although these phenomena 
would be consistent across all samples, the formation of highly reactive aminoxyl radical is 
noted in the literature to occur under oxidising conditions and thus, may account for the 
elevated reactivity observed in amine-modified SiNPs (Lind and Merényi, 2006). 
Furthermore, the incomplete surface functionalisation, as denoted by zeta potential 
measurements, would likely leave surface silanol groups exposed and open to reactivity. 
Incubation with mesoporous nanoparticles (MSNs) resulted in significantly lower reactivity 
compared to amphorous SiNPs. This is surprising, given the increased total surface area of 
MSNs, increased reactivity with surface silanol groups would be expected. Similar findings 
have been observed using electron spin resonance spectroscopy, identifying a 7-fold 
reduction in •OH formation from MSNs compared to non-porous SiNPs (Lehman et al., 
2016). These observations may be related to the isotropic motion of molecules (radicals), 
limiting diffusion; resulting in flux through the porous network being heavily reliant on 
concentration gradients. Hence, whilst MSNs possess a much larger surface area, the 
majority is located within the pores; thus, the surface area in direct contact per unit time with 
the reactive molecules is much lower in the porous material and may explain why 
mesoporous material gives rise to lower reactivity than that of the nonporous material. 
Despite the prevalence of DCFH for the quantification of ROS, several notable limitations 
must be considered. DCFH is a multi-stage reaction and thus does not operate as a direct 
measure of H2O2 and/or •OH, introducing the possibility of external interference. Secondly, 
the intermediate radical, DCF, formed via the one-electron oxidation of DCFH, reacts with 
O2 to form O2•-.  The SOD mimetic activity of CeO2 leads to the dismutation of O2•-, yielding 
additional H2O2. This redox-cycling mechanism has the potential for artefactual 
amplification of fluorescence signal intensity, confounding findings (Folkes et al., 2009). 
Finally, DCFH-DA is conventionally used as a cell-based assay, with activation requiring 
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esterase cleavage. In order to adapt the protocol to work in a cell-free system, chemical 
cleavage is required; hence, it is not directly comparable to other studies and impurities in 
chemical reagents might introduce artefacts.  
The antioxidant capacity of the SiNPs was also assessed using a direct measurement 
technique. Amplex red was able to successfully confirm the antioxidant capacity of PEG-
ceria-modified SiNPs, with a similar trend to DCFH identified. Following its addition into a 
H2O2 solution, ceria-modified SiNPs were capable of quenching significantly more H2O2 in 
comparison to its non-modified counterpart, highlighting the CAT mimetic activity and ROS 
quenching capacity of CeO2. Previous studies have also demonstrated similar CAT mimetic 
activity using Amplex red in a cell-free system (Baldim et al., 2018). In contrast to DCFH, 
oxidation of the Amplex red probe is catalysed by HRP in the presence of H2O2 and is highly 
efficient, vastly increasing the yield of resorufin. 
 
3.2.3 SiNPs are successfully taken up by endothelial cells 
 
Uptake into HCAECs was confirmed within 24-hours of exposure of the cell to the SiNPs, 
which were observed throughout the cytosol, appearing to localise around the nucleus. 
Previous literature has observed the localisation of SiNPs within endosomal/lysosomal 
structures in the cytoplasm of the cell, with none present within the nucleus (Pritz et al., 
2013; Shukur et al., 2016). In contrast to the highly organised actin filaments of control cells, 
SiNP treated cells appeared to have a disorganised actin structure. Nanoparticles (e.g. silica, 
silver) have previously been shown to cause cytoskeletal disturbances, causing disruption 
and disorganisation of F-actin fibres in primary human endothelial cells (Xu et al., 2013; 
Duan et al., 2014); potentially explaining the altered distribution and/or inadequate staining 
of actin within cells. Fluorescence imaging would be beneficial in assessing the time-
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dependent uptake of SiNPs, as well as expulsion at later time-points. However, in the case 
of polydisperse samples, fluorescence should be avoided as a reliable means of 
quantification, with variations in SiNP size likely resulting in variable FITC loading capacity 
which may result in over or under-representation of SiNP uptake.  SiNP uptake was 
successfully demonstrated over 4-hours using TEM, localising within endosomal structures; 
consistent with fluorescence data. SiNPs are endocytosed by cells and stored in small 
clusters within cytoplasmic endosomes, providing further evidence that an endocytic 
pathway of uptake may be involved (Pritz et al., 2013; Shukur et al., 2016). However, 
internalisation of SiNPs resulted in the apparent fusion and degradation of SiNPs after 
several hours. SiNP degradation is known to be dependent on several factors, including pH 
(Yang et al., 2018; Hadipour et al., 2019). The pH of endosomes/lysosomes (6.5 to 4.5) is 
significantly lower than that of the surrounding cytoplasm (pH 7.0), which may partially 
account for the degradation observed (Yang et al., 2018). SiNP degradation products have 
been studied extensively, with orthosilicic acid, (Si(OH)4) identified as a major by-product  
(Quignard et al., 2017). Si(OH)4 is soluble, non-toxic and has been shown to be distributed 
throughout tissues, blood vessels before excretion through the urinary system (Jurkić et al., 
2013).  
 
3.2.4 PEG-ceria-modification improves endothelial cell viability 
 
Consistent with studies investigating the effects of SiNPs exposure on endothelial cells, 
SiNPs had no effect at lower concentrations, whilst reducing viability at higher 
concentrations (Nemmar et al., 2014; Guo et al., 2016). Conventionally, SiNP dosages are 
calculated as µg/ml; however, reactions mediated at the nanoparticle surface have been 
shown to be the predominant factor involved in ROS mediated toxicity, propagated by their 
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high surface area to volume ratio (Duan et al., 2013b, 2014). In light of this, the use of µg/ml 
does not reflect the total surface area of the nanoparticles; hence, in our studies, 
concentrations were calculated and displayed as NPs/ml, as opposed to mass (Shin et al., 
2015). PEG-modification significantly improved cell viability at high SiNP concentrations, 
which may be attributed to its reduced uptake, steric hindrance, and repulsion forces exerted 
by surface chains against surrounding contents. In addition to the benefits conferred by PEG, 
functionalisation with cerium-oxide facilitates antioxidant reactions following their eventual 
uptake, minimising ROS mediated damage to cellular proteins and lipids (Rzigalinski et al., 
2006; Korsvik et al., 2007) 
 
3.3 Chapter summary 
 
In summary, this part of the study aimed to develop a nanoparticle-based delivery platform 
for the potential loading and release of antioxidant compounds, with the ultimate goal being 
the development of a potential therapeutic tool for the treatment of diseases associated with 
elevated ROS in future applications. CeO2 functionalisation of SiNPs successfully 
attenuated surface reactivity, and demonstrated antioxidant capacity, resulting in heightened 
biocompatibility in vitro. However, several limitations were identified that would preclude 
their further use in this study; notably, their polydispersity and rapid degradation, which 
would result in inaccurate loading and uncontrolled release of drug. Consequently, it was 
concluded that subsequent work in this study would next investigate the effects of organic 
nanodelivery modalities to determine if they had improved drug delivery capacity, as will 
be described in the next chapter. 
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4 Chapter 4: Synthesis and 
characterisation of organic 
nanoparticles 
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CeO2 functionalised SiNPs displayed promising antioxidant potential and improved 
biocompatibility in the previous chapter; however, due to the limitations associated with 
their synthesis, this chapter will focus on the use of organic nanolipid carriers (NLCs) and 
liposomes for the sustained delivery of antioxidant compounds for the treatment of CVD. 
The hypothesis of this part of study is that RV-loaded NLCs will enhance the delivery 
and release of drug, reducing oxidative stress in vitro. This hypothesis will be addressed 
through the following specific objective: 
 
 Characterise organic lipid nanoparticles and define their antioxidant capacity and 
effect on endothelial cell viability in vitro. 
 
RV-NLCs were supplied by our collaborators from the University of Central Lancashire 
(Prof. Singh, UCLAN). TMS-liposomes were supplied by our collaborators from the 
University of Manchester (Dr. Harris, UoM). They were prepared using a hot melt 
emulsification technique and thin film process, respectively. Dye and drug-loading were 
determined in the present study using ultra-violet visible spectroscopy (UV-VIS) and 
fluorescence-spectroscopy; composition was assessed using fourier transform infrared 
spectroscopy (FTIR). Hydrodynamic size and zeta potential were determined by dynamic 
light scattering (DLS) and laser doppler micro-electrophoresis (LDME). Size and 
morphology were also assessed using transmission electron microscopy (TEM). The in 
vitro release profile of RV-NLCs was assessed using the dialysis bag diffusion method. 
The effect of organic lipid nanoparticles on viability and uptake were assessed in vitro 
using alamar blue and fluorescence microscopy, respectively. The effects of RV-NLCs 
on HCAEC mitochondrial and cytosolic O2•- were determined using MitoSOX and 
dihydroethidium (DHE), respectively.  
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4.1 Results 
 
4.1.1 RV-NLCs were successfully characterised  
 
RV-loaded NLCs were synthesised and characterised in PSS solution. Using UV-VIS and 
fluorescence spectroscopy,  RV- and RV-dye-loaded NLCs each displayed characteristic 
absorbance peaks at approximately 304 nm, confirming the presence of RV which was 
characteristically absent from the blank-NLCs (Figure 4.1A); a fluorescence peak was 
detected at 500 nm in RV-dye-loaded NLCs, confirming coumarin-6 loading (Figure 
4.1B).  
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Figure 4.1. Confirmation of drug and dye-encapsulation within NLCs. 
Characterisation of blank-, RV- and RV-dye-loaded nanolipid carriers (NLCs). (A) 
Ultraviolet-visible spectroscopy (UV-Vis) displaying absorbance spectra between 240-
500 nm. Absorbance peaks were observed at 304nm in RV- and RV-dye-loaded NLCs, 
confirming the presence of RV; which was characteristically absent from the blank-NLCs. 
(B) Fluorescence-spectroscopy displaying spectra between 460-680 nm. A fluorescence 
peak was detected at 500 nm in RV-dye-loaded NLCs, confirming coumarin-6 loading. 
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FTIR was used to confirm the molecular structure of the RV-NLCs. The strong, broad 
band characteristic for trans-RV can be observed between 3550-3200 cm-1, originating 
from the OH valence vibrations of phenolic groups (Figure 4.2A). The bands 3021 cm-1 
and 2924 cm-1 are a result of the valence vibration of ethenyl groups (=C-H) and C-H 
bonds, respectively. Phenolic compounds are consistently accompanied by characteristic 
aromatic hydrocarbons (benzene). The valence vibrations of the benzene ring (C=C) were 
observable at 1601, 1587, 1512 and 1444 cm-1. The presence of RV could not be 
confirmed in the RV-NLCs using FTIR, due to the absence of corresponding peaks 
(Figure 4.2B). However, the infrared spectrum of NLCs highlight peaks corresponding to 
its parent lipid constituents, with peaks at 2950-2850 and 1730 cm-1 corresponding with 
the presence of alkane (C-H) and carbonyl ester groups (C=O), consistent to the lipid 
components trimystrin and glyceryl trioleate, respectively. The weak, broad band 
observed at 3400 cm−1 is attributed to OH stretching. 
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Figure 4.2. Confirmation of NLC molecular structure. Fourier transform infrared 
spectroscopy (FTIR) spectra of (A) RV-powder (purple), and (B) blank- (blue), RV- (red), 
and RV-dye-NLCs (green) respectively, displaying transmittance (%) between 500-4000 
cm-1. Characteristic transmittance peaks are indicated on the figure itself (for 
interpretation of the reference values, refer to main text). 
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Having confirmed the molecular structure of the RV-NLCs, the next characteristics to be 
assessed were size, stability and electrophoretic mobility. Following sonication, RV-
NLCs were significantly reduced in size, characterised as having a size of 55.78 ± 2.964 
nm and polydispersity index of 0.244 ± 0.003, demonstrating that the particles were 
monodispersed in comparison to their pre-sonicated, polydispersed state (996 ± 206 nm; 
P = < 0.01; Figure 4.3A). Sonication had a negligible effect on surface charge, with an 
average zeta potential of 25.6 ± 0.251 mV and a PDI of 0.252, indicating good stability 
(Figure 4.3B). Incubation of RV-NLCs (0.45 µM) in PSS led to an increase in size after 
30-minutes, from 68.97 ± 1.36 nm to 98.7 ± 4.5 nm (P = < 0.0001; Figure 4.3C); 
incubation in media had no effect. Surface charge after incubation in PSS and media is 
similar over the 4-hour period, indicating stability of the RV-NLCs (Figure 4.3D).  
TEM was used to determine the morphological structure and size of the NLCs, 
successfully confirming them to be spherical and monodispersed, with an average particle 
size of 82.5 ± 4.65 nm (Figure 4.4).  
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Figure 4.3. Stability and electrophoretic mobility of RV-NLCs in aqueous medium. 
Resveratrol-loaded nanolipid carrier (RV-NLC) stability was assessed in water using 
dynamic light scattering and laser doppler micro-electrophoresis, pre- and post-
sonication. (A) Sonication led to a significant decrease in size (996 ± 206 nm to 55.78 ± 
2.964 nm; P = < 0.01) and had a negligible effect on surface charge, with an average 
zeta potential of 25.6 ± 0.251 mV (B).  (C) RV-NLC size and zeta potential were assessed 
in PSS and cell culture medium over 4-hours (0-, 0.5-, 1-, 2- and 4-hours). Incubation of 
RV-NLCs (0.45 µM) in PSS led to a significant increase in size after 30-minutes (68.97 ± 
1.36 nm to 98.7 ± 4.5 nm; P = < 0.0001); size was unaffected in media. (D) Surface 
charge was unaffected over the 4-hour period, indicating stability of the RV-NLCs in PSS 
and media. Experiment performed in triplicate and repeated three times. The effects of 
sonication and time-dependent stability of RV-NLCs were analysed using an unpaired t-
test and two-way ANOVA followed by Tukey’s multiple comparisons, respectively (n = 
3). Data are presented as mean ± SEM. * P < 0.05.**** P < 0.0001. 
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Figure 4.4. Morphological structure of NLCs. Representative transmission electron 
(TEM) micrographs of nanolipid carriers (NLCs). NLCs were fixed with osmium tetroxide 
and stained with uranyl acetate, dried and imaged. NLCs are seen as spherical and 
monodispersed, with an average particle size of 82.5 ± 4.65 nm. Random measurement 
sampling (n = 31) from micrographs (ImageJ). Magnification 13,000 x. Scale bars = 200 
nm and 100 nm, respectively.  
 
Next, the pharmacokinetic release profile of RV-NLCs and RV-solution were determined 
in order to assess the effects of encapsulation on RV diffusion. RV-loading within NLCs 
significantly reduced the release of RV into the surrounding medium, with maximum 
release (27.7 %) observed after 12-hours; significantly less than the maximal release 
observed from the RV-solution after 11-hours (71.5 %; P = < 0.0001). This confirms the 
ability of NLCs to hold the entrapped drug and protect it, reducing its release and 
degradation in the outer media (Figure 4.5) (Khurana et al., 2017).               
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Figure 4.5. Dissolution of RV-NLCs and RV-solution in vitro. The in vitro release 
profile was determined using a dialysis bag diffusion method (37 °C, pH 7.4) over 24-
hours. Samples were taken at predetermined time intervals and analysed using high-
performance liquid chromatography. RV-loading within NLCs significantly reduced the 
drug release into the surrounding medium, with a maximum release (27.7 %) observed 
after 12-hours; significantly less than the maximal release observed from the RV-solution 
after 11-hours (71.5 %; P = < 0.0001). Drug release was analysed by a two-way AVONA. 
Data are presented as mean ± SEM. **** P < 0.0001. 
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4.1.2 RV-NLCs maintain endothelial cell viability and diminish H2O2 induced 
superoxide generation, in vitro  
 
Having characterised the properties of the RV-NLCs, it was next of interest to assess their 
effects on endothelial cells in vitro.  Following 24-hours co-incubation of NLCs or RV-
solution with HCAECs, no significant change in cell viability was observed (Figure 
4.6A); however, at the highest dose (90 µM), a significant reduction in viability of 23 % 
was detected between blank- and RV-dye- NLCs (P = < 0.01). Continued exposure over 
48- and 72-hours resulted in a significant reduction in viability in cells exposed to NLCs 
(< 40 %), in comparison to those treated with the RV-solution at concentrations of 90 µM 
and 45 µM (P = < 0.0001; Figure 4.6B and C, respectively).  
 
 
 
 
 
 
 
 
 
 
Continued… 
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Figure 4.6. Effect of RV-NLCs on cell viability. Human coronary artery endothelial cell 
(HCAEC) viability following exposure to NLCs (blank-, RV-, RV- dye-loaded) and RV-
solution at concentrations ranging between 0.045-90 µM over (A) 24-, (B) 48- and (C) 
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72-hours. RV-NLCs had no significant effect on cell viability, other than at 90µM (P = < 
0.01) after 24-hours. After 48- and 72-hours, NLCs (blank-, RV- and RV-dye) 
significantly reduced cell viability at 90 µM and 45 µM, in comparison to RV-solution (P 
< 0.0001). Cell viability was determined using an Alamar blue assay (n = 3). Data 
normalised to control wells (untreated). Experiment performed in triplicate and repeated 
three times. Cell viability was analysed by a two-way ANOVA followed by a Tukey’s 
multiple comparison. Data are presented as mean ± SEM.** P < 0.01. **** P < 0.0001. 
 
Having identified the most biocompatible concentrations for use, it was of interest to 
assess RV-NLC uptake and localisation within cells. Fluorescence microscopy 
demonstrated that RV-dye-loaded NLCs (0.45 µM) were taken up by >90 % of HCAECs 
after 30-minutes (Figure 4.7).  
 
Figure 4.7. RV-NLC uptake within HCAECs. Representative fluorescence micrographs 
of human coronary artery endothelial cells (HCAECs) incubated with growth medium or 
RV-dye-loaded (coumarin-6) NLCs for 30-minutes, followed by DAPI (nuclear) and 
phalloidin (actin) staining. RV-NLCs (0.45 µM) displayed good uptake following 30-
minutes incubation. Magnification 20 x. Scale bar = 100 µm. Images acquired from 1 of 
5 representative slides. 
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After confirming the biocompatibility and uptake of RV-NLCs (0.45 µM), their 
antioxidant potential within an oxidative environment was assessed in vitro. Initially, 
HCAEC tolerances were determined following 30-minutes exposure to H2O2 (0-500 µM), 
whereby a significant reduction in cell viability was observable at 500 µM (P = < 0.001; 
Figure 4.8A). Exposure to H2O2 (100 µM; 30-minutes) followed by fresh media (30-
minutes) significantly elevated mitochondrial and cytosolic O2•- levels in HCAECs (P = 
< 0.001; < 0.01; Figure 4.8B). Incubation with RV-NLCs significantly reduced 
mitochondrial and cytosolic superoxide levels compared to treatment with media alone 
(P = < 0.01; < 0.001, respectively). In vitro studies demonstrated that NLCs are well 
tolerated across a range of concentrations, whilst also displaying good uptake and 
antioxidant capability following 30-minutes incubation with 0.45 µM RV-NLCs. To 
mitigate potential future pharmatoxicological effects, ex vivo studies were conducted 
using this concentration.  
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Figure 4.8. Effect of H2O2 and RV-NLCs on oxidative reactivity in vitro.  (A) Human 
coronary artery endothelial cell (HCAEC) viability following exposure to hydrogen 
peroxide (H2O2; 0-500µM) for 30-minutes. H2O2 exposure had no significant effects on 
cell viability, other than at 500 µM (P = < 0.001). Cell viability determined using an 
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Alamar blue assay (n = 3). Data normalised to control wells (untreated). (B) Exposure to 
H2O2 (100 µM; 30-minutes) followed by fresh media (30-minutes) significantly elevated 
mitochondrial (MitoSOX) and cytosolic (dihydroethidium; DHE) superoxide levels in 
HCAECs (P = < 0.001; < 0.01) compared to control cells (untreated). Incubation with 
RV-NLCs (0.45 µM) significantly reduced mitochondrial and cytosolic superoxide levels 
compared to treatment with media alone (P = < 0.01; < 0.001, respectively). Data 
expressed as a fold-change change from control (untreated cells – no H2O2/RV; n = 3). 
Experiment performed in triplicate and repeated three times. Cell viability and oxidative 
reactivity were analysed using a one-way ANOVA followed by Bonferroni correction and 
two-way ANOVA followed by Tukey’s multiple comparisons, respectively. Data are 
presented as mean ± SEM. ** P < 0.01. *** P < 0.001. 
 
4.1.3 TMS-liposomes were successfully characterised  
 
TMS-loaded liposomes were characterised in PSS solution. Using UV-VIS and 
fluorescence spectroscopy, TMS-solution showed two characteristic absorbance peaks at 
315 nm and 341 nm (Figure 4.9A). No corresponding peaks were observable in blank-, 
TMS- or TMS-dye-liposomes. TMS-dye-liposomes had an absorbance peak at 492 nm, 
characteristic of the 5'6 carboxyfluorescein dye. A fluorescence peak was detected at 517 
nm in TMS-dye-liposomes, further confirming dye loading. No peaks were detectable 
from blank- or TMS-liposomes, confirming the absence of dye-loading (Figure 4.9B).  
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Figure 4.9. Confirmation of drug and dye-encapsulation within liposomes. 
Characterisation of blank-, TMS-, TMS-dye-liposomes and TMS-solution. (A) 
Ultraviolet-visible spectroscopy (UV-Vis) displaying absorbance spectra between 200-
600 nm. Absorbance peaks were identified at 315 nm and 341 nm in TMS-solution but 
was absent from other samples. TMS-dye-liposomes had an absorbance peak at 492 nm, 
associated with the 5'6 carboxyfluorescein dye. Blank-, TMS-, and TMS-dye-liposomes 
had a spectral peak identifiable at 207 nm, attributable to cholesterol. (B) Fluorescence-
spectroscopy displaying spectra between 500-700 nm. A fluorescence peak was detected 
at 500 nm in RV-dye-loaded NLCs, confirming coumarin-6 loading. 
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FTIR was used to confirm the molecular structure of the TMS-liposomes. FTIR revealed 
that TMS has a similar infra-red profile to its well-characterised parent compound RV, 
with characteristic benzene valence (C=C) vibrations identifiable at 1587 and 1570 cm-1 
(Figure 4.10A). The strong, broad band characteristics of trans-RV are noticeably absent 
between 3550-3200 cm-1; however, several bands are identifiable at 2850, 2952 and 3000 
cm-1, corresponding to the valence vibration of O-CH3 bonds within synthetically 
conjugated methyl groups. At 1444 cm-1, additional CH3 bending is observed. Ether 
bonds (C-O-C) originating from phenolic groups are identifiable at 1026, 1154, and 1248 
cm-1 (Figure 4.10B). The bands at 675 cm-1 and 831 cm-1 correspond to the deformational 
vibration of OH groups and C-H bonds, originating from the benzene ring. 
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Figure 4.10. Confirmation of TMS and RV molecular structure. (A) Fourier transform 
infrared spectroscopy (FTIR) spectra of TMS-powder (red), displaying transmittance (%) 
between 500-4000 cm-1. (B) Juxtapositional comparison of the ‘fingerprint’ region of the 
spectra (500-1600 cm-1) between TMS- and RV-powder. Characteristic transmittance 
peaks are indicated on the figure itself (for interpretation of the reference values, refer to 
main text). 
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The presence of TMS could not be identified in the liposomes due to the absence of 
corresponding peaks (Figure 4.11). The individual components of the liposomal structure, 
1,2-distearoyl-sn-glycero-3-phosphocholine and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] ammonium salt were 
identifiable with peaks between 2950-2850 and 1750 cm-1, corresponding with the 
presence of alkane (C-H) and carbonyl ester groups (C=O). The broad peak observed 
between 3550-3200 cm-1 is a result of OH groups found within fatty acids (cholesterol).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. Confirmation of entrapment and molecular structure. Fourier transform 
infrared spectroscopy (FTIR) spectra of blank- (purple) and TMS-loaded liposomes 
(blue), displaying transmittance (%) between 500-4000 cm-1. Characteristic 
transmittance peaks are indicated on figures (for interpretation of the references, refer 
to main text).   
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Next, the size, stability and electrophoretic mobility of TMS-liposomes were assessed. 
TMS-liposomes incubated in PSS were stable over 4-hours, with an average size, PDI 
and zeta potential of 157 ± 3 nm, 0.097 and 13.13 ± 0.67 mV, respectively (Figure 4.12A, 
B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12. Stability and electrophoretic mobility of TMS-liposomes in aqueous 
medium. TMS-liposome size and zeta potential were assessed in PSS over 4-hours (0-, 
0.5-, 1-, 2- and 4-hours) using dynamic light scattering and laser doppler micro-
electrophoresis, respectively (n = 3). Incubation of TMS-liposomes (1000 nM) in PSS had 
no effect on (A) size or (B) zeta potential over the 4-hour period, indicating stability of 
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the TMS-liposomes. Experiment performed in triplicate and repeated three times. Data 
analysed using a one-way ANOVA followed by Bonferroni correction. 
 
 
TEM was used to determine the morphological structure and size of the liposomes, 
successfully confirming them to be spherical and monodispersed, with an average size of 
148.3 ± 7.9 nm (Figure 4.13).  
 
Figure 4.13. Morphological structure of liposomes. Representative transmission 
electron (TEM) micrographs of liposomes. Liposomes were fixed with osmium tetroxide 
and stained with uranyl acetate, dried and imaged. Liposomes are seen as spherical and 
monodispersed, with an average particle size of 148.3 ± 7.9 nm. Random measurement 
sampling (n = 26) from micrographs (ImageJ). Magnification 13,000 x. Scale bar = 200 
nm. 
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4.1.4 TMS-liposomes maintain endothelial cell viability  
 
Having characterised the properties of the TMS-liposomes, it was next of interest to 
assess their effects on endothelial cells in vitro.  Following 24-hours co-incubation of 
TMS-liposomes or TMS solution with HCAECs, no significant change in cell viability 
was observed at concentrations ranging between 1000 nM and 1 nM; however, at 0.01 
nM and 0.1 nM, TMS-solution resulted in significant reductions in viability of 26 % and 
21 %, respectively (P = < 0.05; Figure 4.14A). Continued exposure over 48-hours resulted 
in further reductions in viability at 0.01 nM in TMS-, TMS-dye-liposomes and TMS-
solution (P = < 0.001; Figure 4.14B). After 72-hours, blank-, TMS-, TMS-dye-liposomes 
and TMS-solution each led to significant reductions in viability at 0.01 nM (P = < 0.05; 
P = < 0.001 and P = < 0.0001, respectively; Figure 4.14C).  
 
 
 
 
 
 
 
 
 
Continued… 
118 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14. Effect of TMS-liposomes on cell viability. Human coronary artery 
endothelial cell (HCAEC) viability following exposure to liposomes (blank-, TMS-, TMS 
+ dye-loaded) and TMS-solution at concentrations ranging between 0.01-1000 nM over 
(A) 24-, (B) 48- and (C) 72-hours. No overall change in cell viability was observed at 
concentrations ranging between 1000 nM and 1 nM after 24-hours; however, at 0.01 nM 
and 0.1 nM, TMS-solution resulted in a significant reduction in viability (P = < 0.05). 
After 48-hours, further reductions in viability were observed in liposomes (TMS-, TMS-
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dye) and TMS-solution at 0.01 nM (P = < 0.001). After 72-hours, liposomes (blank-, 
TMS-, TMS-dye) and TMS-solution each led to significant reductions in viability at 0.01 
nM (P = < 0.05; P = < 0.01 and P = < 0.0001, respectively). Cell viability was 
determined using an Alamar blue assay (n = 3). Data normalised to control wells 
(untreated). Experiment performed in triplicate and repeated three times. Data was 
analysed by comparing to control wells (untreated (i.e. 100% viable); not shown) using 
a two-way ANOVA followed by a Tukey’s multiple comparison. Data are presented as 
mean ± SEM. * P = < 0.05. *** P < 0.001.**** P < 0.0001. 
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4.2 Discussion 
 
4.2.1 RV-NLCs were successfully characterised 
 
Organic NLCs were synthesised and characterised using the same range of analytical 
techniques as described in the previous chapter, with drug and dye entrapment confirmed 
using UV-VIS and fluorescence spectroscopy. The absorption spectra confirmed the 
presence of the trans-RV isomer at approximately 304 nm, defining it from its less 
characterised, less potent cis-isomer, which has a characteristic absorbance peak at 285 
nm (Camont et al., 2009).  FTIR was able to successfully confirm the presence of 
constituent compounds used to synthesise the NLCs; however, the spectrographic profile 
for RV was not distinguishable. Despite the popularity of FTIR, the sensitivity of the 
technique is often limited, particularly for materials with poor infrared absorption or when 
the spectral bands of major components overlap. Similar observations have been reported 
previously by several research groups, where nanoparticles are capable of obscuring the 
absorption peaks of encapsulated drugs, showing only the predominant parent compounds 
(Pople and Singh, 2011). In addition, the lack of any additional new peaks observed in 
the RV-NLC spectra suggests no strong/adverse interactions or incompatibility. 
Given the translational goal of this project to develop a clinical tool for drug delivery in 
patients, it is of great importance to consider the nanoparticle absorption and their 
interdependence with physicochemical properties of drug carrier systems, which 
currently are not well understood. Size has been postulated as a crucial determinant of 
nanoparticle efficacy, with studies identifying improved stability, uptake, and permeation 
ability in both the gastrointestinal system and blood with nanoparticles of smaller size (< 
100 nm) (Li et al., 2016). The 10-fold reduction in size observed in our samples are 
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indicative of the importance and significant effects of sonication prior to administration; 
whilst maintenance of surface charge confirms it has no detrimental effect on nanoparticle 
stability (Al-Kaysi et al., 2005).  
A rapid increase in particle size was identified following incubation in PSS, attributable 
to ionic adsorption on the nanoparticle surface. This is also reflected in the higher zeta 
potential values observed in PSS (pH 7.2-7.4; -9 mV) when compared to stock solution 
pre- and post-sonication (water, pH 6.8; -25 mV). No increase in size was observed for 
several hours in the culture medium, likely due to the low percentage of serum proteins 
(<5 %) present within the culture medium (leading to time-dependent corona formation). 
Not much change in zeta potential was observed over several hours due to the absence of 
any ions in the culture media (pH 7.2 - 7.4; -5 mV); however, the surface charge was still 
higher relative to zeta potential measurements in water, suggesting interaction. It should 
be noted that in aqueous media, the pH of the sample is directly related to its zeta 
potential. Many nanoparticles exhibit an effective charge change in aqueous conditions, 
from positive (at low pH) to negative (at high pH) with an isoelectric point (0 mV, 
unstable) in between (Salgin et al., 2013). Variations in pH e.g. water, pH 6.8 vs PSS, pH 
7.4, are likely to account, in part, for the observed fluctuation in zeta potential between 
solutions. NLCs incubated in PSS showed an increased PDI over several hours, with a 
maximum PDI of 0.377. Similarly, NLCs in media resulted in progressively increasing 
PDI over time, however, in each instance to a lower extent than in PSS with a maximum 
PDI of 0.274. These results demonstrated that NLCs were within acceptable levels of 
monodispersity.  
Despite its overarching popularity in the nanomaterial field, DLS is still considered a low-
resolution technique; several limitations are affiliated with its use, including the inability 
to accurately determine nanoparticle size in biologically relevant environments. Due to 
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their high surface free energy, nanoparticles adsorb ions (electrostatic attraction) upon 
interaction with abiotic environments, forming a diffuse electrical double layer. Ions trapped 
within this electrical double layer otherwise referred to as the ‘slipping plane’, lead to size 
overestimation when measured using techniques such as DLS. Due to the limited capability 
of DLS, measuring the hydrodynamic diameter of the particle, as opposed to the particle 
itself; SEM or TEM are utilised to provide a more accurate representation of nanoparticle 
diameter.  TEM identified an average size of 82.5 nm, a 17 % reduction when compared 
to DLS, highlighting the techniques ability to mitigate the artificial increases in size. 
The drug release profile of RV-NLCs was measured in vitro. RV-NLCs displayed an 
extended, slow-release of RV over 12-hours with no burst effect. In comparison, non-
encapsulated RV resulted in a much faster release. The sustained release observed is 
likely attributable to the slow diffusion of RV entrapped within the lipid matrix, with a 
maximal release of RV observed following 12-hours (27.7 %) compared to the diffusion 
of the non-encapsulated RV alone (maximum diffusion 71.5 % at 11-hours). The three 
bent carbon chains of triolein disrupt the packing of trimyristin crystals, offering better 
stability and higher drug loading (Yang et al., 2014). This confirms the ability of NLC to 
hold the entrapped drug and protect it, reducing its release and degradation in the outer 
media (Khurana et al., 2017).  
 
4.2.2 RV-NLCs maintain endothelial cell viability  
 
While the exposure to RV encapsulated-NLCs had no overall effect on endothelial cell 
viability, incorporation of the dye within RV-NLCs led to reduced viability at higher 
concentrations. The toxic effects of fluorophores have been previously investigated, 
which may account for this reduction in viability (Farooq, 2014). Previous studies have 
123 
 
demonstrated the dose-dependent effects of the unencapsulated form of RV on 
endothelial proliferation and apoptosis, with concentrations above 50 µM resulting in 20-
50 % cell death following 24-hours incubation (Szende and Tyihák, 2000; In et al., 2006; 
Maria et al., 2015). These findings contrast with the data obtained from this study, 
suggesting that the improved biocompatibility of our RV-NLCs may be attributable to 
encapsulation, resulting in a slower, sustained release of RV over time. Prolonged 
exposure (48- and 72-hours) to blank- and RV-NLCs led to a significant reduction in 
viability at higher concentrations, which was not observed with the RV-solution. High 
concentrations of RV have been shown to induce pro-oxidant effects, dependant on 
exposure time, dose and cell type (Giordo et al., 2013; Martins et al., 2014). The RV 
mediated generation of O2•- and •OH can result in the formation of lipid peroxides via 
interactions with, e.g. membrane lipids; these lipid peroxides are ultimately degraded into 
alkoxyl and peroxyl radicals, initiating further oxidation and cytotoxicity (Gutteridge, 
1984). In cells treated with NLCs, the particle capsule provides a rich source of lipid 
available for oxidation. In contrast, in cells treated with RV-solution, the primary source 
of lipid resides within the cell membrane only. At high concentrations, a more substantial 
reduction in viability might be expected following incubation with RV-solution; however, 
our laboratory has previously demonstrated the rapid degradation of unencapsulated-RV 
over a one-hour test period (Diaz et al., 2019). Additionally, limited information is 
available regarding the degradation products of RV and their long-term toxicological 
effects. Elevated accumulation of these products may account for the increased toxicity 
observed at high concentrations. However, this is unlikely to be the case as a more 
substantial reduction in viability would be expected following exposure to an RV-
solution.  
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Interestingly, a subtle trend is observed at lower concentrations (0.045 - 4.5 µM), with 
the lowest concentration resulting in reduced viability too. Several reasons may account 
for these changes. RV is known to have concentration-dependent biphasic effects (e.g. 
inducer of apoptosis vs proliferation). This hormetic response has been observed across 
a broad range of biological models (Calabrese et al., 2010). Additionally, RV has been 
shown to be a regulator of metabolic activity, mediated via AMPK/SIRT-1 and 
subsequent peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-
1) modulation. However, despite the frequent use of alamar blue as a cell viability assay, 
it is, in fact, an indicator of cellular metabolism and may, therefore, be influenced by 
metabolic modulation by RV. Uptake into HCAECs was confirmed within 30-minutes of 
exposure of the cell to the RV-NLCs, which were observed throughout the cytosol; the 
presence of the triglyceride triolein within the NLCs likely contributing to its improved 
uptake via modulation of the cell membrane (Prades et al., 2003). RV-NLCs were 
identified diffusely throughout the cytoplasmic compartment and were notably absent 
within the nucleus, which is consistent with findings previously reported in HUVEC and 
HepG2 cells following RV exposure (Lançon et al., 2004; Chen et al., 2013). This 
accumulation and retention of RV within the cytoplasm of endothelial cells might explain 
the paradoxical observations that RV has low bioavailability in humans while exerting 
noticeable bioactivities (Magyar et al., 2012). The apparent lack of nuclear uptake 
demonstrated by us and others suggests the indirect effects of RV are mediated by second 
messengers within the cytosol, modulating gene expression. Amongst the cytoplasmic 
compartment, RV-NLCs appeared to form clusters which may be indicative of clathrin-
dependent or clathrin-independent (caveolin-dependent) endocytic uptake. Previous 
research investigating the uptake mechanics of intestinal epithelial cells observed reduced 
cellular uptake of NLCs when performed at 4 oC and in the presence of energy inhibitors 
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such as sodium azide; with a dependency on cellular energy potentially indicative of an 
endocytic mechanism. This was further corroborated following inhibition of clathrin- and 
caveolin-dependent endocytosis, each limiting uptake; however, clathrin-mediated 
uptake was identified as the predominant pathway (Neves and Queiroz, 2016; Piazzini et 
al., 2018). In each instance, however, the NLCs were >180 nm in diameter. Endocytic 
processes are highly regulated, with nanoparticle size being heavily influential on 
respective uptake pathways (He et al., 2010). Although variation exists, clathrin-coated 
vesicles have an approximate diameter of 100-200 nm, whilst caveosomes are smaller 
measuring between 60-100 nm (Rejman et al., 2004; Wang et al., 2009). As the average 
size of our NLCs was 82.5 ± 4.65 nm (based on TEM), preferential uptake of NLCs by 
caveolin-dependent endocytosis would be expected.  
 
4.2.3 RV-NLCs diminish H2O2 induced superoxide generation 
 
The generation of mitochondrial and cytosolic O2•- in HCAECs exposed to H2O2 was 
significantly reduced in the presence of RV-NLCs compared to untreated controls. 
Mitochondrial and cytosolic O2•- is a significant contributor to NO quenching and has 
previously been found to be increased in isolated arteries following elevated pressure, 
interfering with flow mediated-dilation and endothelial-dependent dilation in multiple 
vascular beds (Ungvari et al., 2003; Christensen et al., 2007; Peluffo et al., 2009). As a 
means of replicating the elevated O2•- levels observed in the vasculature following 
pressure elevation, cells were stimulated with H2O2. Previous studies have observed 
elevated intracellular O2•- generation following brief periods of exposure (< 10-minutes) 
to H2O2, potentially mediated via the NADPH oxidase and xanthine oxidase pathways, as 
well as through NOS uncoupling (Carter et al., 1994; Coyle et al., 2006; Coyle and Kader, 
126 
 
2007). Our findings are consistent with previously observed results, whereby RV resulted 
in attenuated mitochondrial O2•- in HCAECs following hyperglycaemia-induced 
mitochondrial ROS generation (Ungvari et al., 2009). However, differences in the mode 
of ROS generation, means of RV delivery and varied exposure times make direct 
comparisons difficult. RV has been found to reduce O2•- through both direct and indirect 
mechanisms and has demonstrated a strong ability to directly remove free radicals. This 
property is primarily attributed to the presence of hydroxyl groups in both phenyl rings 
of the stilbene scaffold, promoting hydrogen-atom transfer (HAT) from hydroxyl groups 
to surrounding reactive oxidants, a common feature amongst phenolic compounds (Cao 
et al., 2003; Caruso et al., 2004; Iuga et al., 2012). In addition to its direct antioxidant 
ability, RV has been associated the activation and upregulation of several molecular 
targets involved in the propagation of dilation and regulation of basal antioxidant activity 
including eNOS, SOD, CAT, and nuclear factor erythroid 2-related factor 2 (Nrf2) (Xia 
et al., 2017). However, due to the limited/short incubation period, it is unlikely that these 
effects relate to the upregulation of antioxidant genes, but are attributable to post-
translational modification, e.g. increased phosphorylation of eNOS.  
Whilst the effects of RV-loaded NLCs appear to be beneficial in reducing intracellular 
O2•-, the effect of blank-NLCs were not investigated. In the absence of RV and its 
antioxidant benefit, elevated O2•- may be expected as the particle capsule provides a rich 
source of lipid available for oxidation. However, the administration of exogenous lipid 
has also been shown to be beneficial, promoting the release of EDRF and EDHF in the 
vasculature, as well as demonstrating antioxidant capacity, although, this is highly 
dependent of the type of lipid utilised (Ruisanchez et al., 2014; Limbu et al., 2018). There 
are a limited number of studies that have investigated the antioxidant activity of the 
constituent lipid capsule components, trimystrin and triolein. A study by Luo et al., 
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demonstrated the indirect antioxidant capacity of triolein following oxidative LDL 
stimulated ROS generation over 24-hours, significantly improving cell viability and 
increasing the expression of SOD. However, at 10 µM, the concentration was several 
fold-higher than that utilised in our studies; whilst 0.45 µM RV-NLCs were used in our 
studies, triolein accounts for only a small proportion of the total contents. Moreover, our 
studies have focused on acute exposure to RV-NLCs over 30-minutes, due to the 
limited/short incubation period, it is unlikely that these effects relate to the upregulation 
of antioxidant genes; which in combination with the limited concentration, may explain 
the apparent lack of benefit. Furthermore, whilst successfully demonstrating upregulation 
of SOD, O2•- levels were not directly assessed and is therefore not a direct reflection of 
antioxidant ability (Luo et al., 2014). A further study by Chan et al. demonstrated the 
direct ability of triolein to scavenge oxygen-derived free radicals, resulting in up to a 
31.9% reduction at concentrations ranging between 1 µM and 10 nM, however, this was 
performed using pure triolein extract (Chan et al., 1996). Whilst trimystrin is another 
major constituent component of the lipid capsule, a review of the literature has not 
revealed any reports of antioxidant capacity. No definitive conclusions can be drawn 
pertaining to the potential effects of blank-NLCs from the literature, however given the 
concentrations and length of exposure used in these studies it is unlikely the effects we 
observe could be caused by the lipid components alone. To confirm this, future studies 
would need to evaluate the response to blank-NLCs. 
Due to its successful uptake in vitro and impressive O2•- reducing capacity at a minimal 
dose of 0.45 µM RV-NLCs, this dosage was used for subsequent ex vivo studies. 
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4.2.4 TMS-liposomes were successfully characterised  
 
Drug and dye entrapment were assessed using UV-VIS and fluorescence spectroscopy. 
Independent analysis of TMS-solution identified two absorbance peaks at 315 nm and 
341 nm, similar to that of the parent compound RV. This is not unexpected for synthetic 
analogues; following the synthetic conjugation of methyl groups, heightened 
delocalisation of pi bonding orbitals within the molecule in response to photonic 
stimulation would be observed, reducing the energy required to induce chromophoric 
absorption and thus, producing a rightward shift towards the visible wavelength region 
(Suzuki, 1967). Despite the successful detection of TMS-solution, no peaks relating to 
TMS were distinguishable in either of the TMS-loaded samples. Due to the limited 
content encapsulated within liposomes, a substantial absorptance peak would not be 
expected and may, therefore, become obscured by more prominent absorption peaks, as 
seen at 207 nm. Intense absorption peaks in the high-frequency range have previously 
been documented in liposomes and have been attributed to the presence of cholesterol. 
Cholesterol and other well-known oxysterols have been shown to absorb light in the 
vacuum-UV region (< 200 nm). However, light scattering results in the λ max (peak 
absorbance) shifting rightwards towards a lower energy state, producing an effect commonly 
referred to as false energy. This results in a spectral ‘redshift’, with the λ max now 
appearing in the 207 nm region (Gupta et al., 2014).  
FTIR identified several peaks which corresponded with the parent compound RV, 
confirming its derived nature. FTIR confirmed the presence of constituent compounds 
used to synthesise the liposomes; however, the spectrographic profile for TMS was not 
distinguishable. Similar observations have been reported previously by several research 
groups, where nanoparticles can obscure the absorption peaks of encapsulated drugs, 
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showing only the predominant parent compounds (Pople and Singh, 2011). In the context 
of polyphenolic compounds, the presence of OH groups are commonplace and would be 
expected at around 3500 cm-1. Despite originating from a polyphenolic compound, it is 
crucial to note that in TMS, OH groups have been substituted for synthetically conjugated 
methyl groups, and as a result would not expect valance vibration bands at 3500 cm-1. 
Consequently, the presence of a broad peak on both blank and TMS-liposomes at 
approximately 3500 cm-1 may be solely attributed to the lipid components; not TMS. An 
in-depth examination of the fingerprint region (500-1600 cm-1); an area characterised by 
its high specificity for a given compound, identified several similarities between the 
spectral profile of RV and TMS; they are, however, distinctly unique. The distribution 
and intensity of absorption (% transmission) bands (blank vs TMS- loaded liposome) are 
a direct reflection of the range and quantity of chemical bonds present within a given 
sample. In some instances, this may reflect an increase or decrease in band intensity, as a 
result of sample modification and altered chemical composition. In this case, however, 
the varied intensities observed between samples can be attributed to different dilution 
ratios of stock samples. 
Incubation in PSS over several hours had no effect on size, with small, yet non-significant 
fluctuations in zeta potential, indicating the stability of the colloidal system. TEM 
determined an average size of 148.3 ± 7.9 nm. Closer inspection of the liposomes 
highlighted aberrant morphology, appearing concave in structure. Similar observations 
have been documented previously, with a large dependency on the mode of processing 
and technical implementation employed (e.g. scanning-, cryo-, low-voltage-). Due to the 
limited contrast of lipids, samples were rapidly fixed using osmium tetroxide and 
negatively stained with uranyl acetate, an electron-dense metal with the ability to embed 
directly into the membrane. Exclusion of the stain from the volume occupied by the 
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sample provides contrast to the surrounding membrane. During staining and subsequent 
drying, liposomes lose their hydration shell and are prone to collapse, leading to an 
accumulation of negative stain around the periphery of the liposomes; resulting in the 
‘halo’ effect observed in our samples. In future, the use of cryo-TEM in conjunction with 
perforated carbon supports should be used to mitigate the processing artefacts discussed 
above.  
4.2.5 TMS-liposomes maintain endothelial cell viability  
Limited information exists on the potential effects of TMS on endothelial cells, with a 
primary focus to date being placed on cancer cells as a result of its potent antiproliferative 
potential. Exposure to TMS and TMS-liposomes had no effect on cell viability at higher 
concentrations.  In our studies, TMS-liposomes showed improved viability at each 
concentration in comparison to TMS-solution after 24-hours, although, this was not 
significant. Liposomes have been found to improve overall uptake and reduce systemic 
drug toxicity in a multitude of studies; liposome-enveloped substances are protected from 
enzyme-mediated degradation or inactivation by the immune system and similar to NLCs, 
result in the sustained release of internalised contents (Szoka  Jr et al., 1987; Mehta, 1996; 
Raj et al., 2013). After 48- and 72-hours, viability was maintained (>80 %), other than at 
0.01 nM. The increased toxicity observed at lower concentrations is consistent with 
observations made in RV. 
 
4.3 Chapter summary 
 
This part of the study aimed to assess the potential of RV loaded within trimyristin-
triolein NLCs, and TMS loaded within liposomes as a therapeutic platform for the 
treatment of ROS-associated disease. Using chemi-analytical techniques, stable NLCs 
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with the ability to entrap and release RV (as a model organic molecule) over sustained 
periods of time were successfully characterised. Furthermore, RV-NLCs have 
demonstrated their ability to successfully deliver and release in vitro, reducing both 
cytosolic and mitochondrial O2•- anion levels; highlighting their potential use as an 
antioxidant in future applications. Stable TMS-liposomes were synthesised, with no effect 
on cell viability. The effects of RV-NLCs and TMS liposomes on the coronary and/or 
cerebral vasculature will be assessed in the subsequent chapters. 
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5 Chapter 5: Development of an ex vivo 
model of acute hypertension for the 
evaluation of novel treatment strategies 
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Having successfully identified NLCs as a suitable delivery platform that may be loaded 
with an antioxidant, the next objective was to develop an ex vivo model of acute 
hypertension as a means of replicating the oxidative environment associated with 
hypertension mediated endothelial dysregulation; allowing an evaluation of novel 
treatment strategies, their efficacy and mechanisms of action within the vasculature in 
future applications. The hypothesis of this part of the study is that acute pressure elevation 
will significantly attenuate endothelial-dependent dilator responses, which will be 
restored following exposure to antioxidant compounds. This hypothesis will be addressed 
through the following specific objective: 
 
 Establish alterations in vascular function in coronary and cerebral arteries 
following acute pressure elevation using an ex vivo model of acute hypertension, 
via pressure myography. 
 
First-order septal coronary arteries and middle cerebral arteries were excised and 
mounted on a pressure myograph system. Endothelial-dependent and independent 
responses were assessed prior to, following or one hour after acute pressure elevation. 
The contribution of ROS was assessed using SOD, CAT or apocynin. The dilator 
component was assessed in coronary arteries using pharmacological inhibitors of NO-, 
PGI- and EDHF-pathways.  
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5.1 Results 
5.1.1 Coronary artery 
5.1.1.1 Control responses 
 
Initial studies were conducted to establish the viability of tissues and the repeatability of 
vascular responses. The repeatability of responses is an integral component in 
experimental design as it informs the appropriate methodological approach. Coronary 
vessels were isolated and exposed to pressure at 60mmHg for 30-minutes. All vessels 
(resting diameter = 192 ± 8 µm; n = 18) constricted in response to high potassium (KCl, 
60 mM; 48 ± 5 %; n = 18) and also to 5-HT in a dose-dependent manner, confirming the 
viability of vessels and identifying the sub-maximal concentrations of 5-HT as 10-5 - 10-
6 M (Figure 5.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Constrictor response to 5-HT in coronary arteries. The dose-response effect 
of serotonin (5-HT; 10-10 M – 10-3 M) in coronary arteries of young Wistar rats (2-month) 
under normotensive pressure (60 mmHg). All vessels constricted to 5-HT in a dose-
dependent manner (n = 8). Repeats represent vessels from different animals. Data are 
presented as mean ± SEM. 
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Pressure elevation (150mmHg; 30-minutes) had no effect on 5-HT-mediated constriction 
compared to control vessels maintained at 60mmHg (maximal constriction:  58 ± 2 % and 
57 ± 7 %, respectively; 10-6 M; Figure 5.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Effect of elevated pressure on the constrictor response to 5-HT. Serotonin 
(5-HT; sub-maximal; 10-6 M) induced constrictor responses in the coronary arteries of 
young Wistar rats (2-month). Elevated pressure (150mmHg; 30-minutes) had no effect 
on 5-HT induced constrictor responses. Control (n = 4); elevated pressure (n = 8). 
Repeats represent vessels from different animals. Data analysed using an unpaired t-test. 
Data are presented as mean ± SEM. 
 
All 5-HT pre-constricted (sub-maximal; 10-6M) vessels dilated to ACh (10-9 – 10-3 M) in 
a dose-dependent manner. Responses to incremental ACh administration pre- and post-
incubation (60 mmHg/1-hour) in PSS resulted in dose-dependent dilation, with a similar 
magnitude of dilation observed (maximal dilation: 74 ± 4 % and 70 ± 6 %, respectively; 
Figure 5.3). 
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Figure 5.3. Effect of repeated ACh exposure on the dilator response to ACh. 
Endothelial-dependent acetylcholine (ACh) induced dilator responses in the coronary 
arteries of young Wistar rats (2-month), pre- and post-incubation (60 mmHg/1-hour). 
Repeated exposure to ACh had no effect on endothelial-dependent dilator responses. Pre-
incubation (n = 4); post-incubation (n = 4). Repeats represent vessels from different 
animals. Data analysed using a two-way ANOVA followed by Tukey’s multiple 
comparisons. Data are presented as mean ± SEM. 
 
5.1.1.2 Acute pressure elevation attenuates endothelial-dependent dilator responses via 
NADPH oxidase mediated ROS generation 
 
Initial studies were conducted to assess the influence of acute pressure elevation on the 
magnitude of dilator responses in isolated coronary arteries. Following pressure elevation 
(150 mmHg; 30-minutes), a significant reduction in ACh responses (10-9 – 10-3 M) was 
observed (P = < 0.01 Figure 5.4A). Co-incubation with SOD (500 U-ml; P = < 0.0001; 
Figure 5.4A) or apocynin (30 µM; P = < 0.0001; Figure 5.4B) significantly improved 
endothelial-dependent dilation, suggesting that NADPH mediated ROS generation may 
play an important role in attenuating the dilator responses, after pressure elevation. 
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Figure 5.4. Effect of acute pressure elevation on the dilator response to ACh.  
Endothelial-dependent acetylcholine (ACh) induced dilator responses in the coronary 
arteries of young Wistar rats (2-month). (A) Elevated pressure (150mmHg; 30-minutes) 
significantly attenuated dilator responses (P = < 0.01), which were restored following 
co-incubation with superoxide dismutase (SOD; 500 U-ml; P = < 0.0001). (B) Incubation 
with the NADPH oxidase inhibitor apocynin (30 µM) resulted in restoration of dilation 
(P = < 0.0001). Control (n = 4); elevated pressure (n = 8); elevated pressure + SOD (n 
= 3); elevated pressure + apocynin (n = 3). Repeats represent vessels from different 
animals. Data analysed using a two-way ANOVA followed by Tukey’s multiple 
comparisons test.   * P < 0.05. ** P < 0.01. *** P < 0.001. 
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5.1.1.3 Following acute pressure elevation, endothelial-dependent dilator responses are 
mediated by NO in coronary arteries 
 
 
In order to establish the relative contribution of each vasodilator pathway to the dilator 
component following acute pressure elevation (150mmHg; 30-minutes), inhibitors of the 
respective pathways were used. Incubation with L-NNA (100 µM), a NO synthase 
inhibitor, resulted in a reduction in dilation (P = < 0.0001; Figure 5.5A), while incubation 
with the nonselective inhibitor of COX 1 and 2, indomethacin (10 µM), a significant 
potentiation of dilation is observed (P = < 0.0001; Figure 5.5B). Incubation with the small 
and intermediate calcium-activated potassium channel blockers apamin (100 nM) and 
TRAM-34 (1 µM) resulted in the potentiation of dilation (P = < 0.0001; Figure 5.5C). 
Co-incubation of vessels with L-NNA and EDH inhibitors (apamin and TRAM-34) 
resulted in attenuation, suggesting the potentiation observed following incubation with 
EDH inhibitors may be a compensatory dilator mechanism, involving mediators such as 
NO (P = < 0.0001; Figure 5.5D). Incubation with L-NNA, apamin, TRAM-34 and 
indomethacin resulted in the loss of the dilator component (P = < 0.0001; Figure 5.5E).  
 
5.1.1.4 Endothelial-independent dilator responses are maintained following elevated 
pressure  
Following elevated pressure (150mmHg; 30-minutes), endothelial-independent responses 
to papaverine (PAPA; cAMP inhibitor; 100 µM) and sodium nitroprusside (SNP; NO 
donor; 100 µM) were unaffected (PAPA: 85 ± 8 % and 74 ± 10 %, respectively; SNP: 66 
± 10 % and 69 ± 7 %, respectively) and comparable to control vessels maintained at 
60mmHg (Figure 5.6A and B, respectively). 
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Figure 5.5. Characterisation of the dilator response to ACh following acute pressure 
elevation. The influence of the inhibitors NΩ-nitro-L-arginine (A; 100 µM; n = 3), 
indomethacin (B; 10 µM; n = 4), apamin (100 nM) and TRAM-34 (1 µM) C; n = 3), L-
NNA, apamin and TRAM-34 (D; n = 3) or L-NNA, indomethacin, apamin and TRAM-34 
in combination (E; n = 3) on endothelial-dependent acetylcholine (ACh) induced dilator 
responses in the coronary arteries of young Wistar rats (2-month) following elevated 
pressure (150mmHg; 30-minutes). Incubation with L-NNA resulted in a significant 
constriction (P = < 0.0001). Incubation with indomethacin resulted in a significant 
potentiation of dilation (P = < 0.0001). Incubation with apamin and TRAM-34 resulted 
in the potentiation of dilation (P = < 0.0001). Co-incubation of vessels with L-NNA and 
EDHF inhibitors (apamin and TRAM-34) resulted in attenuated dilation (P = < 0.0001). 
Incubation with L-NNA, apamin, TRAM-34 and indomethacin resulted in the loss of 
dilator component (P = < 0.0001). Repeats represent vessels from different animals. Data 
analysed using a two-way ANOVA followed by Tukey’s multiple comparisons. Data are 
presented as mean ± SEM.* P < 0.05. ** P < 0.01. **** P < 0.0001. 
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Figure 5.6. Effect of elevated pressure on the dilator response to PAPA and SNP. 
Endothelial-independent papaverine (PAPA) and sodium nitroprusside (SNP) induced 
dilator responses in the coronary arteries of young Wistar rats (2-month). Elevated 
pressure (150mmHg; 30-minutes) had no effect on PAPA (A; 100 µM; Control (n = 3); 
elevated pressure (n = 4)) or SNP (B; 100 µM; Control (n = 3); elevated pressure (n = 
7)) induced dilator responses. Repeats represent vessels from different animals. Data 
analysed using an unpaired t-test. Data are presented as mean ± SEM. 
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5.1.1.5 Acute elevation in pressure has no effect on the structural integrity of the vessel 
wall 
 
In order to establish whether acute pressure elevation was capable of affecting the 
structural integrity of the vessels, the structural morphology of vessels was assessed using 
TEM. Pressure elevation had no overall effect on the structural integrity of vessels 
maintained under normotensive (60 mmHg), or hypertensive (150 mmHg) pressure, with 
minor endothelial detachment observable (Figure 5.7A and B, respectively).  
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Figure 5.7. The effect of elevated pressure on the vascular integrity of the coronary 
artery. Representative transmission electron (TEM) micrographs of the rat coronary 
artery. Maintaining vessels under normotensive pressure (A; 60 mmHg) and elevated 
pressure (B; 150 mmHg) had no overall effect of endothelial or smooth muscle cell 
integrity. However, minor endothelial detachment is observable. Control (n = 3), elevated 
(n = 3). Magnification 690 x. Scale bar = 5 µm. Micrograph legend: endothelial cell 
(EC); internal elastic lamina (IEL); vascular smooth muscle cell (VSMC). Red arrows 
indicate sites of endothelial detachment. 
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5.1.2 Cerebral artery  
 
5.1.2.1 Control responses  
 
Initial studies were conducted to establish the viability of tissues and the repeatability of 
vascular responses. Cerebral vessels were isolated and exposed to pressure at 60mmHg 
for 30-minutes. All vessels (resting diameter = 169 ± 8 µm; n = 21) constricted in response 
to high potassium (KCl, 60 mM; 49 ± 4 %; n = 21) and also to 5-HT in a dose-dependent 
manner, confirming the viability of vessels and identifying the sub-maximal 
concentrations of 5-HT as 10-6 - 10-7 M (n = 6) (Figure 5.8).  
 
 
 
 
 
 
 
 
 
 
Figure 5.8. Constrictor response to 5-HT in cerebral arteries. The dose-response effect 
of serotonin (5-HT; 10-10 M – 10-4 M) in cerebral arteries of young Wistar rats (2-month) 
under normotensive pressure (60 mmHg). All vessels constricted to 5-HT in a dose-
dependent manner (n = 6). Repeats represent vessels from different animals. Data are 
presented as mean ± SEM. 
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Pressure elevation (150mmHg; 30-minutes) had no effect on 5-HT-mediated constriction 
compared to control vessels maintained at 60mmHg (maximal constriction: 60 ± 7% and 
66 ± 16%, respectively 10-7 M; Figure 5.9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9. Effect of elevated pressure on the constrictor response to 5-HT. Serotonin 
(5-HT; sub-maximal; 10-7 M) induced constrictor responses in the cerebral arteries of 
young Wistar rats (2-month). Elevated pressure (150mmHg; 30-minutes) had no effect 
on 5-HT induced constrictor responses. Control (n = 6); elevated pressure (n = 5). 
Repeats represent vessels from different animals. Data analysed using an unpaired t-test. 
Data are presented as mean ± SEM. 
 
All 5-HT pre-constricted (sub-maximal; 10-7 M) vessels dilated to ACh (10-9 – 10-3 M) in 
a dose-dependent manner. Responses to ACh pre- and post-incubation (60 mmHg/1-hour) 
resulted in dose-dependent dilation, which was significantly reduced post-incubation 
(maximal dilation: 62 ± 7 % and 38 ± 7 %, respectively; P = < 0.001; Figure 5.10). 
Consequently, only post-incubation responses were evaluated. 
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Figure 5.10. Effect of repeated ACh exposure on the dilator response to ACh. 
Endothelial-dependent acetylcholine (ACh) induced dilator responses in the cerebral 
arteries of young Wistar rats (2-month), pre- and post-incubation (60 mmHg/1-hour). 
Repeated exposure to ACh significantly attenuated ACh induced dilation (P = < 0.001). 
Pre-incubation (n = 6); post-incubation (n = 5). Repeats represent vessels from different 
animals. Data analysed using a two-way ANOVA followed by Tukey’s multiple 
comparisons. Data are presented as mean ± SEM. * P < 0.05. ** P < 0.01. *** P < 
0.001. 
 
5.1.2.2 Acute pressure elevation attenuates endothelial-dependent dilator responses 
 
Following elevated pressure (150 mmHg; 30-minutes), a significant reduction in ACh 
responses was observed (P = < 0.0001). Co-incubation with SOD (500 U-ml) in the 
absence or presence of CAT (300 U-ml) had no effect on attenuated dilator responses 
(Figure 5.11).  
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Figure 5.11. Effect of acute pressure elevation ± SOD/CAT on the dilator response to 
ACh. Endothelial-dependent acetylcholine (ACh) induced dilator responses in the 
cerebral arteries of young Wistar rats (2-month). Elevated pressure (150mmHg; 30-
minutes) significantly attenuated dilator responses (P = < 0.0001). Co-incubation with 
superoxide dismutase (SOD; 500 U-ml) had no effect on attenuated dilator responses. 
Co-incubation with SOD and catalase (CAT; 300U-ml) had no effect on attenuated dilator 
responses. Control (n = 6); elevated pressure (n = 5); elevated pressure + SOD (n = 5); 
elevated pressure + SOD/CAT (n = 5). Repeats represent vessels from different animals. 
Data assessed using a two-way ANOVA followed by Tukey’s multiple comparisons. Data 
are presented as mean ± SEM. ** P < 0.01. **** P < 0.0001. 
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5.1.2.3 Endothelial-independent dilator responses are affected by H2O2 
 
Endothelial-independent responses to PAPA were unaffected, with dilator responses 
comparable to control vessels maintained at 60mmHg (Figure 5.12A). Following acute 
pressure elevation (150mmHg; 30-minutes), SNP mediated dilation was comparable to 
that of control vessels (normotensive pressure @ 60 mmHg). Co-incubation with SOD 
(500 U-ml) significantly attenuated dilator responses (P = < 0.05), which were restorable 
in the presence of SOD/CAT (P = < 0.05; Figure 5.12B).  
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Figure 5.12. Effect of elevated pressure on the dilator response to PAPA and SNP. 
Endothelial-independent papaverine (PAPA) and sodium nitroprusside (SNP) induced 
dilator responses in the cerebral arteries of young Wistar rats (2-month) following 
elevated pressure (150mmHg; 30-minutes). (A) Treatment had no effect on PAPA (100 
µM) induced dilator responses. (B) Co-incubation with superoxide dismutase (SOD; 
300U-/ml) significantly attenuated SNP (100 µM) mediated dilator responses (P = < 
0.05). Co-incubation with SOD and catalase (CAT; 500U-/ml) significantly improved 
dilator responses, compared to SOD alone. Control (n = 7); elevated pressure (n = 5); 
elevated pressure + SOD (n = 5); elevated pressure + SOD/CAT (n = 4). Repeats 
represent vessels from different animals. Data analysed using a one-way ANOVA followed 
by Dunnett’s comparison. Data are presented as mean ± SEM. * P < 0.05. 
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5.1.2.4 Acute elevation in pressure has no effect on the structural integrity of the vessel 
wall 
 In order to establish whether acute pressure elevation was capable of affecting the 
structural integrity of the vessels, the structural morphology of vessels was assessed using 
TEM. Pressure elevation had no overall effect on the structural integrity of vessels 
maintained under normotensive (60 mmHg), or hypertensive (150 mmHg) pressure, with 
minor endothelial detachment observable (Figure 5.13A and B, respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13. Effect of elevated pressure on the vascular integrity of the cerebral artery. 
Representative transmission electron (TEM) micrographs of the rat middle cerebral 
artery. Maintaining vessels under normotensive pressure (A; 60 mmHg) and elevated 
pressure (B; 150 mmHg) had no overall effect of endothelial or smooth muscle cell 
integrity. However, minor endothelial detachment is observable. Control (n = 3), elevated 
(n = 3). Magnification 690 x. Scale bar = 5 µm. Micrograph legend: endothelial cell 
(EC); internal elastic lamina (IEL); vascular smooth muscle cell (VSMC). Red arrows 
indicate sites of endothelial detachment.  
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5.2 Discussion 
 
5.2.1 Acute pressure elevation attenuates endothelial-dependent dilator responses via 
activation of NADPH oxidase in coronary arteries 
 
Following acute pressure elevation, a significant reduction in endothelial-dependent 
dilation in isolated coronary arteries ex vivo was observed. Previous in vivo and ex vivo 
studies employing experimental models of hypertension (pharmacological-, genetically-, 
pressure-induced) using isolated arteries have attributed the impairment of endothelial-
dependent dilation in several vascular beds (cerebral, coronary, femoral) to increased O2•- 
generation (Wei et al., 1985; De Bruyn et al., 1994; Ungvari et al., 2003); affirmed 
following incubation of vessels with SOD and CAT, reducing endogenously-derived 
ROS and restoring attenuated responses. Several sources of ROS have been identified in 
the vasculature following hypertension, with inhibition studies identifying NADPH 
oxidase as the predominant candidate (leading to the generation of O2•-). In order to 
ascertain whether coronary vessels subjected to elevated pressure possess similar 
mechanisms and sources of ROS generation, vessels were incubated with SOD or 
apocynin to assess the contribution of O2•- and NADPH oxidase, respectively (Guillermo 
et al., 2000; Cooke and Davidge, 2003). Consistent with previous studies, SOD 
incubation following pressure elevation lead to the restoration and potentiation of dilation 
(Huang et al., 1998; Ungvari et al., 2004). Similarly, co-incubation with apocynin resulted 
in the restoration of dilation, implicating NADPH oxidase in the generation of vascular 
O2•.  
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5.2.2 Following acute pressure elevation, endothelial-dependent dilator responses are 
mediated by NO in coronary arteries 
 
Stimulation of endothelial cells leads to endothelial-dependent dilation via NO-, PGI- and 
EDH-mediated pathways; however, considerable heterogeneity exists among vascular 
beds and species. Both NO and EDH play an integral role in regulating dilation in the 
coronary arteries, whereby patients administered NO inhibitors observe active 
upregulation of EDH, suggesting potential cross-talk and dynamic compensatory 
mechanisms between pathways (Urakami et al., 1997; Miura et al., 2001; Ozkor et al., 
2011). The disruptive potential of hypertension on NO and EDHF-mediated dilator 
pathways has been demonstrated in vivo and ex vivo (Dunn et al., 2017). Consequently, 
in order to assess the influence of potential treatment strategies, an accurate understanding 
of the mechanistic pathways mediating endothelial-dependent dilation and their relative 
contributions under an elevated pressure environment was required. 
Our inhibition studies demonstrate that following acute pressure elevation, NO is the 
major dilator component in coronary arteries with modulation by the COX and EDHF 
pathways, as previously documented in vessels from aged mice (Vessieres et al., 2010).  
Inhibition using L-NNA significantly compromised dilation, resulting in constriction of 
the vessel. This is likely attributable to a global reduction in dilator bioavailability, 
resulting in constrictor prostanoids (such as thromboxane A2 (TXA2) and prostaglandin 
H2 (PGH2)) having a more pronounced effect on the vasculature. These observations 
suggest that the release of NO from the endothelium following acute pressure elevation 
has a significant dilator influence on the coronary vasculature. This is in agreement with 
previous studies, where NO was identified as playing an integral role in maintaining 
vasomotor tone in both conduit and resistance vessels in the coronary circulation 
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(Quyyumi et al., 1995; Nishikawa and Ogawa, 1997). Nonetheless, these findings were 
unexpected, given the exacerbated production of O2•- observed in hypertensive 
environments and its potential inhibitory effects on NO, limiting its bioavailability and 
dilator capacity. However, the agonist-induced dilation of pre-constricted vessels has 
been shown to be reduced or eliminated by inhibitors of eNOS in isolated coronary 
vessels from hypertensive human and murine models, suggesting that NO continues to 
play an important role in the regulation of dilation, despite its bioavailability being 
reduced in hypertension (Pourageaud and Freslon, 1995; Quyyumi et al., 1995). Whilst a 
body of evidence supports the principal contribution of NO, several studies contest this 
notion, arguing that EDHFs are of greater significance in the regulation of coronary 
dilation (Nishikawa et al., 1999; Miura et al., 2001).  
In our ex vivo model, a potentiation of dilation was observed following inhibition of EDH. 
As previously described, studies have demonstrated the ability of the vasculature to 
actively compensate for the loss of normal dilator responses, minimising disruption to the 
systemic circulation. In order to ascertain whether the potentiated response was 
attributable to EDH, or a possible compensatory mechanism facilitated by NO, vessels 
were co-incubated in both apamin, TRAM-34 and L-NNA. The addition of L-NNA 
resulted in the loss of the dilator response, confirming compensation by NO. The apparent 
lack of EDH response differs from observations produced by some studies, identifying 
EDHF as the major dilator component in human and murine coronary arteries (Miura and 
Gutterman, 1998; Simone et al., 2003). However, this discrepancy can be attributed to 
experimental design. The influence of vessel size on the distribution and expression of 
EDRFs is well documented, with studies identifying a proportional increase in EDHF 
activity as vessel size decreases within the arterial network, with predominant EDHF 
activity in the resistance vessels (Nagao et al., 1992; Nishikawa et al., 1999). In studies 
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documenting prominent EDHF activity, isolated vessels with an average diameter < 100 
µm were used; associated with elevated EDHF localisation. In contrast, vessels utilised 
in our studies were > 100 µm, and hence, preferentially subject to NO-mediated dilation. 
The differing dilator components reported are therefore, unsurprising. The decision to use 
vessels > 100 µm is related to arterial pressure. Pressure distribution within the arterial 
network is well documented, with elevated pressure associated with larger vessels. Hence, 
superior (larger) segments of the coronary arteries were isolated, as opposed to the 
inferior (smaller), as these would be expected to undergo elevated pressure during systole. 
In addition to NO- and EDH-mediated dilator pathways, other dilators include 
prostanoids such as PGI2, a COX derived metabolite. The effects of COX derived 
products were investigated using indomethacin, which significantly potentiated dilation; 
likely attributable to its inhibitory effect on downstream COX constrictors such as PGH2 
and TXA2 (Brace et al., 1985). Similar responses have been observed in the mesenteric 
arteries of clinically hypertensive rats (i.e. spontaneously hypertensive/co-morbidity 
associated) following the administration of indomethacin, suggesting the involvement of 
vasoconstrictor prostanoids (Watt and Thurston, 1989; Vessieres et al., 2010). The 
complex interplay between COX-mediated dilator and constrictor generation has 
generated considerable ambiguity in the interpretation of experimental data, whereby 
several studies have revealed conflicting results, noting enhanced constriction in the 
absence of functional COX. In isolated murine aortic rings incubated with COX 
inhibitors, a significant enhancement of phenylephrine-induced constriction was found, 
but only in the presence of  L-NAME (NOS inhibitor), implicating NO in the suppression 
of vasoconstrictive prostanoid generation (Anning et al., 2006). Hence, it is possible that 
our observations are a consequence of having a partially intact NO-dilator pathway, 
preventing adverse effects of constrictors on the vasculature and promoting dilation. 
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It is unclear why incubation with inhibitors of NO-, PGI -and EDHF-pathways were 
incapable of abolishing dilation, retaining only a minimal dilator influence (< 8 ± 3 %); 
however, it could suggest the presence of a possible further dilator pathway in the 
coronary artery. In small coronary resistance size arteries, it has been reported that 
stimulation of Ca2+ permeable cation channels such as transient receptor potential 
vanilloid 4 (TRPV4), contribute to and perpetuate signalling mechanisms mediating 
smooth muscle cell hyperpolarisation and dilation. To date, members of the TRP family 
have been identified in numerous tissues, including coronary arterioles, with the TRPV4 
subtype being highly expressed in vascular endothelial cells (Mendoza et al., 2010; 
Bubolz et al., 2012). TRPV4 activation and signal transduction is subject to a broad range 
of mechanical (e.g. membrane distension and shear stress) and chemical stimuli, 
including endogenous lipid activators such as arachidonic acid (AA) and downstream 
metabolically derived products of CYP450 epoxygenases; such as EETs (Zheng et al., 
2013; Cao et al., 2016). Despite the ability of indomethacin to successfully inhibit the 
production of downstream AA metabolic products, AA production is itself upstream of 
COX 1/2 and is consequently not subject to inhibition, and may therefore, account for the 
modest dilator influence observed.  
Whilst the dilator component under normotensive conditions were not characterised in 
this study, previous work conducted by our group has characterised the effects of 
intravascular and extravascular pressure on myogenic responses in the coronary arteries 
of rats (Azzawi and Austin, 2004, 2006). However, it would be important to evaluate the 
effect of potential therapeutics on normal vessels and vessels undergoing hypertension 
(see Chapter 6) in to develop a comprehensive understanding of the mechanisms 
underlying potential therapeutics. 
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5.2.3 Endothelial-independent dilator responses are maintained following elevated 
pressure  
 
In order to ascertain whether the effects observed were localised to the endothelium or 
were also affecting the VSMCs, endothelial-independent responses were assessed. 
Endothelial-independent dilator responses following PAPA and SNP were unaffected, 
suggesting that VSMC integrity and responsiveness were not influenced by acute 
elevation in pressure. This was also shown by some (Fresquet et al., 2006; Agostino et 
al., 2013), but not all models of hypertension (Huang et al., 1998; Ungvari et al., 2003), 
suggesting that in our case, O2•- generation may be localised to the endothelial cells. 
 
5.2.4 Acute elevation in pressure has no effect on the structural integrity of the vessel 
wall  
 
In addition to the molecular impairment associated with ROS, physical damage to the 
endothelium is known to impair dilator responses and, in some cases, (e.g. endothelial 
denudation), promote constriction due to the reduction of basal NO (Azzawi and Austin, 
2006). TEM was performed to assess the integrity of the endothelial and smooth muscle 
layers following exposure to normotensive and hypertensive pressures. Overall, pressure 
elevation had no effect on vessel integrity, suggesting the impaired dilator function 
observed is the result of aberrant mechanistic control, rather than structurally related 
damage. The lack of pressure-induced damage is unsurprising, given the high, sustained 
perfusion pressures expected of intramuscular blood vessels (Ramanathan and Skinner, 
2005). Many studies using experimental models of hypertension have documented 
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remodelling of the vasculature; however, these are chronic models and alterations would 
therefore be expected (Hamasaki et al., 2000; Arnalich-Montiel et al., 2014). 
TEM imaging shows that in the case of both normotensive and hypertensive vessels, 
minor detachment of endothelial cells from the basement membrane is evident. There are 
several possible explanations, the most likely being processing artefacts, involving the 
shrinkage of the elastin layer underneath the endothelium, in addition to some damage 
(maybe hypoxia or mechanical action). Elastin shrinkage occurs when vessels are fixed 
with aldehydes without sufficient pressure inside to counteract this shrinkage (McDonald 
and Chandler, 1981). Following treatment, vessels were preserved via immersion 
fixation, requiring removal and depressurisation of the vessel. Retrospectively, perfusion 
fixation of pressurised vessels would be a more appropriate technique, mitigating the 
hypertonic effects of fixatives on tissue specimens. Collectively, these observations 
suggest that impaired dilator function is a result of mechanistic dysregulation mediated 
via ROS and not a result of hypertension-induced structural damage. 
 
5.2.5 Acute pressure elevation attenuates endothelial-dependent dilator responses in 
cerebral arteries 
 
Constriction of cerebral arteries showed a higher potency to 5-HT compared to coronary 
(LogEC50: 0.78 µM and 3.12 µM, respectively) and is likely attributable to the varied 
expression and density of 5-HT receptors in the cerebral and peripheral vasculature. 
Repeated exposure to ACh significantly attenuated dilator responses. ACh receptors are 
subject to agonist-mediated desensitisation and sequestration, as demonstrated with M5 
receptors following acute exposure to cholinomimetic compounds (Tsuga et al., 1998). 
The prominence of the M5 receptor in the cerebral vasculature has been documented, 
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whereby deletion of genes encoding the M5 receptor subtype abolished the dilator 
response to ACh in cerebral blood vessels but did not affect dilation of coronary arteries 
(Yamada et al., 2001; Araya et al., 2006). Hence, incremental exposure to ACh may result 
in partial M5 receptor desensitisation, limiting second messenger generation and 
accounting for the impaired dilator response observed in the cerebral arteries, and not the 
coronary. 
Acute pressure elevation significantly attenuated ACh-dependent dilation. Analogous to 
the coronary artery, O2•- generation has been associated with impaired dilator function in 
genetic, pharmacological and pressure-induced models of hypertension in cerebral 
arteries (Wei et al., 1985; Didion and Frank, 2003; Faraci et al., 2006). In order to 
determine whether O2•- contributes to impaired dilation in our own acute hypertension 
model, vessels were co-incubated with SOD. In contrast to previous studies performed in 
the coronary artery, co-incubation with SOD did not improve ACh-induced dilation. 
Several possibilities may account for these observations; 1) metabolic by-products of O2•- 
dismutation, i.e. H2O2, may themselves be causing toxicity or elevated constriction. The 
generation of O2•- and its subsequent impairment of vascular responses have previously 
been observed using a pharmacological model of hypertension in feline cerebral arteries, 
which demonstrated dilation was restorable following co-incubation with SOD and CAT, 
implicating O2•- as well as and H2O2 in impaired dilation (Wei et al., 1985). However, the 
effects of H2O2 on the cerebral vasculature vary with the artery and species studied, with 
the paradoxical effects of H2O2 being well documented (Wei et al., 1996; Sobey et al., 
1997). In murine MCAs, H2O2 has been identified as an inducer of constriction, mediating 
the oxidant-dependent stimulation of cerebral arterial smooth muscle L-type calcium 
channels (Chaplin and Amberg, 2012). In order to assess whether by-products of O2•- 
dismutation, specifically H2O2, were causing and or contributing to impaired dilation, 
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vessels were co-incubated with SOD and CAT. Co-incubation did not result in improved 
dilation, seemingly absolving the influence of H2O2. 
 
5.2.6 Endothelial-independent dilator responses are affected by H2O2  
 
VSMCs contain the contractile apparatus and are paramount in regulating constrictor and 
dilator responses, with pressure-induced damage/injury having been shown to 
compromise VSMC function (Ungvari et al., 2003; Gündüz et al., 2008). To determine 
whether acute pressure elevation might have compromised smooth muscle cell integrity, 
endothelial-independent dilator responses to PAPA and SNP were assessed. The ability 
of PAPA to induce relaxation of smooth muscle cells (via inhibition of cAMP-dependent 
phosphodiesterase) suggests that acute pressure had no overall effect on the contractile 
machinery or the integrity of the VSMCs. In contrast, the responsiveness of vessels to the 
NO donor SNP was varied. Co-incubation of vessels with SOD resulted in attenuated 
dilator responses, which were restored following co-incubation with CAT; implicating 
H2O2 in the impairment of endothelial-independent responses. As with most cell types, 
the primary sources of H2O2 in VSMCs include NADPH oxidase enzyme complexes and 
the mitochondrial electron transport chain, generated by SODs (Lennicke et al., 2015); 
catalysing the dismutation of O2•- anions into the less chemically reactive H2O2 and O2. 
Despite its comparatively low reactivity, H2O2 is a mild oxidant with the ability to diffuse 
freely through cellular membranes due to its solubility in both lipid and aqueous 
environments. The capacity of H2O2 to induce alterations in the activity and function of 
molecules has been reported previously, with incubation alongside NO propagating the 
generation of singlet oxygen species and reducing NO bioavailability (Noronha-Dutra et 
al., 1993). The significance of SOD as a source of H2O2 was further established following 
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the exogenous administration of SOD, enhancing the generation of ROS, whilst CAT 
inhibited the reaction; affirming the detrimental effects of exogenous antioxidant 
administration. These observations differ significantly from those of the coronary 
vasculature following incubation with SOD.  This is unsurprising, given the abundance 
of polyunsaturated fatty acids susceptible to oxidation, and the increased concentration 
of transition metals such as iron or copper liable to Fenton-like reactions (•OH generation) 
in cerebral tissues (Crichton and Ward, 2013). Following an assessment of endothelial-
dependent and independent responses, evidence has arisen vindicating but also 
implicating the influence of H2O2. However, it should be noted that whilst endothelial-
independent SNP responses suggest H2O2 is affecting VSMCs, it provides no indication 
of endothelial viability/integrity. The endothelium could, therefore, be damaged, 
accounting for the limited dilator response. TEM was performed to assess the integrity of 
the endothelial and smooth muscle layers following exposure of vessels to normotensive 
and hypertensive pressure. Pressure elevation had no overall effect on vessel integrity. 
Similar to observations made on coronary arteries, fixation resulted in minor endothelial 
detachment. 
 
5.3 Chapter summary 
 
In summary, this part of the study aimed to develop an ex vivo model of acute 
hypertension and determine the mechanisms underlying attenuated dilation, as a means 
of replicating the oxidative environment observed in hypertension. Using the ex vivo 
model, NADPH-oxidase derived O2•- was shown to play an integral role in attenuating 
dilator responses in the coronary artery; with inhibition studies identifying NO as the 
principal dilator component, despite the presence of elevated O2•-. In contrast, pressure 
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mediated attenuated dilation in cerebral vessels was not restored by incubation with SOD 
or CAT, suggesting a role for other ROS moieties. Consideration of anatomical, 
functional and physiological differences between vascular beds are important in the 
development and implementation of safe, effective and innovative treatments for the 
strategic improvement of cardiovascular health. Consequently, the ex vivo model was 
deemed suitable as a means of replicating an oxidative environment, allowing an 
investigation into the use of novel strategies for treating ROS-mediated impairment. 
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The objective of this next part of the study was to utilise the ex vivo model of hypertension 
described in chapter 5 and use the organic RV-NLCs characterised and described in 
chapter 4 to establish their capacity to ameliorate oxidative injury. The hypothesis of this 
part of the study is that RV-NLCs will restore attenuated endothelial-dependent dilator 
responses which will be maintained over sustained time-periods. This hypothesis will be 
addressed through the following specific objective: 
 
 Determine whether RV-NLCs have the capacity to restore attenuated dilation 
following acute pressure elevation. 
 
First-order septal coronary arteries were excised and mounted on a pressure myograph 
system. Endothelial-dependent and independent responses were assessed following and 
one hour after acute pressure elevation in the presence of RV-NLCs or RV-solution. The 
dilator component was investigated using inhibitors of NO, PGI and EDHF-mediated 
relaxation. Mechanisms leading to dilation were investigated using inhibitors of SIRT-1 
and AMPK. 
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6.1 Results  
 
6.1.1 Control responses  
Coronary vessels were isolated and exposed to pressure at 60mmHg for 30-minutes. The 
viability of vessels was assessed by ascertaining initial responses to KPSS. All vessels 
(resting diameter = 187 ± 7 µm; n = 40) constricted to high potassium, confirming the 
viability of vessels (KCl, 60 mM; 49 ± 7 %; n = 40). Pressure elevation (150mmHg; 30-
minutes) + RV-NLC/RV-solution (0.45 µM) had no effect on 5-HT-mediated constriction 
(10-6 M; Figure 6.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. Effect of RV-NLCs on the constrictor response to 5-HT. Serotonin (5-HT; 
sub-maximal; 10-6 M) induced constrictor responses in the coronary arteries of young 
Wistar rats (2-month). Pressure elevation (150mmHg; 30-minutes) ± RV-NLCs/RV-
solution (0.45 µM; 30-minutes) had no effect on 5-HT induced constrictor responses. 
Elevated pressure (n = 8); elevated pressure + RV-NLC (n = 4); elevated pressure + RV-
solution (n = 3). Repeats represent vessels from different animals. Data analysed using 
a one-way ANOVA followed by a Dunnett’s multiple comparison. Data are presented as 
mean ± SEM. 
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6.1.2 RV-NLCs restore the magnitude of dilation following acute pressure elevation 
 
The influence of RV-NLCs on the magnitude of dilator responses following acute pressure 
elevation was examined. Acute pressure elevation (150mmHg; 30-minutes) followed by 
incubation with 0.45 µM RV-NLCs resulted in significant improvement in endothelium-
dependent (ACh; 10-9 – 10-3 M) dilation in comparison to incubation in PSS alone (P = < 
0.0001). Similar responses were observed following incubation with a 0.45 µM RV-
solution (P = < 0.0001). In order to define the respective contributions of the entrapped 
RV and surrounding lipid capsule, vessels were incubated with blank-NLCs. Acute 
pressure elevation followed by incubation with 0.45 µM blank-NLCs had no overall 
effect on attenuated dilator responses (Figure 6.2A). 
A significant shift in LogEC50 values were observed between initial RV-NLC and RV-
solution responses, with mean values of 4.73 x 10-7 M (0.47 µM) and 1.16 x 10-7 M (0.16 
µM), respectively (P = < 0.0001; Figure 6.2B). Sustained dilator responses were reduced 
for both RV-NLCs and RV-solution, one-hour post-incubation when compared to initial 
responses. Blank NLCs had no effect on sustained dilator responses, with results 
comparable to control. Endothelium-dependent responses were significantly higher 
following RV-NLC incubation, in comparison to RV-solution, but not significantly 
different from control (P = < 0.0001; Figure 6.2C). A significant rightward shift in 
LogEC50 values was observed, with RV-NLCs displaying increased potency in 
comparison to RV-solution, with values of 1.13 x 10-6 M (1.13 µM) and 5.33 x 10-6 M 
(5.33 µM), respectively (P = < 0.01; Figure 6.2D).  
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Figure 6.2. Effect of RV-NLCs on initial and sustained dilator responses to ACh. The 
influence of resveratrol-loaded nanostructured lipid carriers (RV-NLCs; 0.45 µM; 30-
minutes) on initial and sustained endothelial-dependent acetylcholine (ACh) induced 
dilator responses in the coronary arteries of young Wistar rats (2-month) following acute 
pressure elevation (150mmHg; 30-minutes). (A) RV-NLCs and RV-solution (0.45 µM; 
30-minutes) significantly improved attenuated dilation (P = < 0.0001 and P = < 0.0001, 
respectively), whereas Blank-NLCs (0.45 µM; 30-minutes) had no effect. (B) A significant 
shift in LogEC50 values was observed between responses to RV-NLCs and RV-solution, 
with mean values of 4.73 x 10-7 M (0.47 µM) and 1.64 x 10-7 M (0.16 µM) respectively (P 
= < 0.0001). (C) Sustained dilator responses of RV-NLCs and Blank-NLCs were 
maintained to comparable levels as control tissue, in comparison to RV-solution (P = < 
0.0001). (D) A significant shift in LogEC50 values were observed between sustained 
responses to RV-NLCs and RV-solution, with mean values of 1.13 x 10-6 M (1.13 µM) and 
5.33 x 10-6 M (5.33 µM), respectively (P = < 0.01). Elevated pressure (n = 8); elevated 
pressure + RV-NLC (n = 4); elevated pressure + Blank-NLC (n = 4); elevated pressure 
+ RV-solution (n = 3); control (sustained; n = 3); control + RV-NLC (sustained; n = 4); 
control + Blank-NLC (sustained; n = 5); control + RV-solution (sustained; n = 3). 
Repeats represent vessels from different animals. Dilator responses analysed using a two-
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way ANOVA followed by Tukey’s multiple comparisons. LogEC50 values calculated by 
normalising, transforming and plotting data using a nonlinear regression model; 
LogEC50 values were compared using an extra-sum-of-squares F test. Data are presented 
as mean ± SEM.** P < 0.01. *** P < 0.001. **** P < 0.0001.  
 
 
Initial and sustained LogEC50 values for RV-NLC and RV-solution responses were 
independently assessed. RV-NLCs and RV-solution each observed significant reductions 
in potency over time, with LogEC50 values of RV-NLCs shifting from 4.73 x 10-7 M (0.47 
µM) to 1.13 x 10-6 M (1.13 µM; P = < 0.05; Figure 6.3A); and RV-solution from 1.64 x 
10-7 M (0.16 µM) to 5.33 x 10-6 M (5.33 µM), respectively (P = < 0.0001; Figure 6.3B).  
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Figure 6.3. Comparison of initial and sustained potency effects of the RV-NLCs and 
RV-solution. The effect of resveratrol (RV) loading within nanolipid carriers (NLCs) on 
the maintenance of potency. (A) The potency (LogEC50) of the RV-NLCs was assessed by 
comparing initial and sustained responses. A significant shift in LogEC50 values was 
observed between initial and sustained RV-NLC responses, with mean values of 4.73 x 
10-7 M (0.47 µM) and 1.13 x 10-6 M (1.13 µM), respectively (P = < 0.05). (B) A significant 
shift in LogEC50 values was observed between initial and sustained RV-solution 
responses, with mean values of 1.64 x 10-7 M (0.16 µM) and 5.33 x 10-6 M (5.33 µM) 
respectively (P = < 0.0001). LogEC50 values calculated by normalising, transforming 
and plotting data using a nonlinear regression model; LogEC50 values were compared 
using an extra-sum-of-squares F test. * P < 0.05. **** P < 0.0001. 
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6.1.3 RV-NLCs restore dilation via NO and COX following elevated pressure, 
mediated via AMPK.  
 
To define the dilator pathways that RV-NLCs may be stimulating to potentiate 
endothelial-dependent dilation, inhibition studies were carried out in the presence of RV-
NLCs (0.45 µM). Incubation with L-NNA (100 µM) resulted in significant attenuation of 
dilation (P = < 0.0001; Figure 6.4A). Similarly, co-incubation of vessels with 
indomethacin (10 µM) resulted in a significant attenuation of dilation (P = < 0.01; Figure 
6.4B). Incubation with apamin (100 nM) and TRAM-34 (1 µM) had no influence on 
dilation, suggesting the RV-NLCs may be acting via EDHF independent mechanisms 
(Figure 6.4C). L-NNA, apamin, TRAM-34 and indomethacin resulted in a further 
reduction of the dilator component (P = < 0.0001; Figure 6.4D). Co-incubation with 
dorsomorphin (AMPK inhibitor; 20 µM) led to a significant reduction in dilation (P = < 
0.001), resulting in a dilator capacity similar to that observed following acute pressure 
elevation, without intervention (Figure 6.4E). In contrast, incubation with EX-527 (SIRT-
1 inhibitor; 10 µM) did not influence dilator responses (Figure 6.4F). Denudation resulted 
in the complete abolishment of dilation, confirming that RV-NLCs potentiate dilation via 
endothelial-dependent mechanisms (P = < 0.0001; Figure 6.4G).  
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Figure 6.4. Characterisation of the dilator response to ACh following acute pressure 
elevation in the presence of RV-NLCs.  The influence of the inhibitors NΩ-nitro-L-
arginine (A; 100 µM; n = 6), indomethacin (B; 10 µM; n = 3), apamin (100 nM) and 
TRAM-34 (C; 1 µM; n = 4), L-NNA, indomethacin, apamin and TRAM-34 (D; n = 5),  
dorsomorphin (E; 20 µM; n = 5), and EX-527 (F; 10 µM; n = 3) on endothelial-
dependent acetylcholine (ACh) induced dilator responses in the coronary arteries of 
young Wistar rats (2-month) following elevated pressure (150mmHg; 30-minutes) and 
incubation with resveratrol-loaded nanostructured lipid carriers (RV-NLCs; 0.45uM; 30-
minutes). Incubation with L-NNA or indomethacin resulted in significant attenuation (P 
= < 0.0001 and P = < 0.01, respectively). Incubation with apamin and TRAM-34 had no 
influence on dilator responses. Co-incubation of vessels with L-NNA, indomethacin, 
apamin and TRAM-34 resulted in attenuated dilation (P = < 0.0001). Incubation with 
dorsomorphin resulted in attenuated dilation (P = < 0.001), whilst EX-527 had no effect. 
Endothelial denudation resulted in loss of the dilator component (P = < 0.0001), (G; n 
= 4). Repeats represent vessels from different animals. Data analysed using a two-way 
ANOVA followed by Tukey’s multiple comparisons. Data are presented as mean ± SEM.* 
P < 0.05. ** P < 0.01. **** P < 0.0001. 
 
 
6.1.4 Endothelial-independent dilator responses to SNP are influenced by RV 
 
Endothelial-independent responses to PAPA were unaffected, with responses comparable 
to elevated pressure (150mmHg) alone (Figure 6.5A). Responses to SNP were varied, 
with RV-NLCs or L-NNA, apamin, TRAM-34 and indomethacin leading to a significant 
improvement in dilation (P = < 0.05; Figure 6.5B). 
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Figure 6.5. Effect of treatment on the dilator response to PAPA and SNP. Endothelial-
independent papaverine (PAPA) and sodium nitroprusside (SNP) induced dilator 
responses in the coronary arteries of young Wistar rats (2-month) following elevated 
pressure (150mmHg; 30-minutes). Treatment had no effect on PAPA (A; 100 µM) induced 
dilator responses. RV-NLCs and L-NNA + apamin + TRAM-34 + indomethacin 
significantly improved SNP (B; 100 µM) induced dilator responses (P < 0.05 and P < 
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0.05, respectively; B). Elevated pressure (n = 4/7, respectively); RV-NLC (n = 4); RV-
solution (n = 3/4, respectively); blank-NLC (n = 4/5, respectively); L-NNA (n = 4); 
indomethacin (n = 3); apamin + TRAM-34 (n = 4); L-NNA + apamin + TRAM-34 + 
indomethacin (n = 5); dorsomorphin (n = 5); EX-527 (n = 3); denuded endothelium (n 
= 4). Repeats represent vessels from different animals. One way-ANOVA followed by 
Dunnett’s comparison. Data are presented as mean ± SEM. * P < 0.05. 
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6.2 Discussion 
 
6.2.1 RV-NLCs restore the magnitude of dilation following acute pressure elevation 
 
RV-NLCs significantly improved the attenuated dilation after acute pressure elevation, to 
a similar magnitude as that following SOD treatment (see previous chapter). These 
findings are maybe attributable to RV’s antioxidant properties (Burns et al., 2002), 
replicating the role of endogenous enzymes by scavenging a range of ROS moieties 
(Leonard et al., 2003; Iuga et al., 2012). In addition to its direct antioxidant ability, RV 
has been associated with the activation and upregulation of several molecular targets 
involved in the prorogation of dilation and regulation of basal antioxidant activity 
including eNOS, SOD, CAT, and nuclear factor erythroid 2-related factor 2 (Nrf2) 
(Thomas et al., 2002; Sayin et al., 2012; Xia et al., 2017). However, due to the 
limited/short incubation period in the present study, it is unlikely that the observed effects 
relate to the upregulation of antioxidant genes, but maybe attributable to post-translational 
modification, e.g. increased phosphorylation of eNOS. Consistent with liposomes and 
solid lipid nanoparticles, encapsulation of content within NLCs has been associated with 
enhanced stability and protection from metabolic degradation (Cirri et al., 2018). In order 
to assess this, the non-encapsulated RV-solution was used for comparison. Although RV-
solution displayed increased efficacy and magnitude of dilation, likely attributable to 
superior diffusion kinetics over time in comparison to RV-NLCs, sustained responses 
were significantly less than that induced by RV-NLCs, with a nearly 5-fold improvement 
in potency demonstrated by the RV-NLCs (as shown by the LogEC50 data). A 
comparative examination of initial and sustained responses (i.e. RV-NLC initial vs RV-
NLC sustained) from each treatment allowed the assessment of treatment potency as a 
measure of time. Incubation with RV-NLCs over the one-hour test period resulted in a 
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2.4-fold reduction in potency, in comparison to the much larger 32-fold reduction 
demonstrated by RV-solution; confirming the ability of NLCs to successfully entrap and 
release RV over sustained time-periods. This is consistent with previous findings, 
whereby studies have demonstrated NLCs increase the bioavailability of poorly soluble 
antihypertensive drugs (Cirri et al., 2018; Son et al., 2019) and vasoprotective 
nutraceutical products such as RV (Magyar et al., 2012; Theodotou et al., 2017), 
protecting it from rapid metabolism, whilst also allowing fine manipulation of release 
kinetics (Burns et al., 2002; Teskac and Kristl, 2010; Neves et al., 2013; Khan et al., 
2018).  
 
The reduced potency of RV-solution in comparison to RV-NLCs may be attributable to 
RV’s degradation. This is supported by previous observations in the Azzawi laboratory 
whereby the concentration of RV was reduced by 27 % one-hour after circulation in the 
ex vivo pressure myography setup (Diaz et al., 2019). This may partially be due to the 
high sensitivity of RV to photochemical and photocatalytic degradation, leading to UV 
light-induced trans-cis isomerization (Silva et al., 2013); with cis-RV having been shown 
to have reduced stability and potency in comparison to its trans- counterpart. Lipid 
encapsulation, on the other hand,  has been found to stabilise contents, reducing the effects 
of UV-damage (Bandak et al., 1999; Tursilli et al., 2006). Additionally, the degradation 
of RV has been shown to produce several ill-investigated breakdown products, including 
aldehydes and carboxylic acids; many of which are highly toxic and may accumulate 
resulting in modulation of vascular activity (Bader et al., 2008). These may account for 
the loss of sustained dilator response observed following incubation with the RV-solution, 
as opposed to RV-NLCs; releasing contents over a prolonged period, mitigating any 
detrimental effects.  
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In addition to the documented benefits of RV, exposure to exogenous lipid has been found 
to promote vascular function in several tissue beds. The generation of endothelium-
dependent vasodilator substance following lipid exposure has been demonstrated via NO 
and EDHF generation in conduit and resistance size arteries, respectively (Ruisanchez et 
al., 2014; Limbu et al., 2018). Replacement of oxidised phospholipids via 
incorporation/integration of the lipid carrier, as well as usage of catabolised products (e.g. 
ATP) may potentially restore aberrant membrane functionality. In order to assess whether 
constituent components of the phospholipid-capsule may contribute to improved dilation, 
vessels were incubated with blank-NLCs. Co-incubation with blank-NLCs did not 
improve initial or sustained responses, confirming the restorative effects were attributable 
to RV. Potentially, the lack of apparent benefit observed following blank-NLC 
administration may be due to the specificity of lipids involved, their relative 
concentrations and overall ratios. Thus, the results of the present study support the notion 
that encapsulation of RV leads to increased potency in the coronary artery over sustained 
periods of time, and encapsulation protects from degradation when compared to RV-
solution alone.  
 
6.2.2 RV-NLCs restore dilation via NO and COX following elevated pressure, 
mediated via AMPK.  
 
In the present study, dilator pathway inhibition studies suggest that RV-NLCs can 
potentiate dilation (after acute pressure elevation) by modulating the NO and COX 
pathways. Potentiation of the NO pathway has been extensively reported across several 
species and vascular beds, including the coronary artery (Naderali et al., 2000; El-
Mowafy, 2002; Rakici et al., 2005; Li et al., 2006). In contrast, the influence on 
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indomethacin-sensitive prostaglandins are sparse. Previous studies using human internal 
mammary arteries  and guinea pig uterine arteries,  suggest that RV may reduce levels of 
vasoconstrictor prostaglandins (PGH2 and TXA2) (Naderali et al., 2000; Rakici et al., 
2005). In porcine coronary arteries, however, indomethacin did not influence RV-
mediated dilation (Li et al., 2006). In the latter study, vessels were pre-incubated with 
indomethacin for only 20-minutes, suggesting insufficient inhibition (> 45-minutes 
utilised in our study and others). It is also likely that the influence of vasoconstrictor 
prostanoids on vascular reactivity in response to RV is tissue-dependent and requires 
further investigation. 
 
The vasodilator component induced by RV-NLCs after acute pressure elevation was not 
influenced by incubation with apamin and TRAM-34, suggesting that RV has a minimal 
effect on the EDH pathway. In the murine femoral artery exposed to normal pressure, RV 
potentiated dilation via NO and EDHF (Diaz et al., 2019). Also, a study characterising 
the dilator component of the porcine coronary artery following administration of red wine 
polyphenols identified EDHF as a primary contributor to dilation alongside NO, whereby 
inhibiting channels associated with potassium entry significantly attenuated responses 
(Dell’Agli et al., 2004). These findings suggest that RV’s mechanism of potentiated 
dilation may differ, following normal or elevated pressure, given that ROS has previously 
been shown to inactivate potassium channels (hence EDH responses) (Brzezinska et al., 
2000; Yanping et al., 2002). Following incubation with all four inhibitors in the presence 
of RV-NLCs, a small dilator component remained. Consistent with previously noted 
observations during the characterisation of the ex vivo model, this residual dilation may 
be attributable to TRPV4 activation.   
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In order to investigate the mechanisms involved in RV-NLC mediated dilator responses, 
further inhibition studies were carried out. RV has been associated with the activation 
of several cell surface receptors, and is widely thought to convey its beneficial 
characteristics via the activation/upregulation of SIRT-1 and/or AMPK (Schmitt et al., 
2010). However, NLCs are capable of being endocytosed into cells and releasing RV 
into the cytosol, thus, it was of interest to assess whether RV delivery via NLCs, 
potentiated dilation via an alternate mechanism. Incubation with dorsomorphin resulted 
in a partial reduction in dilation, suggesting a limited involvement of AMPK in mediating 
the effects of RV. In contrast, co-incubation with the SIRT-1 inhibitor EX-527 did not 
influence dilator responses, suggesting the absent participation of SIRT-1 in RV-
mediated dilation. These data contrast previous findings which have attributed the effects 
of RV to SIRT-1; however, in vitro studies in which the effects of SIRT-1 have been 
observed in the coronary artery are often performed following several days/weeks’ 
exposure to agonistic stimulus and/or treatment with RV, which is likely to modulate 
SIRT-1/AMPK activity. Finally, there is considerable variability in the experimental 
concentrations used; with AMPK activation being found to be cell-type and 
concentration-dependent (Lan et al., 2017). Interestingly, AMPK is known to be an 
upstream signalling mediator of COX-2, with the capacity to regulate its function (Hou 
et al., 2008). Inhibition of AMPK resulted in observations consistent with those using 
indomethacin, whereby inhibition of COX resulted in attenuated dilation. However, 
indomethacin is a non-selective COX inhibitor, and it has a preferential affinity for COX-
1. Our data show that endothelial denudation abolished the vasodilation induced by RV, 
after acute pressure elevation, and promoted constriction, ascribed to the binding of ACh 
to the muscarinic acetylcholine receptors (M3) present in smooth muscle cells; suggesting 
that RV-NLCs exert an endothelial-dependent response. Although previous studies have 
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examined the contribution of the endothelium in RV-mediated responses, the effects of 
endothelial-denudation on RV-induced dilation has been inconsistently reported. Some 
studies observed partial or complete endothelial dependency in the coronary artery and 
aorta under normotensive pressure (El-Mowafy, 2002; Li et al., 2006), respectively, 
whereas a shifting from partial endothelium-dependent to complete endothelium-
independent was reported in rat mesenteric arteries following dietary-induced obesity or 
humans with coronary artery disease  (Naderali et al., 2001; Cruz et al., 2006). It appears 
that the role of the endothelium in RV-induced dilation depends on the tissue, species, 
and perhaps disease states.  
 
6.2.3 Endothelial-independent dilator responses to SNP are influenced by RV 
 
Interestingly, RV-NLCs significantly improved SNP mediated dilation. The lack of 
endothelial-dependent dilator response following denudation, and improved dilation in 
the presence of a NO donating agent (simulating endothelial-dependent responses) 
suggest RV-NLCs may increase SMC sensitivity to NO. 
 
6.3 Chapter summary 
 
The experiments performed in this part of the study aimed to assess the potential of RV 
loaded within NLCs to restore dilator responses in an ex vivo model of acute hypertension. 
Using this model, RV-NLCs demonstrated the ability to restore and potentiate attenuated 
dilator responses to comparable levels as that observed by endogenous antioxidants (e.g. 
SOD), highlighting their successful delivery into tissues and antioxidant capacity in the 
coronary vasculature. These responses were sustained over a more prolonged period, in 
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comparison to a RV-solution alone; confirming the ability of NLCs to protect internalised 
contents. Through inhibition studies, RV-NLCs were found to potentiate dilation via the 
modulation of NO and COX pathways, partially mediated by AMPK; as opposed to the 
conventionally accepted SIRT-1. In the following chapter, an investigation of the effects 
of RV-NLCs in the cerebral vasculature will be described.  
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In the preceding chapter, RV-loaded NLCs successfully demonstrated their capacity to 
restore attenuated dilator responses in the coronary artery; however, differential 
receptivity to EDRF might not make these findings applicable across vascular beds. Using 
the same ex vivo model of hypertension described, the objective of this study was to assess 
the use of antioxidant-loaded organic nanoparticles in the cerebral vasculature. The 
hypothesis of this study is that RV-NLCs and TMS-liposomes will restore attenuated 
endothelial-dependent dilator responses of cerebral arteries after acute pressure elevation. 
This hypothesis will be addressed through the following specific objective: 
 
 Determine whether RV-NLCs and TMS-liposomes have the capacity to restore 
attenuated dilation following acute pressure elevation.  
 
First-order middle cerebral arteries were excised and mounted on a pressure myograph 
system. Endothelial-dependent and independent responses were assessed following acute 
pressure elevation in the presence of organic nanoparticles (as described in the previous 
chapter). Additionally, TMS-liposomes were supplied by our collaborators from the 
University of Manchester (Dr. Harris, UoM); potentially offering improved uptake 
efficiency in the cerebral vasculature due to functionalisation with a brain targeting 
peptide, compared to RV-NLCs. They were prepared using a thin film process and 
characterised in the present study using the same analytical techniques described in 
chapters 3 and 4.  
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7.1 Results 
 
7.1.1 Control responses  
 
Coronary vessels were isolated and exposed to pressure at 60mmHg for 30-minutes. The 
viability of vessels was assessed by ascertaining initial responses to KPSS. All vessels 
(resting diameter = 187 ± 9 µm; n = 10) constricted to high potassium, confirming the 
viability of vessels (KCl, 60 mM; 47 ± 9 %; n = 10). Pressure elevation (150mmHg; 30-
minutes) ± RV-NLCs (0.45 µM) had no effect on 5-HT-mediated constriction compared 
to vessels subjected to pressure elevation alone (maximal constriction: 66 ± 6 % and 75 
± 8 %, respectively; 10-7 M; Figure 7.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1. Effect of RV-NLCs on the constrictor response to 5-HT in cerebral arteries. 
Serotonin (5-HT; sub-maximal; 10-7 M) induced constrictor responses in the cerebral 
arteries of young Wistar rats (2-month). Pressure elevation (150mmHg; 30-minutes) ± 
RV-NLCs (0.45 µM; 30-minutes) had no effect on 5-HT induced constrictor responses. 
Elevated pressure (n = 5); elevated pressure + RV-NLCs (n = 4). Repeats represent 
vessels from different animals. Data analysed using an unpaired t-test. Data are 
presented as mean ± SEM. 
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7.1.2 RV-NLCs do not restore attenuated dilation following acute pressure elevation 
 
The influence of RV-NLCs on the magnitude of dilator responses following acute pressure 
elevation was examined. Acute pressure elevation (150mmHg; 30-minutes) followed by 
incubation with 0.45 µM RV-NLCs had no effect on attenuated dilator responses (Figure 
7.2).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2. Effect of RV-NLCs on the dilator response to ACh. Endothelial-dependent 
acetylcholine (ACh) induced dilator responses in the cerebral arteries of young Wistar 
rats (2-month) following elevated pressure (150mmHg; 30-minutes). RV-NLCs (0.45 µM; 
30-minutes) had no effect on attenuated dilator responses. Elevated pressure (n = 5); 
elevated pressure + RV-NLCs (n = 4). Repeats represent vessels from different animals. 
Data analysed by a two-way ANOVA followed by Tukey’s multiple comparison. Data are 
presented as mean ± SEM. 
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7.1.3 Control responses 
 
The viability of vessels was assessed by ascertaining initial responses to KPSS. All 
vessels (resting diameter = 169 ± 12 µm; n = 11) constricted to high potassium, 
confirming the viability of vessels (KCl, 60 mM; 48 ± 7 %; n = 15). Pressure elevation 
(150mmHg; 30-minutes) ± TMS-liposomes/solution (1 nM and 10 nM, respectively) had 
no effect on 5-HT-mediated constriction (10-7 M; Figure 7.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3. Effect of treatment on the constrictor response to 5-HT. Serotonin (5-HT; 
sub-maximal; 10-7 M) induced constrictor responses in the cerebral arteries of young 
Wistar rats (2-month) following elevated pressure (150mmHg; 30-minutes). Elevated 
pressure ± TMS-liposomes/solution (1 nM and 10 nM, respectively; 30-minutes) had no 
effect on 5-HT induced constrictor responses. Elevated pressure (n = 5); elevated 
pressure + TMS-liposome (n = 3); elevated pressure + TMS-solution (n = 3). Repeats 
represent vessels from different animals. One way-ANOVA followed by Dunnett’s 
comparison. Data are presented as mean ± SEM. 
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7.1.4 TMS-liposomes do not restore attenuated dilation following acute pressure 
elevation 
 
The influence of TMS-liposomes and TMS-solution on the magnitude of dilator responses 
following acute pressure elevation was examined. Acute pressure elevation (150mmHg; 
30-minutes) followed by incubation with TMS-liposomes (1 nM, Figure 7.4A) or TMS-
solution (10 nM; Figure 7.4B) had no effect on attenuated dilator responses. 
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Figure 7.4. Effect of TMS-liposomes on the dilator response to ACh. Endothelial-
dependent acetylcholine (ACh) induced dilator responses in the cerebral arteries of 
young Wistar rats (2-month) following elevated pressure (150mmHg; 30-minutes). TMS-
liposomes (A; 1 nM) and TMS-solution (B; 10 nM) had no effect on attenuated dilator 
responses after 30-minutes incubation. Elevated pressure (n = 5); elevated pressure + 
TMS-liposome (n = 3); TMS-solution (n = 3). Repeats represent vessels from different 
animals. Data analysed by a two-way ANOVA followed by Tukey’s multiple comparison. 
Data are presented as mean ± SEM. 
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7.1.5 RV-NLCs attenuate endothelial-independent SNP responses, but are unaffected 
by TMS-liposomes 
  
Endothelium-independent responses to PAPA (100 µM) remained unchanged, despite 
RV-NLCs (0.45 µM) showing a tendency for reduction (Figure 7.5A). In contrast, SNP 
(100 µM) responses were varied (Figure 7.5B). Co-incubation with RV-NLCs resulted in 
significantly attenuated SNP responses (P = < 0.0001). SNP responses following 
incubation with TMS-liposomes (1 nM) and TMS-solution (10 nM) were significantly 
higher in comparison to RV-NLCs, respectively (P = < 0.001). 
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Figure 7.5. Effect of treatment on the dilator response to PAPA and SNP. Endothelial-
independent papaverine (PAPA) and sodium nitroprusside (SNP) induced dilator 
responses in the cerebral arteries of young Wistar rats (2-month) following elevated 
pressure (150mmHg; 30-minutes). (A) Treatment had no effect on PAPA (100 µM) induced 
dilator responses. (B) RV-NLCs significantly attenuated SNP (100 µM) induced dilator 
responses (P = < 0.0001); dilator responses were unaffected following incubation with 
TMS-liposomes or TMS-solution, and significantly higher compared to RV-NLCs (P = < 
0.001). Control (n = 6); elevated pressure (n = 5); elevated pressure + RV-NLC (n = 4); 
elevated pressure + TMS-liposome (n = 3); elevated pressure + TMS-solution (n = 3). 
Repeats represent vessels from different animals. One way-ANOVA followed by Tukey’s 
multiple comparison. Data are presented as mean ± SEM. *** P < 0.001. **** P < 
0.0001. 
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7.2 Discussion 
 
7.2.1 RV-NLCs do not restore attenuated dilation following acute pressure elevation in 
cerebral arteries  
 
Whilst the effects of RV-solution were not assessed in this study due to the limited 
availability of tissue, the effects of RV on the cerebral vasculature has been extensively 
studied, with RV having been shown to be effective at improving impaired cerebral 
function across a range of in vivo disease models (diabetes, focal ischemia, hypertension-
induced oxidative stress) and species (Sinha et al., 2002; Toth et al., 2015; Wong et al., 
2016; Xu et al., 2018). Furthermore, NLCs are considered to be promising delivery 
mechanisms for the treatment of cerebrovascular dysfunction, owing to their lipophilicity 
and ability to enter the cerebral vasculature in vivo (Fang et al., 2012). These findings 
differ significantly from our own observations, whereby RV-NLCs were incapable of 
restoring attenuated dilator responses after acute pressure elevation, with responses 
comparable to that of control tissue. One potential variable that may account for these 
observations is the length of exposure. In contrast to the acute exposure (30-minutes) 
utilised in our studies, these studies have focused on chronic exposure to RV over days 
or weeks, whereby RV has been associated with the activation and upregulation of several 
molecular targets involved in the prorogation of dilation and regulation of basal 
antioxidant activity.  
In order to assess whether the RV or NLC delivery modality may be limiting factors, 
2,3’,4,5’-tetramethoxystilbene (TMS), a potent RV-derived analogue, was encapsulated 
within liposomes; tagged with a specific brain peptide which has demonstrated an ability 
190 
 
to cross the blood-brain barrier and bind to cerebral vasculature (Jennings et al., 2014; 
Urich et al., 2015).   
 
7.2.2 TMS-liposomes do not restore attenuated dilation following acute pressure 
elevation in cerebral arteries  
 
Previous work in our laboratory has demonstrated the capacity of  TMS-liposomes (1 
nM) to restore ROS-mediated attenuation of dilator responses in rat aortic vessels ex vivo, 
following 30-minutes incubation (Zaabalawi et al., 2019). In the cerebral arteries, 
however, responses were unaffected.  In order to assess whether the concentration and/or 
release of drug from the liposomal carrier might be the limiting factor, vessels were 
incubated with a TMS-solution (10 nM). Previous experiments conducted on the coronary 
artery (see Chapter 6) demonstrated that exposure to the non-encapsulated drug had 
greater efficacy than encapsulated counterparts over the one-hour test period, likely 
attributable to superior diffusion kinetics. However, incubation with TMS-solution had 
no effect. These findings, in conjunction with information obtained following the 
characterisation of our cerebral ex vivo model (see chapter 5), whereby attenuated dilator 
responses were not restored following incubation with SOD and CAT; may suggest that 
ROS generation following acute pressure elevation may be less prevalent in the cerebral 
architecture, with attenuated endothelial-dependent responses underlined by another, 
unknown mechanism. One example may be the effect of circumferential stretching 
(pressure-mediated) on endothelial mechanics; with previous studies demonstrating the 
detrimental effects of axial stretching, observing actin remodelling which correlated with 
impaired endothelial-dependent dilation, yet intact endothelial-independent dilation 
(Sipkema et al., 2003). 
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7.2.3 RV-NLCs attenuate endothelial-independent SNP responses, but an unaffected by 
TMS-liposomes 
 
In order to ascertain whether treatment was also affecting the VSMCs, endothelial-
independent responses were assessed. Endothelium-independent responses to PAPA were 
unaffected, suggesting the cAMP pathway remains intact. In contrast, SNP responses 
were varied. Co-incubation of vessels with RV-NLCs significantly attenuated dilator 
responses. Despite RV’s standing as a promising antioxidant, previous research has 
demonstrated its ability to induce pro-oxidant effects. One mechanism postulated to 
account for these observations involves transition metal-mediated oxidation. Transition 
metals, such as iron and copper (Cu), are unique in their ability actively redox-cycle 
between reduced and oxidised states (i.e. Cu2+, Cu1+); however, this electron-donating 
ability can result in the indiscriminate oxidisation of surrounding molecules, generating 
ROS (Popescu and Nichol, 2011). In the presence of Cu2+, RV has been demonstrated to 
undergo oxidation; generating phenoxyl radicals capable of propagating the further 
reduction of Cu2+, inducing DNA damage and cell death (Ahmad et al., 2000). The 
oxidation likely occurs with surface hydroxyl groups on the benzene scaffold of RV; these 
observations were confirmed in later studies, whereby the reactivity of trans-stilbene (no 
hydroxyl groups) and RV was compared in the presence of Cu2+. Trans-stilbene showed 
little to no reactivity in comparison to its hydroxylated counterpart (Azmi et al., 2005). 
Furthermore, copper-mediated oxidation reactions were found to be promoted in the 
presence of biological chelators and reductants, such as ascorbate (Vidrio et al., 2008).  
The brain is a major metal repository and has a high density of transition metals which 
are integral in maintaining normal function, acting as essential co-factors in regulating a 
wealth of physiological processes including; gene expression and neurotransmission. The 
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abundance of transition metals and reductants (i.e. ascorbate (Harrison and May, 2009)) 
in cerebral tissues are likely to foster a supportive and propagative environment for the 
oxidation of RV, which in its oxidised state may have the capacity to quench NO; 
potentially accounting for the impaired SNP-mediated dilator response observed in our 
study. In contrast to the attenuated dilator response observed following RV-NLC 
incubation, SNP-mediated dilator responses following incubation with TMS-liposomes 
and TMS-solution were unremarkable, with responses similar to control; yet significantly 
improved compared to RV-NLCs. Despite originating from a polyphenolic compound 
(RV-analogue), it is crucial to note that in TMS, OH groups have been substituted for 
synthetically conjugated methyl groups. This substitution may account for the vast 
differences in response observed. Some reactions may be tissue-specific, depending on 
complex interplay with surrounding environmental factors. Although interaction with 
methoxy groups are possible, it may be that the cerebral environment is not conducive to 
such reactions.  
 
7.3 Chapter summary 
 
The experiments performed in this part of the study aimed to assess the influence of RV 
loaded within NLCs to restore dilator responses in an ex vivo model of acute hypertension 
using cerebral arteries. RV-NLCs were incapable of restoring attenuated responses; 
furthermore, incubation with TMS, an analogue of higher potency, was also unable to 
restore responses in solution or following liposomal encapsulation; highlighting tissue 
bed dependent variability in the vasculature. In conjunction with information from 
chapter 5, it is conceivable that ROS generation following acute pressure elevation may 
be less prevalent in the cerebral architecture, with attenuated-endothelial dependant 
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responses underlined by another, unknown mechanism. Additionally, RV-NLCs appear 
detrimental to VSMC reactivity, in comparison to the synthetically modified TMS. These 
studies highlight the need for accurate, in-depth, comparative studies to develop an 
understanding of tissue-bed and time-specific effects whilst generating novel treatment 
strategies for clinical use.  
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8 Chapter 8: General Discussion 
and Conclusions 
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Given the global burden of hypertension, there is an unmet clinical need for 
alternative/complementary therapy. While RV is promising, it suffers low stability and 
bioavailability. Encapsulation of RV within nanoparticles may preserve drug stability, 
resulting in improved bioavailability and clinical outcome. The hypothesis of the present 
study is that RV (and analogues), delivered via NPs, will enable the restoration of 
attenuated dilation after acute pressure elevation ex vivo, and will provide a more 
sustained dilator response than the unencapsulated form. NPs (inorganic and organic) 
were characterised and their antioxidant capacity assessed in solution, within cells and/or 
isolated vessels using an ex vivo model of acute hypertension. 
 
8.1 Cerium oxide modification of SiNPs attenuates their surface reactivity and 
demonstrates antioxidant capacity, improving their biocompatibility in vitro. 
 
SiNPs (inorganic) are considered an attractive delivery modality for drugs in the treatment 
of CVD; however, oxidative reactivity at the particle surface is associated with attenuated 
vascular responses that may preclude their use (Corbalan et al., 2012; Ahamed, 2013; 
Duan et al., 2013a; Farooq et al., 2014b). The work reported in this thesis demonstrates 
that functionalisation of SiNPs with CeO2 (with its unique redox cycling activity) 
provides a means of attenuating surface reactivity and promoting antioxidant capacity, 
resulting in heightened biocompatibility in vitro. Whilst the effects of CeO2 
functionalised silica have been documented in the context of stability enhancement/ex 
vivo (Farooq et al., 2014b; Munusamy et al., 2014); we are the first to document the 
physiochemical effects of CeO2 functionalisation in solution. Whilst deemed unsuitable 
for further investigation in this thesis, these studies highlight the importance of 
understanding the fundamental mechanisms underlying the use of nanomaterials, to 
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promote research into the development of safer, silica-based delivery modalities for the 
release of drugs.   
 
8.2 Novel RV-NLCs reduce ROS in human coronary artery endothelial cells in vitro.  
 
 
Lipidic delivery systems (organic) are an alternate delivery platform, with noted benefits 
over inorganic strategies including improved biocompatibility, and the ability to traverse 
challenging physiological barriers. The findings presented in Chapter 3 demonstrate the 
potential of novel trimyristin-triolein NLCs to entrap and release RV over sustained 
periods of time, within an oxidative environment in vitro, reducing both cytosolic and 
mitochondrial O2•- anion levels. This data is consistent with previous observations, 
whereby RV-solution reduced mitochondrial O2•- in HCAECs following hyperglycaemia-
induced mitochondrial ROS generation (Ungvari et al., 2009); highlighting the potential 
of RV-NLCs as an antioxidant in future therapeutic applications. Whilst several studies 
have documented the effects of RV in solution and in encapsulated forms (e.g. solid lipid 
nanoparticles) on endothelial viability and oxidative capacity (Leonard et al., 2003; Neves 
et al., 2016), this study is the first to document the effects of these novel NLCs composed 
of trimyristin-triolein (which incurs enhanced stability, RV entrapment and uptake) using 
physiologically relevant HCAECs. 
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8.3 Acute pressure elevation attenuates endothelial-dependent dilator responses via the 
activation of NADPH oxidase in isolated arteries 
 
Elevated oxidative stress is a crucial contributor to the pathogenesis of endothelial 
dysfunction in hypertension (Higashi et al., 2002; Mollnau et al., 2002). Several 
experimental models have attempted to simulate hypertensive environments ex vivo, with 
studies demonstrating that high pressure itself could lead to the production of oxidative 
stress in the absence of neurohumoral factors (Ungvari et al., 2003). I have used this ex 
vivo, acute pressure model, throughout this thesis to examine the potential of RV to 
restore dilator capacity using isolated vessels. The findings presented in Chapter 5 
confirm that acute pressure is an appropriate model for replicating the oxidative 
environment observed in hypertension in the coronary artery, demonstrating that 
NADPH-oxidase derived O2•- plays an integral role in attenuating dilator responses, as 
previously described in femoral and aortic arteries (Ungvari et al., 2003, 2004). In 
addition, inhibition studies identified NO as the principal dilator component, under 
elevated pressure, despite the presence of elevated O2•-, which usually quenches NO. The 
role of NO as a key vasodilator in hypertension has also been confirmed by studies 
demonstrating that agonist-induced dilation of pre-constricted vessels is reduced or 
eliminated by inhibitors of eNOS in isolated coronary vessels from hypertensive human 
and murine models (Pourageaud and Freslon, 1995; Quyyumi et al., 1995). In contrast to 
findings in coronary arteries, notable ROS moieties such as O2•- and H2O2 do not appear 
to contribute to attenuated endothelial-dependent dilator responses in cerebral arteries; 
highlighting the disparity between potential mechanisms of action between tissue beds. 
These studies are integral in understanding and interpreting functional responses in the 
vasculature in disease states and developing appropriate treatment strategies.  
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8.4 RV-NLCs restore the magnitude of dilation via NO following acute pressure 
elevation, mediated via AMPK. 
 
A number of studies have shown that polyphenols such as RV and its analogues have 
antioxidant potential but are hindered by poor bioavailability (Cottart et al., 2010; 
Chachay et al., 2014; van der Made et al., 2015; Zortea et al., 2016). The findings from 
Chapter 6 confirmed the ability of RV loaded within NLCs to restore dilator responses in 
the ex vivo model of acute hypertension. Using this model, RV-NLCs restored and 
potentiated attenuated dilator responses to comparable levels as that observed by 
endogenous antioxidants (e.g. SOD), highlighting their successful delivery into tissues 
and antioxidant capacity in the coronary vasculature. These responses were sustained over 
a more prolonged period, in comparison to RV-solution alone; confirming the ability of 
NLCs to protect encapsulated content. Through inhibition studies, RV-NLCs were found 
to potentiate dilation via the modulation of NO and COX pathways, partially mediated 
by AMPK; as opposed to the conventionally accepted SIRT-1 pathway (Figure 8.1) (Ma 
et al., 2017). Whilst studies have investigated the use of NLC-encapsulated RV; to our 
knowledge, this is the first time that novel trimystrin-trioleate NLCs have been used for 
the delivery of RV into the vasculature using pressure myography. Thus, differences in 
mode of delivery and uptake of RV may reflect different regulatory pathways and have 
implications on treatment efficacy and outcome. These findings have important 
implications for the future design and implementation of anti-hypertensive treatment 
strategies.  
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Figure 8.1. Potential mechanisms mediating endothelial dependent dilation in the 
coronary artery following acute pressure elevation. Acute pressure elevation results in 
the activation of NAD/NADPH and subsequent generation of O2•-, which indiscriminately 
oxidises NO and downregulates eNOS, impairing dilation. Following release into the 
coronary vasculature, RV may exhibit a range of mechanisms including direct antioxidant 
activity via the promotion of HAT, and indirect activity via the activation of AMPK. The 
activation of AMPK results in the generation of NO, potentially via eNOS 
phosphorylation. Concurrently, AMPK may also modulate COX activity, reducing levels 
of vasoconstrictors such as PGH2 and TXA2, resulting in improved dilator responses. 
Whilst no direct evidence implicating a relationship between SIRT-1 and RV was found, 
it remains to be seen whether AMPK and SIRT-1 act in a compensatory manner via 
mediation by LKB1; potentially contributing further via eNOS acetylation. Resveratrol 
(RV); nitric oxide (NO); endothelial nitric oxide synthase (eNOS); 5' adenosine 
monophosphate-activated protein kinase (AMPK); liver kinase B1 (LKB1); 
cyclooxygenase (COX); prostaglandin H2 (PGH2); thromboxane A2 (TXA2); hydrogen 
atom transfer (HAT); nicotinamide adenine dinucleotide (NAD); sirtuin (silent mating 
type information regulation 2 homolog) 1 (SIRT1); oxygen (O2), superoxide (O2•-); 
soluble guanylate cyclase (sGC); guanosine triphosphate (GTP); cyclic guanosine 
monophosphate (sGMP); calcium (Ca2+); myosin light chain kinase (MCLK). 
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8.5 Organic nanoparticles (RV-NLCs and TMS-liposomes) are incapable of restoring 
elevated pressure induced attenuated dilation in cerebral arteries  
 
The findings from Chapter 7 demonstrate the inability of organic nanoparticles (RV-
NLCs and TMS-liposomes) to restore attenuated dilator responses in the cerebral arteries 
following acute pressure elevation; differing significantly from findings using coronary 
arteries, suggesting tissue-specific variability in the control of vessel diameter. 
Furthermore, RV-NLCs appear detrimental to VSMC reactivity, potentially acting as a 
pro-oxidant and quenching NO, compared to the synthetically modified TMS-liposomes. 
The pro-oxidant effects of RV have previously been documented; whilst TMS is an 
analogue of RV, the disparity between responses are likely a result of its synthetic 
modification,  resulting in reduced chemical reactivity (Ahmad et al., 2000; Azmi et al., 
2005). However, this differs from current literature, whereby prolonged RV exposure has 
demonstrated antioxidant and restorative abilities in the cerebral vasculature subjected to 
hypertension-induced oxidative stress (Toth et al., 2015); suggesting treatment may be 
time-dependent and thus, RV may be unsuitable for treating acute vascular damage 
(Figure 8.2).  
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Figure 8.2. Potential mechanisms of disparity between RV and TMS mediated effects 
in the cerebral vasculature. Following release into the cerebral vasculature, RV may be 
subject to transition metal mediated (Fe2+ and Cu2+) oxidation of surface hydroxyl groups 
(OH), resulting in the generation of highly reactive phenoxyl radical; leading to the 
indiscriminate oxidisation of surrounding molecules such as NO, impairing dilation. In 
contrast, TMS has had OH groups substituted for synthetically conjugated methyl groups 
which are not subject to oxidation, thus leaving NO intact. Resveratrol (RV); iron (Fe); 
copper (Cu); nitric oxide (NO); soluble guanylate cyclase (sGC); guanosine triphosphate 
(GTP); cyclic guanosine monophosphate (sGMP); calcium (Ca2+); myosin light chain 
kinase (MCLK). Active redox cycling between reduced and oxidised states (i.e. Cu2+, 
Cu1+; red stars). Phenoxyl radical oxidative reactivity (yellow stars). 
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8.6 Translatability of experimental findings  
 
To date, there are a limited number of publications that have conducted ex vivo studies 
using human tissue. Due to the requirements for live and healthy vessels in these ex vivo 
experiments, obtaining them ethically is a major hurdle. This makes translating findings 
from rat coronary and cerebral arteries to human very challenging. 
However, various studies have demonstrated fundamental mechanisms are evolutionary 
conserved between rat and human and is considered an acceptable model for the 
evaluation of cardiovascular disease. Toth et al. investigated the effects of intraluminal 
pressure and flow on constrictor responses and underlying mechanism of action in both 
the human and rat cerebral arteries. In response to a progressive increase in flow and/or 
pressure, increased constriction was observed; incubation with inhibitors of 20-HETE and 
COX abolished constriction in both species, implicating ROS and COX activity in flow-
induced constriction (Toth et al., 2011). 
Similarities in the mechanisms underlying endothelial-dependent dilation mimic our own 
observations in the coronary artery, whereby NO continues to play an important role in 
the regulation of dilation, despite its bioavailability being reduced in hypertension. 
Quyyumi et al. investigated the dilator component in the coronary arteries of healthy and 
hypertensive patients undergoing coronary angiography. Following inhibition of NO, 
ACh-mediated dilator responses were supressed, suggesting NO may play an important 
role in maintaining dilation even in a hypertensive state (Quyyumi et al., 1995, 1997). 
These findings were recapitulated by Nishikawa et al. in patients suffering from 
atherosclerosis, whereby NO synthesis maintained basal vasomotor tone in both conduit 
and resistance vessels in the normal human coronary circulation; although NO release 
203 
 
was impaired in the large epicardial coronary arteries in patients with atherosclerosis, NO 
still regulated vascular tone in the small epicardial coronary arteries and arterioles. 
Whilst these studies appear to confirm the translatability of rodent and human studies, 
there are currently no studies that compare the responses seen in healthy rodent and 
human coronary or cerebral arteries. The removal of healthy tissue from essential organs 
is not commonplace and is largely associated with underlying disease, which may directly 
or indirectly influence the vasculature and thus, may not accurately reflect normal 
vascular responses. A more detailed understanding of the similarity of the human 
vasculature response compared to the rodent would be necessary before these potential 
therapeutics could be translated. Due to the difficulty in obtaining tissue for ex vivo 
experiments but the comparative ease in obtaining cells, in future work the molecular 
responses could be compared in a flow culture system utilising primary human or rodent 
arterial cells.   
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8.7 Study Limitations 
 
Several limitations were identified and considered when interpreting the experimental 
data, along with the potential implications for the conclusions drawn. Firstly, whilst our 
model was well characterised and considered suitable for use to study elevated oxidative 
stress; hypertension is a multifactorial disease, with well-documented interactions with 
other physiological components (e.g. humoral factors) which may influence vascular 
responses and/or may alter treatment outcome when assessed in vivo. Affirmation of 
findings would require assessment using in vivo animal models of hypertension, then in 
patients. Furthermore, with the use of any experimental animal, there will be innate 
variability within groups. This could be improved in future by increasing n numbers in 
all experimental conditions. Secondly, the nature of working with small size arteries make 
these experiments technically difficult; requiring microdissection and tissue manipulation 
performed underneath a dissection microscope. This manipulation may cause small 
amounts of endothelial and/or smooth muscle stress and damage. Furthermore, an 
accurate assessment of vascular reactivity ex vivo requires the removal of perivascular 
adipose tissue (PVAT); however, in addition to providing structural support, PVAT has 
demonstrated an ability to modulate vascular contractility and its removal may thus, 
influence responses (Won et al., 2019). Lastly, after mounting tissue on the glass 
cannulae, vessels must be stretched; it is difficult to standardise stretch, which may affect 
signalling due to the presence of mechanoreceptors. Whilst there is a possibility this may 
have had an effect; it may be assumed that this was largely mitigated due to the relatively 
low variability observed with experiments.   
Furthermore, whilst evidence on the EDRF component on small size arteries exists, 
considering the tissue-bed and size-specific distribution of EDRFs, it would be prudent 
205 
 
to investigate the dilator component of coronary arteries under normotensive pressure in 
order to observe how these components are modulated following acute pressure elevation 
in our ex vivo model.  
In these studies, acute pressure elevation has been implicated in the generation of ROS 
and subsequent attenuation of endothelial-dependent dilator responses, with SOD 
restoring and potentiating dilation in the coronary artery; implicating the presence of basal 
ROS. In order to confirm the presence and extent of basal ROS, SOD experiments should 
also be performed under normotensive pressure (60mmHg). For the design of sustained 
drug release strategies, it would be beneficial to observe the effects of treatment on vessel 
reactivity over prolonged periods of time lasting days, not hours. However, this is not 
currently possible due to limitations of the pressure myography technique; although 
vessels can be maintained, the endothelium becomes unresponsive when incubated over 
days. 
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8.8 Future Directions 
 
Whilst this ex vivo study has convincingly shown that oxidative stress plays a critical role 
in promoting hypertension-mediated endothelial dysfunction and the restorative effects 
of RV-NLCs (in the coronary artery); it is evident that several key questions remain to be 
answered. 
Firstly, whilst these data demonstrate the predominant influence of AMPK 
(approximately 50 %) in mediating RV-NLC-mediated dilation in the coronary artery, as 
opposed to the conventionally accepted SIRT-1 pathway; it remains to be seen whether 
AMPK and SIRT-1 act in a compensatory manner. Inhibition of both would likely result 
in total abolishment of RV-NLC-mediated dilation. This would be consistent with 
unpublished observations conducted with aortic tissue ex vivo within the Azzawi 
laboratory; however, substantial differences in vessel size and distribution of EDRF 
signalling do not make these experimental findings readily comparable. Furthermore, 
whilst many reports have documented the effects of RV and its modulatory effects on 
SIRT-1, little is known about its molecular mechanism of action. The effects of RV are 
known to be receptor-mediated, with several potential candidates identified to date (e.g. 
androgen-, estrogen-, troponin-c-receptor) (Wang et al., 2010; Pineda-Sanabria et al., 
2011; Nwachukwu et al., 2014); in contrast, RV-NLCs are capable of being endocytosed 
into cells, releasing RV directly into the cytoplasmic compartment (Neves and Queiroz, 
2016; Piazzini et al., 2018). Activation of these cell surface receptors inherently 
implicates multiple signalling pathways, the mechanisms of which may express 
preferential aversion or affinity towards downstream targets (e.g. SIRT-1 vs AMPK). An 
accurate understanding of the respective pathways activated and modulated by RV and 
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RV-NLCs is essential, as the mode of delivery and uptake may have implications on 
treatment efficacy and outcome.  
Whilst a precise understanding of cell signalling in disease states is vital in the 
development of therapeutic treatment strategies, an accurate understanding of pathways 
in untreated tissue is essential and arguably of greater importance. Following acute 
pressure elevation in the coronary artery (in the presence and absence of treatment), an 
intact dilator component was demonstrated in the presence of EDRF inhibitors L-NNA, 
indomethacin, apamin and TRAM-34. TRPV4 channels have attracted interest in recent 
years and have been reported to contribute to dilation in the coronary artery (Bubolz et 
al., 2012; Cao et al., 2018). Given that TRPV4-mediated dilation is predominantly 
mediated by NO, PGI and EDH; the mechanisms of which are inhibited, the contribution 
of TRPV4 would be unexpected. However, much is still unknown about EDHF 
signalling.          
In small-sized arteries, endothelial SKCa and IKCa channels are thought to be the primary 
mediators of hyperpolarisation. Whilst studies have also demonstrated the presence of 
BKCa channels in coronary artery VSMCs; evidence suggests their threshold for 
activation is x10 higher and likely do not contribute to the maintenance of vessel diameter 
in small size arteries; hence, BKCa channels are not inhibited experimentally. However, 
circumferential stretching of vessels (such as when elevating pressure) has been 
demonstrated to alter the sensitivity of BKCa channels (Hill et al., 2010). Therefore, it may 
be that AA (which is not subject to COX inhibition) activates TRPV4, resulting in 
ryanodine receptor activation and Ca2+ release from the sarcoplasmic reticulum; the now 
sensitive BKCa channels detect elevated intracellular Ca2+ and open, resulting in Ca2+ 
efflux and relaxation. It would be of interest to pharmacologically inhibit TRPV4 and/or 
BKCa channels in order to assess their contribution to endothelial-dependent dilation. 
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Although this potential mechanism may not appear to be influenced by current treatment, 
it may be a pathway that can be exploited using future treatment strategies.  
In this thesis, acute pressure elevation has been implicated in the generation of ROS and 
subsequent attenuation of endothelial-dependent dilator responses, with SOD restoring 
and potentiating dilation in the coronary artery; implicating the presence of basal ROS. 
In order to confirm the presence and extent of basal ROS, SOD experiments should also 
be performed under normotensive pressure (60 mmHg).  
Given the haemodynamics of the in vivo environment, where the nanoparticles would 
ultimately be used, it would be logical to investigate the uptake and influence of the RV-
loaded nanoparticles on cell viability and dilator function under flow conditions. 
Generally, it would be expected that assays performed following the continuous 
circulation of nanoparticles would have improved biocompatibility, as opposed to 
stagnant conditions observed under conventional static assays; this is consistent with 
observations by researchers investigating the toxicological impact of SiNPs 
(Yazdimamaghani et al., 2018). These findings have important clinical implications, 
allowing the optimisation of therapeutic dosing to enhance treatment outcome whilst 
maintaining acceptable levels of toxicity. 
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8.9 Concluding Statements 
 
CVDs are associated with oxidative stress and dysfunction of the vascular endothelium. 
Acute pressure elevation provides a means of replicating the oxidative environment and 
vascular dysregulation associated with hypertension; providing a useful model for the 
development of novel treatment strategies. The use of nanoparticles for encapsulation of 
drugs (e.g. novel antioxidants) offer tissue-bed specific means of improving impaired 
vascular function. Nanoparticles demonstrate excellent potential as delivery platforms for 
the sustained release of metabolically unstable compounds improving their bioavailability 
for the amelioration of CVDs associated with oxidative stress and restoration of 
cardiovascular health. Our findings have important implications for the future design and 
implementation of anti-hypertensive treatment strategies. 
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10.1 Sol-gel 
 
A number of techniques have been developed for the synthesis of nanoparticles, here we 
will describe the most frequently utilised sol-gel method, developed by Stöber et al. in 
1968 (Stöber et al., 1968; Ibrahim et al., 2010). A sol is a dispersion of solid particles (~ 
0.1-1 µm) within a liquid, which are not subjected to standard gravitational forces, only 
to Brownian motion. A gel encompasses both liquid and solid phases, forming an 
integrated network upon solvent evaporation. Generally, sol-gel encompasses the 
hydrolysis and polycondensation reactions of metal alkoxide precursors e.g. the formation 
of a silicon dioxide (SiO2) colloid from tetraethyl-orthosilicate (TEOS). The initial step 
in the reaction involves the hydroxylation of alkoxy groups via the addition of H2O. 
Hydrogen atoms become displaced from H2O, replacing ethyl groups present on TEOS 
(1:1). The remainder of the H2O (OH) proceeds to bind with displaced ethyl groups, 
forming ethanol. Under acidic conditions, this structure remains highly stable. Following 
hydroxylation, condensation reactions are promoted via the addition of a basic compound 
such as ammonium hydroxide, resulting in the formation of polymeric branches. These 
polycondensation reactions involve competitive oxolation (oxygen bridge formation) and 
olation (hydroxo bridge formation). The result is the formation of high energy chemical 
bonds (Si-O-Si) which are stable up to 1200 oC (Figure 10.1). The technique hosts 
numerous advantages over direct alternatives such as coprecipitation or hydrothermal 
processing, the most notable being a greater breadth of control over nanoparticle size and 
morphology. These characteristics are manipulable via alteration of temperature, pH, 
precursor concentration and reaction time.  
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Figure 10.1. A schematic illustration demonstrating the formation of silica 
nanoparticles from TEOS. TEOS precursor (A); addition of H2O promotes hydroxylation 
and ethyl removal (B); excess OH binds to displaced ethyl groups, forming EtOH (C); 
condensation reaction and water removal (D); formation of Si-O-Si bonds (E); formation 
of polymeric branches, resulting in a sol-gel (F). Author generated. 
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10.2 Calculation of NPs/ml (inorganic) 
 
In order to calculate the number of particles present within 1 ml of solvent, nanoparticle 
size (identified using SEM/TEM/DLS), weight (weight/ml) and material density are 
required. The following equations may be used:  
 
Equation 1: Calculates the volume of a sphere, where v is the volume of a sphere, π is 
3.14 and r is the radius of the particle in cm. This equation was used to calculate the 
number of particles per ml.  
 
𝑉 ൌ 43  𝜋𝑟
ଷ 
Equation 2: Calculates the mass of a nanoparticles sphere, where M is mass of a particles 
sphere, v is volume of a sphere and d is the density of silica, which is 1.9.  
 
𝑀 ൌ 𝑉 𝑥 𝐷 
Equation 3: Calculates the number of particles within a given solution, where V is the 
volume of a sphere at a given diameter; m is the mass of dry NP product in 1 ml of SiNPs 
suspension.  
𝑁 ൌ 𝑀 / 𝑉 
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e.g. NP Size = 85 nm = Radius = 42.5 nm = 42.5 x 10-7 cm       
     
Weight in 100 µl = 0.0020 g  
 
Volume of a Sphere = 4/3 x   π x r3 (42.5 x 10-7)3 = 3.21 x 10-16 cm3  
 
Mass of Sphere = Volume x Density = 3.21 x 10-16 cm3 x 1.9 (density of Stöber silica) 
= 6.10 x 10-16g 
 
Number of Particles =   0.0020 g / 6.10 x 10-16   = 3.27 x 1012 particles in 0.1 ml 
                                                                 = 3.27 x 1013 particles in 1 ml 
 
1.00 x 1013 (Required number of NPs) x 1 ml / 3.27 x 1013 = 0.3 ml (300 µl) 
